 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409475]®, Umbilical Cord Blood -Derived Ex Vivo 
Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies  
 
Clinical Phase    Pi[INVESTIGATOR_331157]:     NiCord® 
 IND Number:     [ADDRESS_409476] Nu mber:    2014- 000074- 19 
 
Sponsor   
Gamida Cell Ltd.  
[PO_BOX] Jerusalem [ZIP_CODE] Israel  
Tel: 972- 2-6595666 
Fax:  972- 2-6595616 
 Director, Medical Affairs    Einat Galamidi Cohen , M.D.  
Protocol No.     GC P #02.01.020  
Dated                                               December  8, 2011 
Amendment #    VI 
Dated      December 1 3, 2017 
 This clinical study will be conducted in accordance with the Sponsor's Standard Operating Procedures (SOPs), this protocol, current Good Cli nical Practice (GCP), the Declaration of 
Helsinki,  the provisions of International Conference on Harmonization (ICH) Guidelines and all 
local applicable laws and regulations.  
 
 
 
  
 
 
 CONFIDENTIAL  
The information in this document is considered privileged and confidential, and may not be 
disclosed t o others except to the extent necessary to obtain Institutional Review Board 
(IRB)/Ethics Committee (EC) approval, written informed consent and the approv al of local 
regulatory authorities as required by [CONTACT_1769]. 
  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 2 
 
TABLE OF CONTENTS  
1. INVESTIGATOR’S AGREEMENT  ..........................................................................11  
2. STUDY SYNOPSIS  ...................................................................................................12  
3. BACKGROUND AND RATIONALE  .......................................................................24  
3.1. Overview  .....................................................................................................................24  
3.2. Sickle cell disease morbidity and mortality  ................................................................24  
3.3. Conventional approaches and their limitations  ...........................................................25  
3.4. Role of Hematopoietic stem cell transplantation (HSCT) ..........................................[ADDRESS_409477]  ................28  
3.4.4.  UCB in hemoglobinopathies: increased graft failure – a function of lower 
cell dose  ......................................................................................................................28  
3.4.5.  Strategies to augment cell dose: use of dual UCB grafts  ............................................29  
3.4.6.  Combining 2 UCB grafts: a newly emerging and successful strategy to augment cell dose  .......................................................................................................[ADDRESS_409478]® as a single expanded CBU  ...................[ADDRESS_409479]® and CordIn™ ......................................................[ADDRESS_409480]® Clinical Experience in Hematological Malignancies  ..................................37  
3.7.2.  CordIn™ Clinical Experience in Hemoglobinopathies  ..............................................43  
3.8. Rationale for Study Design & Dosages  ......................................................................43  
3.8.1.  Study Population  .........................................................................................................44  
3.8.2.  CBU Cell Dose  ...........................................................................................................44  
3.8.3.  Selection of CBUs  ......................................................................................................44  
4. STUDY OBJECTIVES, HYPOTHESIS & STUDY ENDPOINTS  ..........................45  
4.1. Objectives  ...................................................................................................................45  
4.2. Hypothesis  ..................................................................................................................46  
4.3. Definition of Study Endpoints  ....................................................................................46  
4.3.1.  Acute Toxicity  ............................................................................................................46  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 3 
4.3.2.  Neutrophil Engraftment  ..............................................................................................46  
4.3.3.  Platelet Engraftment  ...................................................................................................46  
4.3.4.  Autologous Recovery  .................................................................................................46  
4.3.5.  Trans plant Related Mortality  ......................................................................................47  
4.3.6.  Acute and Chronic GvHD  ..........................................................................................47  
4.3.7.  Immune Reconstitution  ...............................................................................................47  
4.3.8.  Chimerism of the Two CBU Grafts  ............................................................................47  
4.3.9.  Life-threatening/Fatal Infection  ..................................................................................47  
4.3.10.  Regimen Rela ted Toxicities  ........................................................................................48  
5. STUDY POPULATION  .............................................................................................49  
5.1. Number of Patients  .....................................................................................................49  
5.2. Eligibility Criteria  .......................................................................................................49  
5.3. Reproductive Restrictions ...........................................................................................53  
5.4. Patient Withdrawals  ....................................................................................................53  
5.4.1.  Withdrawal of Patients from the Study  ......................................................................53  
5.4.2.  Criteria for Withdrawal  ...............................................................................................53  
5.4.3.  Early Discontinu ation of Follow -up ...........................................................................54  
6. CONCOMITANT MEDICATIONS & SUPPORTIVE CARE  .................................55  
6.1. Previous Medications  ..................................................................................................55  
6.2. Disallowed Concomitant Medications ........................................................................55  
6.3. Preparative & Conditioning Regimen  ........................................................................55  
6.3.1.  Hydroxyurea Administration  ......................................................................................55  
6.3.2.  Fludarabine Administration  ........................................................................................56  
6.3.3.  Busulfan Administration  .............................................................................................56  
6.3.4.  Cyclophosphamide (CY) Administration  ...................................................................56  
6.3.5.  Melphalan  ...................................................................................................................57  
6.3.6.  Methylprednisolone  ....................................................................................................57  
6.4. GvHD Prophylaxis Medications  .................................................................................57  
6.5. Acute & Chronic GvHD Treatment  ............................................................................58  
6.6. Supportive Care  ..........................................................................................................58  
6.6.1.  Engraftment Syndrome  ...............................................................................................59  
6.6.2.  Venous Access  ............................................................................................................59  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409481] or Donor Cellular 
Infusion  .......................................................................................................................62  
6.7. Investigational Agents  ................................................................................................62  
6.8. Other Medications  ......................................................................................................62  
7. DET AILED STUDY PLAN  .......................................................................................68  
7.1. Pre-Screening Activities: Search for Matching CBUs  ...............................................68  
7.2. Informed Consent and Registration  ............................................................................68  
7.2.1.  Consent of minors  .......................................................................................................69  
7.3. Eligibility/Screening Assessments (within 45 days prior to CBU shipment to 
the producti on site)  .....................................................................................................69  
7.4. Baseline Assessments (Within 4 weeks prior to start of conditioning)  ......................71  
7.5. CBU’s Shipment & Receipt at the Production Site and Clinical Site  ........................72  
7.6. Preparative Phase (Day –35 to one day prior to start of conditioning 
regimen)  ......................................................................................................................72  
7.7. Eligibility Confirmation: (one week prior to start of conditioning regimen)  .............72  
7.8. Conditioning Phase  .....................................................................................................72  
7.9. Pre-Transplantation Day (Day 0)  ................................................................................[ADDRESS_409482]® ..........................[ADDRESS_409483] Transplantation Follow -Up (Day 0 to 1)  ............................................................76  
7.10.  Scheduled Treatment Visits (As Detailed in Table 4)  ................................................76  
7.10.1.  Scheduled Visits on Day 7/ Days (±3) 14, 21, 28, 35, 42, 70/ Day (±14) 100/ 
Day (±21) 180 .............................................................................................................76  
7.10.2.  Evaluation and Treatment of Graft Failure  .................................................................77  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 5 
7.10.3.  Early Discontinuation of Follow -up ...........................................................................77  
7.10.4.  Criteria for Early Termination/Discontinuation  .........................................................[ADDRESS_409484]-study Follow -up ..................................................................................................78  
7.13.  Data Reporting ............................................................................................................78  
7.13.1.  Criteria for Forms Submission  ....................................................................................78  
8. STUDY MEDICATION  .............................................................................................80  
8.1. Description  ..................................................................................................................80  
8.1.1.  NiCor d® ......................................................................................................................[ADDRESS_409485] Blood Unit  .....................................................................................83  
8.5. Shipment  .....................................................................................................................83  
9. SAFETY MONI TORING ..........................................................................................85  
9.1. Definitions  ..................................................................................................................85  
9.1.1.  Adverse Even t (AE)  ....................................................................................................85  
9.1.2.  Infusion Reaction  ........................................................................................................85  
9.1.3.  Serious Adverse Event (SAE)  ....................................................................................85  
9.1.4.  Suspected Adverse Reaction  .......................................................................................86  
9.1.5.  Causality  .....................................................................................................................86  
9.1.6.  Expec tation  .................................................................................................................86  
9.1.7.  Toxicity Grading  .........................................................................................................86  
9.1.8.  Expedited Reporting  ...................................................................................................86  
9.2. Observation, Detection and Recording of AEs and SAEs  ..........................................87  
9.3. Follow -up of AEs and SAEs  .......................................................................................88  
9.4. Clinical Laboratory Evaluations  .................................................................................88  
9.5. Pregnancy  ...................................................................................................................88  
9.6. Patient W ithdrawal from Study Procedures due to Adverse Events  ..........................89  
9.7. Medical Monitor Revi ew ............................................................................................89  
9.8. Sponsor Obligations  ....................................................................................................89  
9.9. FDA Reporting  ...........................................................................................................89  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409486] ICAL METHODOLOGY  ...........................................................................90  
10.1.  Patients & Analysis Cohorts  .......................................................................................90  
10.1.1.  Per Protocol (PP) Data Analysis Set  ...........................................................................90  
10.1.2.  Withdrawals from the Trial  ........................................................................................91  
10.2.  Sample Size  ................................................................................................................91  
10.3.  Interim Analysis & Early Sto ppi[INVESTIGATOR_007]  ............................................................................91  
10.3.1.  Part 1 Guidelines  .........................................................................................................92  
10.3.2.  Part 2 Guidelines  .........................................................................................................92  
10.4.  Statistical Analysis  ......................................................................................................93  
10.4.1.  Primary Endpoints  ......................................................................................................93  
10.4.2.  Secondary Endpoints & Analysis  ...............................................................................93  
10.4.3.  Exploratory Endpoints & Analyses  ............................................................................[ADDRESS_409487] Study Analysis  ....................................................................................................95  
10.5.  Safety Assessment  ......................................................................................................95  
10.5.1.  Adverse Experiences  ..................................................................................................95  
10.6.  Statistical Software  .....................................................................................................95  
11. CLINICAL DATA MANAGEMENT  ........................................................................96  
11.1.  Data Quality Assurance  ..............................................................................................96  
11.2.  Data Collection  ...........................................................................................................96  
11.3.  Source Documents  ......................................................................................................96  
11.4.  Staff Training  ..............................................................................................................97  
11.5.  Data Monitoring  ..........................................................................................................97  
11.6.  Confidentiality  ............................................................................................................97  
APPENDIX A.  GVHD CLASSIFICATION ..............................................................................98  
APPENDIX B.  SAFETY DATA REPORTING  .......................................................................100  
APPENDIX C.  PROTOCOL SPECIFIED ADVERSE EVENTS  ............................................101  
APPENDIX D.  COMMON TERMINOLOGY CRITERA FOR ADVERSE EVENTS 
V4.03  (CTCAE)  .......................................................................................................[ADDRESS_409488] of Tables  
Table  1:  Methods of Expansion  ....................................................................................................31  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 7 
Table 2: Overview of ongoing clinical studies of NiCord®  ..........................................................37  
Table 3: Overview of ongoing clinical studies of CordIn™  ..........................................................43  
Table 4: E valuations & Examinations Flow Sheet  ........................................................................63  
Table  5: Final Process Quality Control Tests  and Release Criteria for NiCord® CF ....................81  
Table  6: Final Process Quality Control Tests for NiCord® NF .....................................................82  
Table 7: Final Process Qual ity Control Tests for the NiCord® CF/NF Thawing/Infusion 
Solution  .......................................................................................................................[ADDRESS_409489] of Figures  
Figure  1a:  Study Scheme (for Part 1) ...........................................................................................22  
Figure  1b:  Study Scheme (for Part 2)  ...........................................................................................23  
  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409490] Res earch Organization  
Cyclosporine A  
Common Terminology Criteria for Adverse Events  
DCC   Data Coordinating Center  
DLCO   Diffusing Lung Capacity of Carbon Monoxide  
DMC   Data Monitoring Committee  
EBV  
EC  Epstein –Barr Virus  
Ethics Committee  
FPQC   Final Process Quality Controls  
GCP   Good Clinical Practice  
G-CSF  Granulocyte Colony -Stimulating Factor  
GM-CSF 
GFR   Granulocyte -Macrophage Colony -Stimulating Factor  
Glomerular Filtration R ate 
GvHD   Graft-versus -host Disease  
HbS 
HCG  
HIV 
HLA   Hemoglobin S  
Human Chorionic Gonadotropin  
Human Immunodeficiency Virus  
Human L eukocyte Antigen  
HPC  
HSC   Hematopoietic Progenitor Cell  
Hematopoietic Stem C ells 
HSCT   Hematopoietic Stem Cell Transplantation  
HTLV  
IBW   Human T -Lymphotropic Virus  
Ideal Body Weight  
IC  Informe d Consent  
ICH  International Conference on Harmonization  
IPQC   In-process Quality Controls  
IRB  Institutional Review Board  
ITT  Intent to Treat  
IV 
LVEF   Intravenous  
Left Ventricular Ejection Fraction  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409491] of Abbreviati ons 
 
MAC  
mARTs   Myeloablative conditioning  
Mono-ADP -ribosyltransferases  
MM  Medical Monitor  
MMF   Mycophenolate Mofetil  
MRA  
MRI  
NAD+  Magnetic Resonance Angiogram  
Magnetic Resonance Imaging  
Nicotinamide A denine Dinucleotide  
NAM   Nicotinamide  
NF  Non-cultured  Fraction  
NK  Natural Killer 
NMDP  
OOS   Natio nal Marrow Donor Program  
Out of Specification  
PARPs   Poly-ADP -ribose Polymerases  
PB  Peripheral Blood 
PBSC  
PCR   Peripheral Blood Stem Cell  
Polymerase Chain R eaction  
PP  Per Protocol  
PRBC  
QC  Packed Red Blood Cells  
Qual ity C ontrol  
RBC  
SAE   Red Blood C ell 
Serious Adverse Event  
SC 
SCD   Sickle -Hemoglobin C  
Sickle Cell Disease  
SCF 
SCT 
SLM   Stem Cell Factor  
Stem Cell Transplant  
Study Logistics Manager  
SOPs   Standard Operating Procedures  
SRC   SCID Repopulating Cells 
SS 
TCD   Sickle -Cell Anemia  
Trans -Cranial Doppler  
TPO  
TRM   Thrombopoietin  
Transplant -related Mortality  
UCB  
UCBT   Umbilical Cord Blood 
Umbilical Cord Blood Transplantation  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 10 
SPONSOR PROTOCOL APPROVAL PAGE  
 
Protocol Title:  Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-
Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies  
 
 
Clinical Phase    Pi[INVESTIGATOR_331158]:     GC P #02.01.020  
 Amendment Number:   VI 
 Dated:       December 1 3, 2017 
 
 
Approved by:  
 
[INVESTIGATOR_40373], Medical Affairs  
 
Einat Galamidi Cohen, M.D. 
 
 
 
___________________________________  ___________________________ 
Signature       [CONTACT_331299] P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 11 
 
Protocol Title:  Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-
Derived Ex Vivo Expande d Stem and Progenitor Cells, in Patients with Hemoglobinopathies  
 
Clinical Phase    Pi[INVESTIGATOR_331159]:     GC P #02.01.020  
 
Amendment Number:   VI 
 
Dated:      December 1 3, 2017 
1. INVESTIGATOR’S AGREEMENT  
I have carefully read the foregoing protocol including all appendice s and agree that it contains all 
the necessary information for conducting the study safely.  
 
I will conduct this study in strict accordance with this protocol and according to the current GCP regulations and will a ttempt to complete the study within the de signated time frame . 
 I will provide copi[INVESTIGATOR_331160] -clinical and prior 
clinical experience submitted by [CONTACT_331235]. I will discuss this infor mation with them to ensure that they are adequately informed 
regarding the drug and conduct of the study.  
 I agree to keep records on all subject information (CRFs, shipment, and all other information collected dur ing the study) in accordance with the curr ent GCP and local regulations.  
  
  
Principal Investigator’s Name   
 
  
[CONTACT_331300] P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 12 
2. STUDY SYNOPSIS  
Protocol Number  
GC P# 02.01.[ADDRESS_409492]®, Umbilical Cord Blood -Derived Ex Vivo 
Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies  
 Number of Centers and Planned Geographical Distribution Up to [ADDRESS_409493]
® is a cryopreserved stem/progenitor cell -based product comprise d of:  
1) Ex vivo expanded umbilical cord blood -derived hematopoietic CD34+ progenitor  cells (NiCord® 
cultured fraction (CF)).  
2) The non-cultured cell fraction of the same CBU (NiCord® Non-cultured Fraction (NF))  consisting 
of mature myeloid and lymphoid cells .  
Both fractions, i.e. , NiCord® CF and NiCord® NF, will be kept frozen until the y are thawed and 
infused on the  day of transplantation.     
 In Part [ADDRESS_409494]
® will be administered to the patient in conjunc tion with a second, 
unmanipulated CBU.  
 In Part [ADDRESS_409495]
® will be  administered to the patient without  a second, 
unmanipulated CBU.  
 Study Duration  
Total study duration per patient is approximately [ADDRESS_409496] -transplant . 
 Study Objectives  
Part 1: The overall study objectives are to evaluate the safety and efficacy  of co- transplantation 
of NiCord
® and an unmanipulated CBU in  patients with Hemoglobinopathies  (Sickle Cell 
Disease ( SCD), or thalassemia major)  following myeloablative therapy.  
 Part 2: The overall study objectives are to evaluate the safety and efficacy  of transplantation of 
NiCord
® in patients with Hemoglobinopathies ( Sickle C ell Disease ( SCD ), or thalassemia major) 
following myeloablative therapy.  
 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 13 
Primary Objectives  
• Assessment of the acute toxicity associated with the infusion of NiCord®, within [ADDRESS_409497]-infusion  
• Part 1: Assessment of cumulative incidence  of donor -derived neutrophil engraftment by [CONTACT_4475] 
[ADDRESS_409498]® and unmanipulated c ord blood grafts  
• Part 2: Assessment of cumulative incidence  of donor -derived neutrophil engraftment by [CONTACT_4475] 
[ADDRESS_409499]®  
Secondary Objectives  
• Proportion of t ransplant -related  mortality at 100 days  
• Event -free survival at 100 days ( death, autologous recovery, primary or secondary graft 
failure will be considered events for this endpoint)  
• Overall survival at 180 days  
Exploratory Objectives   
• Incidence of  donor cell chimerism (>10%) from either donor  at 100 and 180 days  
• Percentage donor chimerism in whole blood, CD3+ and myeloid ( CD15+  or CD33+)  
fractions at 7, 14, 21, 28, 42, 70, 100,180 days  
• Time from infusion to neutrophil (>500/uL)  and platelet (>50 K/uL) engraftment  
• Incidence of p latelet engraftment (>50 K/uL) at 180 days  
• Incidence of a cute GvHD grade II -IV and III -IV at 100 days  
• Incidence of chronic GvHD (limited or extensive) at 180 days  
• Incidence of regimen -related  toxicity   
• Incidence of life -threatening and fatal infections  at 180 days  
• Immun e reconstitution at [ADDRESS_409500]-study Analysis  
• Event -free survival at 1 year  (death, autologous recovery, primary or secondary graft failure 
will be considered events for this endpoint)  
• Overall survival at 1 year 
• Percentage donor  chimerism in whole blood, CD3+ and myeloid (CD15+ or CD33+) 
fractions at 1 year  
• Incidence of chronic G vHD (limited or extensive) at 1 year  
• Incidence of life- threatening and fatal infections at 1 year  
• Immun e reconstitution at 1 year  
 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 14 
Study Hypothesis   
Part 1: Co -transplantation of NiCord® and an unmanipulated unrelated cord blood graft in 
patients with hemoglobinopathies (SCD, or thalassemia major) following myeloablative 
preparative therapy will be safe and will enable cord blood engraftment.   Part 2: Tra nsplantation of NiCord
® in patients with hemoglobinopathies (SCD, or thalassemia 
major) following myelo ablative preparative therapy will be safe and will enable cord blood 
engraftment.  
 Study Design  This is an open -label, non -randomized, interventional, single group assignment study of NiCord
® 
in patients suffering from hemoglobinopathies. In P art 1, the patients will be  transplanted both 
with NiCord® and an unmanipulated C BU. In P art 2, the patients will be transplanted with 
NiCord® only. 
 Once the best available cord blood units ( CBUs ) have been identified and the patient or legal 
guardian has signed the informed consent (IC), the patient will be screened for the study. The trial consists of four phases:  
 
(I) Eligibility/Screening  Phase  
Patient clinical assessment and eligibility review: [ADDRESS_409501] Blood Bank (CBB) to 
the production site  and received no later than two days before the start of production. 
 
 
(II) Baseline Phase  
Baseli ne clinical a ssessments: w ithin 4 weeks prior to start of conditioning regimen. 
Confirm patient suitability for transplant: 1 week prior to start of conditioning regimen . 
 
(III) Preparative and Conditioning Phase 
Once the patient is consented to the study and found to be eligible, the patient is started on 
hydroxyurea: 30mg/kg/day orally, beginning on day - 35 (may be extended if transplant is 
delayed) until one day prior to the start of conditioning.    In Part 1: The unmanipulated CBU will be shipped from the CBB to the clinical site prior to the 
initiation of conditioning.   
 

 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409502] of:  
• Busulfan:  
o For patients <21 years old:  1mg/kg/dose IV q 6h on days - 9 to - 6 for 16 doses   
o For patients >21 years old:  0.8mg/kg/dose IV q 6h on days - 7 to -4 for 16 
doses  
• Cycl ophosphamide :  
o For patients < 21 years old:  50mg/kg/day IV on days - 5 to -2  
o For patients >21 years old: 60mg/kg/day IV on days - 3 and - 2 
• Fludarabine:   
o For patients <21 years old:  35 mg/m2 IV daily x 5 days (days -14 through - 10)  
o For patients >21 years old: 35 mg/m2 IV daily x 5 days (days -12 through - 8) 
The GvHD prophylaxis regimen will be:  
• Mycophenolate Mofetil (MMF) : beginning day – [ADDRESS_409503] 45 days   
AND  
• Cyclosporine : beginning day - [ADDRESS_409504] day 180 
 
(IV) Transplantatio n and Post Transplantation Follow -up Phase  
NiCord® CF + NF and Infusion Solutions will be shipped to the clinical site before 
transplantation. 
 Day 0:  Part 1: Transplantation of  the unmanipulated CBU followed by [CONTACT_331236]
® with a minimal interval 
of four  hours between the infusions of the two units.  With regards to NiCord® infusion: the 
NiCord® CF will be infused first, followed by [CONTACT_331237]® NF starting no later than [ADDRESS_409505]® CF infusion.  
 Days +1 to +180: Post -transplant supportive care and fol low-up. 
 Throughout the study, all AEs, concomitant medications  and clinically significant procedures 
will be recorded  in both patient’s medical charts and CRF . 
 
Post-study Follow -up 
Clinical outcomes including secondary  graft failure, chronic GvHD , cardiac and pulmonary 
function tests, chimerism, Hb -electropheresis, incidence of life -threatening infections, immune 
reconstitution,  routine labs, vital signs, physical exam, performance scale, and survival status 
(including causes of death), will be collected from the center at six  months post study completion 
([ADDRESS_409506] transplantation), as per site practice.   
 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 16 
Number of Patient s  
Part 1: Up to f ifteen (15) patients who  are evaluable for the engraftment endpoint.   Part 1 will be 
closed to enrollment at the time that this amendment is approved. 
 Part 2: Up to five (5)  patients who are evaluable for the engraftment endpoint.  
 Inclusion Criteria  
1. Patients must be 2 – [ADDRESS_409507] for treatment of SCD  or thalassemia :  
a. Patient must have clinically severe SCD ( e.g., SS, SC or SBeta
0 Thal)  with at least one 
of the following clinical complications:  
• Recurrent painful events (at least 3 in the 2 years prior to enrollment) that cannot be 
explained by [CONTACT_331238]. Pain may occur in typi[INVESTIGATOR_331161] -
occlusive painful events and cannot be explained by [CONTACT_331239] . Pain lasts 
at least [ADDRESS_409508] occur despi[INVESTIGATOR_231066] 
(e.g., hydroxyurea therapy) . 
• Acute chest syndrome (ACS) with at least two epi[INVESTIGATOR_331162] d evelopment of a 
new infiltrate on chest radiograph and/or having a perfusion defect demonstrable on a 
lung ra dioisotope scan within the past two years that required hospi[INVESTIGATOR_059], oxygen 
therapy, and red blood cell (RBC) transfusion.  These epi[INVESTIGATOR_331163] (e.g., hydroxyurea therapy) .  At least one epi[INVESTIGATOR_331164].  
• Any combination of painful event s and ACS epi[INVESTIGATOR_331165]  
• SCD related an d clinically significant neurologic event (stroke or hemorrhage) or 
SCD related neurologic defect lasting more than 24 hours  
• Abnormal cerebral magn etic resonance imaging (MRI) and /or abnormal cerebral 
magnetic resonance angiography (MRA)  
• Abnormal Transcran ial Doppler (TCD), as defined by a TCD velocity that exceeds 
200 cm/sec by [CONTACT_11339]- imaging technique (or TCD measurement of >185 cm/sec by 
[CONTACT_331240]) measured at a minimum of two separate occasions one month 
or more apart  
• Patients on chronic PR BC transfusion therapy, defined as receiving 8 or more 
transfusions per year for > 1 year to prevent vaso- occlusive clinical complications 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 17 
(e.g., pain, stroke, and acute chest syndrome ), with a history of alloimmunization 
which compromises the delivery of adequate transfusion therapy 
OR; 
b. Patients with thalassemia major requiring ≥8 (or >100 ml/kg) RBC transfusions per year 
in the two years preceding enrollment . 
3. Part 1: Patients  must have two  partially HLA -matched CBUs. Units must be HLA -
matched at 4 -6/6 HLA class I (HLA -A & HLA- B, low resolution) and II (HLA -DRB1, 
high resolution)  loci with the subject and 3- 6/6 HLA -A, B, DRB1  loci with each other 
(using same resolution of typi[INVESTIGATOR_007]).  Double mi smatch at any one locus (A, B, or DRB1) is 
not permitted . 
 Part 2: Patients  must have one  partially HLA -matched CBU. Unit must be HLA- matched 
at 4-6/6 HLA class I (HLA -A & HLA- B, low resolution) and II (HLA -DRB1, high 
resolution) loci with the subject . Dou ble mismatch at any one locus (A, B, or DRB1) is 
not permitted . 
a. For patients weighing ≥ [ADDRESS_409509] a pre -
cryopreserv ed (post processing)  total nucleated cell dose of ≥1.8x109 and 
≥1.8x107cells per kg body weight .  
For patients weighing < [ADDRESS_409510] a pre -
cryopreserved  (post processing) total nucleated cell dose of ≥1.6x109.  
Part 1 : The unmanipulated CBU should contain a pre -cryopreserved  (post 
processing) , nucleated cell dose of at least 3.5x107/kg.  T he better matched unit 
will be the  unmanipulated unit (as per inves tigator’s discretion).   
b. The manipulated CBU should contain a pre -cryopreserved  (post processing) , total 
CD34+ cell count  of ≥ 8x106 for patients weighing ≥ 25 kg and a pre -
cryopreserved  (post processing) , total CD34+ cell count  of ≥7x106 for patients 
weigh ing < [ADDRESS_409511] undergone volume reduction (both plasma and 
red blood cell depletion) prior to cryoprese rvation .   
d. The CBU should be procured from a public bank that meet s local applicable 
regulations.  
e.  The selected units should be typed twice ( i.e., initial typi[INVESTIGATOR_331166]). Verification typi[INVESTIGATOR_007] (confirmatory typi[INVESTIGATOR_007])  should be in a laboratory  that is 
ASHI/EFI accredited and must come from an attached segmen t. 
4. Patients’  Performance score ≥70% by [CONTACT_331241]  
5. Patient has sufficient physiologic reserves including:  
• Cardiac: Left ventricular ejection fraction (LVEF) > 50% by [CONTACT_331242] ; or LV shortening fra ction > 26%  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 18 
• Pulmonary: Pulse oximetry with a baseline O2 saturation of ≥ 85% is required for all 
patients ; DLCO > 60% of predicted for age (corrected for hemoglobin) for patients in 
whom pulmonary function testing can be performed.  cDLCO value should be f rom 
testing performed before the administration of a bronchodilator if applicable.   FVC 
and FEV1 > 60% of predicted for age. 
• Renal: Serum creatinine ≤ 1.5 x upper limit of normal for age and GFR > 100 mL/min/1.73 m
2.  For patients ≥16 years of age, GFR should be >70 mL/min/1.73 m2.  
Note, estimated G FR value not acceptable; nuclear GFR testing must be performed.  
• Hepatic: Serum conjugated (direct) bilirubin < 2 x upper limit of normal for age as 
per local laboratory in the absence of gall bladder disease or prior cholecystectomy; 
Hepatic transaminases (ALT and AST) < 5 x upper limit of normal range  
6. In SCD patients,  HbS should be ≤ 45% within 7 days prior to initiation of conditioning 
regimen .  If the HbS level is >45% then the patient must receive RBC transfu sions or 
erythrocyte exchange prior to conditioning regimen  initiation.  
7. Patient must have at least one graft source as a backup in case of graft failure:  
a. Autologous stem cells harvested from bone marrow ; OR  
b.  A related, haplo -identical family member who is  suitable for bone marrow or 
peripheral blood stem cell donation and has agreed to do so in the event of graf t 
failure; OR  
c. An additional HLA -matched CBU, or two CBUs, reserved as a backup.  
8. Females of childbearing potential, defined as any female who has experienced menarche and is not postmenopausal or permanently sterilized ( e.g., tubal occlusion, hysterect omy, 
bilateral salpi[INVESTIGATOR_1656]), agree to use an appropriate method of contraception from at 
least 7 days prior to Hydroxyurea administration until comple tion of follow -up 
procedures.  An appropriate method of contraception is defined as one that results in a 
low failure rate ( i.e., less than 1 percent per year) when used consistently and correctly, 
such as implants, injectables, combined oral contraceptives, some intrauterine 
contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner . 
9. Patient a nd/or legal guardian signs the written informed consent after being made aware 
of the nature of the patient’s disease and willingly consents to the tr eatment program after 
being informed of alternative treatments, potential risks, benefits, and discomforts . 
 
Exclusion Criteria  
1. Evidence of uncontrolled bacterial, viral or fungal infections  or severe concomitant 
diseases, which in the judgment of the Prin cipal Investigator, indicate that the patient 
could not tolerate transplantation.  
2. Evidence of HIV infectio n or HIV positive serology . 
3. Evidence of active Hepatitis B  or Hepatitis C as determined by [CONTACT_331243] . 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 19 
4. Pregnancy as indicated by a positive serum  human chorionic gonadotrophin (HCG) test  
or lactation . 
5. Patients with 8/[ADDRESS_409512]® CBU 
(MFI> 2000 to HLA A, B, C, or DRB1 ). 
8. Prior myeloablative allogeneic hematopoietic stem cell transplant within last [ADDRESS_409513] which may interfere with the 
treatment.  
10. Psychologically i ncapable of undergoing bone marrow transplant (BMT) with associated 
strict isolation or documented history of medical non- compliance and/or p sychiatric 
illness and/or s ocial situations that would limit compliance with study requirements . 
11. Enrolled in anothe r clinical trial or received an investigational treatment within 30 days 
prior to CBU shipment to the production facility , unless documented approval obtained 
from Sponsor . 
 
Statistical Considerations   
The data from Part 1 and Part 2 will be analyzed separately.  A secondary analysis combining the 
data will  be provided; this combined analysis will also present the results f rom each part 
separately.  
 
Primary End -point and Principal Analysis : Cumulative incidence  of donor -derived neutro phil 
engraftment by [CONTACT_4475] 42. Time -to-neutrophil engraftment is defined as the first of three ( 3) 
consecutive measurements on different days that the patient has an absolute neutrophil count 
(ANC) greater than , or equal to , 500 /uL following conditioning regi men-induced nadir . The 
ANC recovery must be of donor origin documented by [CONTACT_331244] : 
a. Mixed chimerism – > 10% host cells  and <90% host cells    
OR 
b. Donor  chimerism – < 10% host  cells  
 
Interim Analysis and Safety Assessment Guidelines:  
Part 1: The data emerging from this study will be reviewed by [CONTACT_3153].  In Part 1, this committee will review the accumulated data after 3 6 (and 1 0, if still recruiting) patients 
have entered the study and have been assessed at day 100 following the transplant. The 
committee will make recommendations to the Sponsor regarding early stoppi[INVESTIGATOR_331167].  
  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 20 
Early safety assessment guidelines will be used to monitor the following events, and alert the 
DMC. The following events will prompt consideration of early stoppi[INVESTIGATOR_331168]:  
• Serious (grade 4  or 5) acute  toxicities: if ≥[ADDRESS_409514] 7 or ≥[ADDRESS_409515] 14 
patients experien ce grade 4 or 5 acute toxicity  
• Neutrophil engraftment: if ≥[ADDRESS_409516] 5 patients or ≥[ADDRESS_409517] 8 patients or ≥[ADDRESS_409518] 11 patients or > [ADDRESS_409519] 14 patients fail to achieve neutrophil engraftment 
(from either NiCord®, the unmanipula ted CBU or both).  Additionally, early 
consideration will be given by [CONTACT_331245] [ADDRESS_409520] 2 patients fail to engraft  
• Secondary graft failure: If ≥[ADDRESS_409521] 5 patients, ≥[ADDRESS_409522] 8 patients, or ≥[ADDRESS_409523] 11 patients or >[ADDRESS_409524] 14 patients experience secondary graft failure, as 
defined in section 4.3.2  
• Treatment -related mortality at 100 days:  if ≥[ADDRESS_409525] 5  patients or ≥ [ADDRESS_409526] 8 patients or ≥ [ADDRESS_409527] 11 patient s or > [ADDRESS_409528] 14 patients  die before 
100 days from treatment -related causes 
 
Part 2:  The data emerging from Part [ADDRESS_409529]® as a standalone graft and have been 
assessed at day [ADDRESS_409530]® recipi[INVESTIGATOR_841].   
 Early safety assessment guidelines will be used to monitor the following events, and alert the DMC. The following events will prompt consideration of early stoppi[INVESTIGATOR_331169] 2 : 
• Serious (grade 4  or 5) acute  toxicities: if [ADDRESS_409531] 1, or ≥[ADDRESS_409532] 5 
patients experience grade 4 or 5 acute  toxicity  
• Neutrophil engraftment: if [ADDRESS_409533] 2, or ≥[ADDRESS_409534] patient fails  to engraft  
• Secondary graft failure: if [ADDRESS_409535] 2, or  ≥[ADDRESS_409536] 5 patients experience 
secondary graft failure, as defined in s ection 4.3.2 
• Treatment -related mortality at 100 days:  if [ADDRESS_409537] 2, or  ≥[ADDRESS_409538] 5 patients 
die before 100 days fro m treatment -related causes 
 
Statistical Notes   
The guidelines in Part 1 and 2 are formulated so that an alert will occur if the posterior 
probability is sufficiently high that the chance of an e vent exceeds a given threshold. 
Specifically:   
• Acute  toxicity:  posterior probability that chance of grade 4 or 5 acute toxicity is greater 
than 5% exceeds 0.95. Prior distribution: Beta (0.05, 0.95). 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 21 
• Neutrophil engraftment: posterior probability that chance of no neutrophil engraftment is 
greater than 20% exceeds 0.9 5. Prior distribution: Beta (0.2, 0.8). 
• Secondary Graft Failure : posterior probabi lity that chance of secondary graft failure  is 
greater than 20% exceeds 0.95. Prior distribution: Beta (0.2, 0.8). 
• Treatment -related mortality: posterior probability that cha nce of treatment -related 
mortality within 100 days of transplant is greater than 20% exceeds 0.95. Prior distribution: Beta (0.2, 0.8). 
 
 
 
GC P#02.01.020   Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol     Page 22 

 
 
GC P#02.01.020   Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol     Page 23 

 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 24 
3. BACKGROUND AND RATIONALE  
3.1. Overview   
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially cura tive procedure 
for a number of hematologic malignancies, non -malignant hematologic diseases, bone marrow 
failure syndromes and inherited metabolic disorders. The application of allogeneic HSCT is limited by [CONTACT_331246] -matched family  donors. Alternative donors include 
mismatched family members or matched unrelated donors, but these approaches are often complicated by [CONTACT_331247] -versus -host disease (GvHD) or prolonged and 
cumbersome search and procurement processes. In addition, far fewer subjects of racial minorities find suitable HLA -matched donors.  
 Umbilical C ord B lood (UCB)  has been increasingly used as an alternative source of stem cells; 
however, in nearly every large single center or registry analysis of outcomes  after umbilical cord 
blood transplantation ( UCBT) , cell dose is identified as an important factor influencing the 
incidence and rate of hematopoietic recovery, risk of transplant- related mortality (TRM) and 
probability of survival and therefore, is a key hurdle precluding broader use of this potentially beneficial stem cell source.  
 To improve outcomes and extend applicability of UCBT , one potential solution is ex vivo 
expansion of UCB -derived stem and progenitor cells.  
 Gamida Cell Ltd. is engaged in the development of NiCord
®, an expanded hematopoietic UCB -
derived stem /progenitor cell graft, as a potential medicinal product for the treatment of subjects 
with high- risk hematological malignancies.  
 The manufacturing of the fresh and the cryopreserved NiCord
® cultured fraction is  exactly the 
same apart for the re- suspension on the la st manufacturing day , the cryopreservation and the 
suspension before transplantation. The cryopreservation of NiCord® allows flexibility in the 
planning and timing of transplantat ion, to accommodate the patient’s disease status and any 
changes required, as resulting from the patient’s medical condition.  
3.2. Sickle cell disease morbidity and mortality  
 SCD is an autosomal recessive genetic disease caused by a single mutation in the bet a globin 
gene, which leads to a multitude of pathophysiologic changes includi ng sickling of hemoglobin 
and vasculopathy resulting in a clinically heterogeneous multisystem disease.
[ADDRESS_409539] – a single amino acid su bstitution (glutamine replaced by [CONTACT_331248]) at the sixth 
position of the β -globin chain of hemoglobin A ( β6 glu  val).[ADDRESS_409540] 
common inherited disorders  worldwide. SCD affects 1 in every 400 African- American live births 
translating into a prevalence of 70,000 in the U.S. alone , and over 50,000 in Europe . When sickle 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 25 
hemoglobin (hemoglobin S) is deoxygenated, it aggregates into large polymers, leading to distortion in shape and rigidity of red cells, which in turn is responsible for vaso- occlusion, the 
hallmark of pathophysiology. Vaso- occlusi on underlies the development of symptoms in various 
target organs including but not limited to the central nervous s ystem, lungs, bones, joints, 
kidneys, and eyes. The most catastrophic clinical syndrome is the development of cerebral infarction. Cerebrova scular accidents, including cerebral infarction (ischemic stroke) and 
cerebral hemorrhage (hemorrhagic stroke) are a  leading cause of death in children and adults 
with SCD. Nearly 10% of patients have a stroke by 20 years of age. In addition, silent stroke  is 
also prevalent in 20% of patients with SCD. Once patients have an epi[INVESTIGATOR_331170], recurrent strokes are commo n in two- thirds of patients without intervention. Other serious complications 
of SCD include chronic lung disease, pulmonary hypertension and cor pulmonale (as a result of recurrent acute chest syndromes), severe vaso -occlusive painful crises, and osteonec rosis of 
bones and joints. Children with SCD are also known to have cognitive impairments because of overt or often, silent strokes. These m orbidities significantly decrease the quality of life and also 
predict a more severe phenotype, such as development of stroke and recurrent acute chest syndromes .
6, 7, [ADDRESS_409541], 
it still represents a decrease in life span by 2 -3 decades as compared to the general population. 
Furthermore, patients often ar e medically and psychologically debilitated from the years of 
chronic problems occurring from childhood and frequently cannot become self -sufficient 
productive members of society as young adults. Taken together, the morbidity and mortality 
related to SCD  represent a public health burden of great magnitude.  
3.3. Conventional approaches and their limitations  
Chronic transfusion has been shown to decrease the risk of recurrent strokes and even employed 
in primary stroke prevention.12, 13 However, de spi[INVESTIGATOR_331171], approximately 
20% patients developed a second stroke in one study.[ADDRESS_409542] well- known of which are iron 
overload, alloimmunizati on, alle rgic reactions and infections. Hydroxyurea has also been shown 
to ameliorate some disease manifestations in some patients with SCD.16 However, many patients 
do not r espond to hydroxyurea and the role in stroke prevention is unclear. Thus, neither c hronic 
transfusions nor hydroxyurea represent a curative therapy for sickle cell anemia.  
3.4. Role of Hematopoietic stem cell transplantation (HSCT) 
HSCT is the only therapy dem onstrated to be curative for patients with SCD. Studies from 
Belgium, [LOCATION_009], and t he U.S. have shown that HSCT from HLA -identical or matched related 
donors  (MRD), using bone marrow or cord blood as graft source, and myeloablative 
conditioning (MAC) consis ting of busulfan, cyclophosphamide and ATG (Bu/Cy/ATG) is 
associated with event -free survival of 80- 85% in pa tients with SCD.17, 18, 19, 20 Further analysis 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409543] for SCD is the lack of HLA -identical related or 
non-related donors. HLA -identical related donor s are available for only 10 -20% of the patients 
and there are no reports of matched unrelated donor H SCT likely because of the difficulty 
finding a suitable matched unrelated donor for SCD patients .
[ADDRESS_409544] blood (CB) transplantation are remarkable but the chances of finding a 
related HLA -identical CB unit are no  better than that of finding an HLA -matched sibling. 
Available data involving the use of mismatched unrelated CBT indicates primary graft failure 
and GvHD as a major concern .[ADDRESS_409545] at leas t a 4/6 HLA -matched donor available.  
3.4.2. Hematopoietic stem cell transplantation for patients with thalasse mia  
Allogeneic hematopoietic stem cell transplantation (HSCT) still remains the only potentially curative treatment for patients with thalassemia, which  represents the most frequent inborn 
genetic disorder in the Mediterranean countries.
[ADDRESS_409546] a worse outcome than children, the probability of survival with transfusion 
independence having been reported to be 58%;
29 among children below the age of 17, three 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409547] recent update of the Pesaro group’s 
experience, the probability of thalassemia -free survival of patients younger than 17 years at time 
of bone marrow transplantation ( BMT ) who received the allograft from an HLA -identical 
relative and belongi ng to class I and II was 87% and 85%, respectively.30. Worse results hav e 
been reported in pediatric patients who had low compliance with iron chelation favoring the occurrence of iron -induced organ damage, in whom the probability of thalassemia -free survi val 
was initially reported to be 53%. Reducing the dosage of cyclophosphamide, used together with busulfan in the preparative regimen of these patients, it has been possible to document a lower incidence of transplant -related mortality for children in clas s III, which remained, however, in 
the order of 25% .
[ADDRESS_409548] for the cure of thalassemia is represented by 
[CONTACT_331249], whose incidence is considerably higher than that observed in patients transplanted for leukemia.
30, 31 Several factors may contribute to the occurrence of this complication, 
including avoidance of any immunosuppressive or myeloablative treatment be fore 
transplantation, possible allo -immu nization related to erythrocyte transfusions and large spleen 
size, especially in older patients. Notably, in patients transplanted from an HLA -identical sibling, 
the incidence of rejection is directly correlated  with the patient’s class of risk, an incidence of 
4%, 8% and 12% being observed in patients belonging to risk class I, II and III, respectively.30, 31 
 
Stable mixed chimerism is also not uncommon among patients transplanted for thalassemia from 
a compatible sibling,35 as seen also in pat ients with acquired aplastic an emia following BMT.36 
Patients with thalass emia developi[INVESTIGATOR_331172], even with a low percentage of donor 
marrow progenitors (20 -30%), have been reported to experience marked enrichment for donor 
cells in the mature red blood cell compartment, which makes them transfusion -independent .35 
This observation has provided a strong biological and clinic al rationale for considering the use of 
reduced -intensity preparative regimens in patients with t halassemia. Thalassemia patients with 
liver/heart damage could represent the ideal candidates for well- controlled, clinical trials of less 
toxic conditioning r egimens by [CONTACT_331250]. So far, few reports have 
demonstrated the feasibility of using reduced -intensity preparative regimens (which may also 
help reduce the incidence of late effects, in particular those concerning growth and fertility, 
resulting from high -dose chemotherapy used for conventional HSCT) for successfully treating 
patient s with haemoglobinopathies.37, 38, 39, 40 Although transplant -related toxicity was mild in all 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409549] been explorations i nto 
the use of alternate hematopoietic grafts, to include allogeneic unrelated UCB.
41, 42, 43 UCB, the 
residual baby’s blood in the placenta, is a by- product from childbirth that historically had been 
discarded.  Experimental studies have demonstrated that UC B is enriched in primitive 
hematopoietic progenitors compared with adult bone marrow (BM) and mobilized peripheral blood stem cell grafts (PBSC).  Notably, long -term engrafting cells are almost eightfold enriched 
among UCB CD34+ cells compared to those in CD34+ cells from PBSC. These biological 
features may well explain the curious clinical fin ding that despi[INVESTIGATOR_040] a slower pace of myeloid 
engraftment after UCB transplantation there is a higher prevalence of early progenitors in the 
marrow space in those childr en who were given UCB as opposed to BM transplant .
[ADDRESS_409550]. Unrelated 4/6 HLA -matched UCBT is an acceptable stem cell 
graft for patients with hematological malignancies for whom matched related or unrelated  donors 
are not available. The main drawback of UCBT result from the relatively low dose of total 
nucleated cells and CD34
+ cells within an umbilical cord  blood unit.  Infusion of high cell dose 
relative to the size of the patient strongly correlates with time to engraftment and probability of overall engraftment and thus, survival .
[ADDRESS_409551] years and rate of successful engraftment is relatively high 
in patients transplanted with an adequate cell dose of 2.5- 3x106/kg. However, delayed 
hematopoietic recovery still substant ially contributes to increased morbidity and transplan t-
related mortality .46 For patients without a single UCB unit with adequate cell dose, double 
UCBT is an acceptable alternative.47 Yet, the problem of delayed hematopoietic recovery 
persists and the risk of GvHD is increased.   
3.4.4. UCB in hemoglobinopathies: in creased graft failure – a function of lower cell 
dose  
Unrelated CBT has been used in a limited number of patients with hemoglobinopathies and with limited success so far. Cell dose is even more critical for the successful of UCBT in SCD and thalassemia patients . It has been reported that cell dose of the UCB graft is an independent 
predictor of engraftment and subsequent event -free survival in hard to engraft patients. 
Combined registry data from Eurocord, CIBMTR and [LOCATION_001] Blood Center on patients with hemoglobinopathies undergoi ng UCBT was recently published.
[ADDRESS_409552] undergone a n unrelated UCB transplant. 
Patients with SCD had an overall survival probability of 94%, but only 50% event -free survival. 
Seven of 16 SCD patients received a reduced -intensity conditioning. Primary graft failure was 
the predominant cause of treatment failure occurring in 7 of 16 patients with SCD and 20 of 35 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 29 
patients with thalassemia. In  multivariate analysis of the overall cohort, engraftment rate and 
EFS were higher with cell dose >5 x 107/kg. The 2- year probability of EFS was 45%  in patients 
who received grafts with cell dose >5 x 107/kg and 13% with lower cell dose. These results 
highlight the critical importance of adequate cell dose in patients with hemoglobinopathies 
undergoing unrelated UCB transplants and suggest more successful results to be obtained by 
[CONTACT_331251] U CB gr aft. 
3.4.5. Strategies to augment cell dose: use of dual UCB grafts  
With the realization of critical importan ce of cell dose in engraftment and survival af ter single 
UCBT, and with the aim of increasing the cell dose for adults and adolescents who could not find 
a single cord with adequate cell dose, transplantation was performed in adults with hematologic malignancies with a combination of 2 UCB units that were partially HLA -matched with the 
recipi[INVESTIGATOR_841] (4 -6/6 HLA match) and with each other .
[ADDRESS_409553] approach in children 
with hematologic maligna ncies for whom a single unit containing ≥2.5 x 107nucleated cells/ kg 
matched at zero, one or two HLA -loci is available.   Double UCBT  however remains a suitable 
alternative in the absence of an adequatel y dosed single UCB unit in children with hematologic 
malignancies . 
 
Importantly, despi[INVESTIGATOR_331173], time -to-neutrophil and platelet 
engraftment (engraftment kinetics) and engraftment rates appear to be comparable between 
single and double CBT .50 Thus the use of DCBT does not appear to improve the hematopoietic 
recovery following transplantation and the risk of GvHD is increased . 
 Another confounding topic to consider is that i n DCBT usually only one of the two CBUs 
engraft s. Early after transplantation  (day 21) both CBUs  contribute to hematopoiesis in 40–50% 
of patients, but by [CONTACT_4475] 100, one CBU predominates in the vast majority of patients
[ADDRESS_409554] demonstrated that early CD3+ PB chimerism predicts 
the long -term engrafting CBU following myeloablative DCB T. The correlation of higher early 
post-transpl ant donor CD3+ PB chimerism with the dominant CBU suggests a rapid immune 
mediated response as a primary mechanism of action for long -term single donor dominance. In 
vivo53 and in vitro54 studies also suggest that t he predominant CB U in the setting of double CBT 
is the CBU able to develop a prevalent cytotoxic activity directed against activated lymphocytes 
and HSC graft of the other CB U. It is therefore possible that a discordant dominance between the 
two CBUs , in terms of stem cell potency and graft -versus -graft alloreactivity, could result in 
graft failure, i.e., when the dominant CBU with respect to alloreactive capacity eradicates the 
CBU able to support a more efficient and robust hematopoietic engraftment .54  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 30 
3.4.6. Combining 2 UCB grafts: a newly emerging and successful strategy to augment cell dose  
With the realization of critical importan ce of cell dose in engraftment and survival after single 
UCBT, and with the aim of incr easing the cell dose for adults and adolescents who could not find 
a single cord with adequate cell dose, transplantation was performed in adults with hematologic malign ancies at University of Minnesota with a combination of 2 UCB units that were partially  
HLA- matched with the recipi[INVESTIGATOR_841] (4 -6/6 HLA match) and with each other .
55, 56, 57 Twenty -three 
patients with a median age of 24 years received 2 UCB units with a median infused cell dose of 3.5 x 10
7/kg after TBI- based myeloablative conditioning. Engraftment w as achieved in all 21 
evaluable patients at a median of 23 days. Mixed chimer ism was noted in 24% of patients at day 
21, however by [CONTACT_4475] 100, only one of the two units predominated. While a significantly higher CD3+ dose was noted in the predominating unit, this observation has not been confirmed in subsequent larger data from the s ame institution. Understanding the kinetics of engraftment with 
double UCBT is an area of active research.  Incidence of grade II GVHD was increased but not that of severe grades III-IV (13%). Disease -free survival was 57% at 1 year, with 72% of patients 
alive if they received transplants while in remission. With safety and feasibility of double UCBT 
demonstrated, increasing number of double UCBT have been performed at several inst itutions 
with similar observations – reproducible engraftment, low transplant  related mortality (TRM), 
and comparable progression free survival (PFS) .
58, [ADDRESS_409555] in pedia tric patients with high risk 
leukemia undergoing myeloablative conditioning, through the NHLBI/NCI -sponsored Blood and 
Marrow Transplant Clinical Trials Network (BMT CTN, Study 0501) has been completed .[ADDRESS_409556] approach in children with 
hematologic  malignancies for whom a single unit containing ≥2.5 x 10
7nucleated cells/ kg 
matched at zero, one or two HLA -loci is available.   Double UCB transplant however remains a 
suitable alternative in the absence of an adequately dosed single UCB unit in children with 
hematologic malignancies . 
3.5. Ex Vivo Expansion Of Cord Blood Cells  
Attempts to increase  the UCB graft cell dose and particularly the CD34+ progenitor cell dose by 
[CONTACT_236326]-vivo expansion led to numerous clinical trials addressing the clinical implications of 
expansion of an UCB unit using various methods of expansion ( Table  1). The double cord 
approach, used in those trials, serves as safe modality  for evaluatin g the safety and potential 
efficacy of graft manipulation.  
 
Laboratory studies characterizing the expanded cell populations have shown promise and some 
of the clinical trials may suggest more rapid hematopoietic recovery in UCB recipi[INVESTIGATOR_840].  
 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 31 
Table 1:  Methods of Expansion  
 
Summary of clinical trials evaluating UCB that has been expanded ex vivo  
3.5.1. Ex-Vivo Expansion by [CONTACT_331252], one method has been liquid c ulture, in whi ch UCB- derived 
progenitor cells (primarily CD133+ or CD34+) are cultured with combinations of cytokines growth factors, serum or serum free medium in various flasks, bags or containers. In the attempts to stimulate the proliferation of primitive hema topoie tic progenitors, various “ cocktails” of 
growth factors and cytokines were tested but the proper mixture has not yet been determined. Pre-clinical and clinical results with cytokine only expansion cultures were not satisfactory and 
prompted at tempts to furt her optimize ex vivo culture conditions
61, 62, 63, 64, 65, 66, [ADDRESS_409557] blood stem cells to 
shorten the time to hematopoietic recovery following myeloablative chemotherapy .72, 73 Myeloid 
engraftment oc curred at a median time of about 15- 16 days and pla telet engraftment at a median 
of about 40-42 days . This is accomplished by [CONTACT_331253] P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409558]
®, a novel product of ex vivo expanded CBU 
to be transplanted with or without a second, unmanipulated CBU. As discussed above, the 
incidence of neutrophil engraftment and time to engraftment following transplantation of either single large CB unit or doubl e CB units are still lower and delayed compared to BM or PB 
transplantations. By [CONTACT_331254]- term reconstitution progenitor cells 
transplanted, NiCord
® has the potential to ameliorate this limitation, enabling broader applicatio n 
of UCBT  in adults and adolescents, and improving the clinical outcomes of tr ansplantation.  
3.5.2. Gamida  Cell Expansion Technology 

 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 33 

 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 34 

 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409559]® as a single expanded CBU  
Ideally, a successfu l expansion technology would obviate the need for DCBT, and in most cases 
would enable the clinician to choose a single, best HLA- matched CBU for the patient. Most ex 
vivo expansion technologies are successful in expanding a subset of hematopoietic progenitor 
cells (HPCs), which  are expected to improve short- term early hematopoietic reconstitution ; while 
the main concern still remains for preser vation of long-term repopulating cells in ex vivo  
conditions106, 107, [ADDRESS_409560]® expansion technology, ex vivo  expansion studies have only been 
successful in demonstrating short- term early hematopoietic reconstitution.  
In light of the accumulated data from the ongoing NiCord® clinical program in hematologic 
malignancies, Part [ADDRESS_409561]® technology provides donor-derived engraftment in  patients  
with hemoglobinopathies following myeloablative therapy.  
The DCBT approach add s a measure of safety to the evaluation of novel approaches to ex vivo  
expansion. However, as previously described, the drawback of this strategy is that graft- versus -
graft immune interactions lead to the engraftment of one of the two CBUs transplanted and 
therefore potentially, the most potent CBU with respect to hematopoietic recon stitution may  be 
eradicated by [CONTACT_331255]. Furthermore, the use of DCBT has not demonstrated any improvement in the rates or kinetics of engraftment.  Current data suggest  that 
unrelated  CBT with NiCord
® may make it possible to choose the best CBU for the patient, 
expand it in culture and transplant it to the patient in a single CBT approach. 

 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409562]® as a standalone graft can rapi[INVESTIGATOR_331174]. S ubsequently, 
patients require a substantially shorter duration of hospi[INVESTIGATOR_331175] , which is 
consistent with more rapid recuperation. Available patient follow -up indicates a safe profile in 
terms of the robustness of engraftment, and the occurrence of GvHD, as compared to unmanipulated CBT despi[INVESTIGATOR_331176]. Moreover, the available data show that patients treated with NiCord
® are able to develop functional hematopoietic systems, 
with the development of myeloid  and lymphoid cells, supporting immune recovery. 
 As detailed in section  [IP_ADDRESS], a study of NiCord
® in hematological malignancies as a standalone 
graft source is  ongoing (GC P#03.01.020). The da taset that served as the basis for the NiCord® 
Phase III hematological malignancies study design comprised patients aged 12-[ADDRESS_409563]
® as a standalone graft. All [ADDRESS_409564]®-only recipi[INVESTIGATOR_331177] [ADDRESS_409565]
® transplant. The median days to neutrophil engraftment in 
NiCord® -only recipi[INVESTIGATOR_331178] [ADDRESS_409566]®-only recipi[INVESTIGATOR_840], the 
cumulative incidence of platelet engraftment to 20k/mm3 and 50k/ mm3 at [ADDRESS_409567] 
transplant was 75% and 64% respectively.  Among the engrafters, the median time to engraftment  to 20k/mm
3 and 50k/mm3 was 32 days and 42 days respectively. Immune 
reconstitution of CD4+, CD8+, CD19+, CD56+/16+ in NiCord®-only recipi[INVESTIGATOR_841] s was comparable 
to unmanipulated cord blood transplantation in historical controls. The overall survival of NiCord
®-only recipi[INVESTIGATOR_319233] 180 and 365 days was 81% and 59 % respectively , and th e cumulative 
incidence of non-relapse mortality at day [ADDRESS_409568] transplant was 12% and 19% respectively.   
Demonstration of successful, rapid and sustained engraftment of a single expanded CBU would 
obviate the need for the use of a second CBU, providing both potentially less GvHD and 
significant cost savings.  NiCord
® could potentially provide an accessible graft for allogeneic 
transplantation in patients with hemoglobinopathies who do not have a matched related  donor 
option, thereby [CONTACT_199740] a critical unmet need . 
3.7. Clinical Experience with  NiCord® and CordIn™   
 

 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409569]® Clinical Experience in Hematological Malignancies  
The clinical experience with NiCord® in Hematological Malignancies  is summarized in Table 2  
below. 
Table 2: Overview of o ngoing clinical studies of NiCord®  
Protocol Number 
(ClinicalTrials.gov 
Number)  Study Title  Study Status  Institution/Principal 
Investigator  
[CONTACT_27199] P#01.01.020  
([STUDY_ID_REMOVED]a) Allogeneic Stem Cell 
Transplantation of 
NiCord®, Umbilical Cord 
Blood-Derived Ex Vivo  
Expanded Stem and 
Progenitor Cells, in 
Combination With  a 
Second, Unmanipulated 
Cord Blood Unit in Patients 
With Hematological 
Malignancies  Complete  Duke University Health System/  
[CONTACT_331303] and [CONTACT_331304] ter, 
Loyola University/  
[CONTACT_331305]  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 38 
Protocol Number 
(ClinicalTrials.gov 
Number)  Study Title  Study Status  Institution/Principal 
Investigator  
[CONTACT_27199] P#03.01.020  
([STUDY_ID_REMOVED]b) Allogeneic Stem Cell 
Transplantation of 
NiCord®, Umbilical Cord 
Blood-derived Ex Vivo 
Expanded Stem and 
Progenitor Cells, in Adolescent and Adult 
Patients with 
Hematological 
Malignanc ies. Enrollment 
completed 
(estimated 
LPLV: Jun e 
2018)  Duke University Health System/  
[CONTACT_331306][INVESTIGATOR_331179] y 
Politécnico La Fe/ 
[CONTACT_331307]/  
[CONTACT_331308][INVESTIGATOR_70218] d'Hebrón/  
[CONTACT_187860] Valcárcel  
AOU San Luigi Gonzaga/ [CONTACT_331309]/ [CONTACT_331310]-Sinai Medical Center/ [CONTACT_331311]/ [CONTACT_331312] of Minnesota / [CONTACT_331313] l Bernardin Cancer Center,  
Loyola University/  
[CONTACT_331314] & Science 
University/ [CONTACT_331315][INVESTIGATOR_307]/ Liang Piu Koh  
Singapore General Hospi[INVESTIGATOR_307]/ 
William Hwang  
GC P#04.01.020/030  
([STUDY_ID_REMOVED]
c) 
 Long Term Follow Up for Patients who have received 
Allogeneic Stem Cell 
Transplantation of 
NiCord
®/CordIn™ , 
Umbilical Cord Blood -
derived Ex Vivo Expa nded 
Stem and Progenitor Cells. Ongoing  Duke University Health System/  
[CONTACT_331316]  and [CONTACT_331317] ital Universitario y 
Politécnico La Fe/ 
[CONTACT_331318][INVESTIGATOR_70218] 
d'Hebrón/  
[CONTACT_187860] Valcárcel  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 39 
Protocol Number 
(ClinicalTrials.gov 
Number)  Study Title  Study Status  Institution/Principal 
Investigator  
[CONTACT_27199] P#05.01.020  
([STUDY_ID_REMOVED]d) 
A Multicenter, Phase III, 
Randomized Trial of 
Transplantation of NiCord
®, Umbilical Cord 
Blood-derived Ex Vivo 
Expanded Stem and 
Progenitor Cells, versus 
Unmanipulated Umbilical 
Cord Blood for Patients 
with Hematological 
Malignancies  Ongoing  Duke University Health System/  
[CONTACT_331306][INVESTIGATOR_331179] y Politécnico La Fe/ 
[CONTACT_331318][INVESTIGATOR_331180] 
d'Hebrón/  
[CONTACT_187860] Valcárcel  
Cleveland Clinic/ [CONTACT_331312] of Minnesota / [CONTACT_331319] din Cancer Center, 
Loyola University/  
[CONTACT_331320]/ [CONTACT_331321]/ [CONTACT_331322] of Kansas Cancer 
Center/ [CONTACT_98702] McGuirk  
a http://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=nicord&rank =1. 
b https://clinicaltrials.g ov/ct2/show/[STUDY_ID_REMOVED]?term=nicord&rank=4  
c https://clinica ltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=Gamida+Cell+ltd&rank=6  
d https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=Gamida+Cell+ltd&rank=5  
The subsequent sections describe the clinical studies mentioned above.  
[IP_ADDRESS]. Study GC P#01.01.[ADDRESS_409570]® in hematological malignancies in combination with a second, 
unmanipulated CBU was completed (GC P#01.01.020). This is a single arm pi[INVESTIGATOR_331181] -transplantation of NiCord® and an unmanipulated CBU to patients 
with hematological malignancies following myeloablative therapy.  
 Patients under the age of [ADDRESS_409571] 2.5x10
7 total nucleated cells per 
kilogram of the recipi[INVESTIGATOR_841]’s body weight. This unit was designat ed as the unmanipulated unit. The 
second unit, designated for NiCord® expansion, contained at least 1.5x107 total nucleated cells 
per kilogram of the recipi[INVESTIGATOR_841]’s body weight. When [ADDRESS_409572] 2.5x107 total nucleated 
cells per kilogram of the recipi[INVESTIGATOR_841]’s body w eight were available, the best -matched unit was 
assigned as the unmanipulated unit. The cord blood units were required to match the recipi[INVESTIGATOR_331182] P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 40 
4 or more HLA loci by [CONTACT_331256] -resolution typi[INVESTIGATOR_331183] I alleles (A and B) and 
high- resolution typi [INVESTIGATOR_331184]1 alleles.  
 The bone marrow  conditioning regimen consisted of 1,350- cGy TBI delivered in 9 fractions on 
days –9 to – 5, and fludarabine 40 mg/m
2 was given on days – 5 to –2 of the transplantation. An 
optional infusion of 60 mg/kg cyclo phosphamide on days –4 and –3 was given at the discretion 
of the managing physician. GvHD prophylaxis was provided by T acrolimus and M ycophenolate 
Mofetil starting 4 days before transplantation. Mycophenolate Mofetil and Tacrolimus were 
conti nued for a minimum of 60 days and 6 months following transplantation, respectively.  
Main results are described below  and in the Clinical Study Report . 
 Efficacy: Twelve patients were enrolled  and transplanted. Eleven of the twelve transplanted 
patients achieved neutroph il engraftment with full donor chimerism (<10% host chimerism). 
Eleven  of the twelve transplanted patients were evaluable (one patient received an 
unmanipulated CBU transplant instead of  NiCord
®). The median days to neutrophil engraftment 
in NiCord® recipi [INVESTIGATOR_331185] 12.[ADDRESS_409573]® recipi[INVESTIGATOR_331186]® as the 
predominating donor source was 10.5 days, ranging from 7 days to 18 days. In comparison, 
historical reports of unmanipulated CB transplants estimate the median days to engraftment at 
23-27 da ys with a range of 13- 80 days.110,111,112. In a  historical contro l group of 17 patients who 
received unmanipulated DCBT with the same conditioning regimen  at the same transplant 
center, median time to engra ftment was 25 days (range 13 -38).113  
 
All engrafted patients maintained ful l donor chimerism throughout follow -up. Seven patients 
maintained predominance (>90%) of NiCord® cells, three patients maintained predominance of 
unmanipulated CBU cells (including one who did not receive NiCord®), and one patient 
exhibited mixed chimerism  throughout follow -up.  
 
Platelets e ngraftment was achieved in nine out of eleven patients who received NiCord®. One 
patient died before achieving platelet recovery and one patient experienced primary engraftment 
failure. The median time to platelet engraftment to 20,000/mm3 was 33 days (ran ge 26 -49 days) 
for all patients transplanted with NiCord® and 30 days (range 26- 41) for the [ADDRESS_409574]®. The median days for platelet recovery to 50,000/mm3 
in patients achieving engraftment were [ADDRESS_409575] -transplantation also demonstrated the 
recovery of all blood cell lineages including CD3, CD4 and CD8 (T cell s), CD19 (B cells) and 
CD56 (NK cells). Immune reconstitution was similar for patients engrafting with the NiCord
® 
unit compared to those engrafting with the unmanipulated CBU.  
Safety:  There was no grade 4 infusion toxicity. Three patients had a  grade 3 t oxicity ( two with 
hypertension and one with hematuria), two patients had grade [ADDRESS_409576] infusion.  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409577]® recipi[INVESTIGATOR_331187]. Five of eleven NiCord® recipi[INVESTIGATOR_331188]. A total of 14 Serious Adverse Events (SAEs) were reported in eight 
of the eleven NiCord® recipi[INVESTIGATOR_840]. One of the 14 SA Es (grade 3 hypertension immediately 
following infusion) was determined to be related to NiCord®. 1-year overall and progression- free 
survival rates were 82% and 73%, respectively.  
 Conclusions:  Infusion of NiCord
® was well tole rated and provided rapid short -term engraftment 
as well as stable, long -term multi- lineage hematopoiesis. The results of this study warranted 
further studies of NiCord® as a solitary graft source.  
[IP_ADDRESS]. Study GC P#03.01.[ADDRESS_409578]® in hematological malignancies as a standalone graft source is 
ongoing (GC P#03.01.020). This is a single arm study to evaluate the ability of NiCord® to 
provide durable engraftment as a single graft source in patients with hematological malignancies 
following condi tioning therapy.  
 The data set that served as the basis for the NiCord
® Phase III hematological malignancies study 
design comprised patients aged 12- [ADDRESS_409579] 8x106 total CD34+ cells  as well as a pre- cryopreserved 
(post -processing) total nuclea ted cell count of ≥1.8x109, and total nucleated cell dose ≥1.5x107 
TNC/kg . The cord blood unit was required to match the recipi[INVESTIGATOR_166585] 4 or more HLA loci by 
[CONTACT_331256] -resolution typi[INVESTIGATOR_331189] I alleles (A and B) and high -resolution typi[INVESTIGATOR_331190]1 alleles.  
 
Multiple conditioning regimens were used, including TBI/Flu/±Cy and Thiotepa/Bu/Flu.  GvHD prophylaxis was provided by [CONTACT_331257] l starting 
three days before transplantation. Mycophenolate Mo fetil and Tacrolimus/Cyclosporine were 
continued for a minimum of 60 days and 5 months following transplantation, respectively.  
 Main results are described below.  
 Efficacy : Eighteen patients receiv ed NiCord
® ([ADDRESS_409580]®-only recipi[INVESTIGATOR_331191]® and the backup CBU) . All [ADDRESS_409581]®-only recipi[INVESTIGATOR_331192] [ADDRESS_409582]
® -only recipi[INVESTIGATOR_331178] [ADDRESS_409583]®-only recipi[INVESTIGATOR_840], the cumulative incidence of platelet engraftment to  20k/mm3 and 
50k/mm3 at [ADDRESS_409584] transplant was 75% (95% CI: 43- 91) and 64% (95% CI: 32 -84) 
respectively .  Two patients died prior to day 100 without 20k/mm3 platelet engraftment, one 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 42 
patient failed to engraft platelets at 20k/mm3 by [CONTACT_4475] 100, two pat ients engrafted 20k/mm3 but not 
50k/mm3 by [CONTACT_4475] 100, and one patient was pe nding engraftment at last follow -up of [ADDRESS_409585] 
transplant.  Among the engrafters, the median time to engraftment to 20k/mm3 and 50k/mm3 was 
[ADDRESS_409586]
®-only recipi[INVESTIGATOR_319233] 180 and 365 days was 81%  (95% CI: 51 -93) 
and 59% (95% CI: 25 -82) respectively.   
 
Immune reconstitution of CD4+, CD8+, CD19+, CD56+/16+ in NiCord®-only recipi[INVESTIGATOR_331193].  
 
Safety: Only one patient experienced secondary graft failure in the year following NiCord® 
transplant.   
 For NiCord
® alone recipi[INVESTIGATOR_840], the cumulative incidence of non- relapse mortality at d ay [ADDRESS_409587] transplant was 12% (95%CI: 2- 34) and 19% (95%CI: 4- 42) respectively.  
 The incidence of acute GvHD grade II -IV and III -IV at [ADDRESS_409588]
® only transplant 
was 50% (95% CI: 23 -72) and 12% (95% CI: 2 -34) respectively.  Eight of the sixteen NiCord®-
only recipi[INVESTIGATOR_331194]® transp lant.  One case 
of chronic GvHD was extensive while the other seven were limited.  
 Among [ADDRESS_409589]
® ([ADDRESS_409590]® only recipi[INVESTIGATOR_331195]® and the backup CBU) , no grade [ADDRESS_409591]® recipi[INVESTIGATOR_331196] a grade 3 toxicity (atrial fibrillation), eight patients had grade [ADDRESS_409592] 
infusion.  Two infusion toxicities (grade 2 serious infusion rela ted hypersensitivity and grade 2 
non-serious hypertension) were reported as related to NiCord®.   
 Forty SAEs were reported in [ADDRESS_409593]
® recipi[INVESTIGATOR_840].  Six of the [ADDRESS_409594]®.  These six related SAEs i ncluded five GvHD events and 
one grade [ADDRESS_409595]
®-only recipi[INVESTIGATOR_840], [ADDRESS_409596]® only recipi[INVESTIGATOR_840]; one patient with a Klebsiella infection 
at day [ADDRESS_409597] transplant, and one patient with three infections (Klebsiella at day [ADDRESS_409598] transp lant).  
 No new malignancies or autoimmune diseases were reported in any of the transplant recipi[INVESTIGATOR_840].  
 Conclusions:   Infusion of NiCord
® was well tolerated and provided rapid short term neutrophil 
engraftment as well as stable, long term multilineage hematopoiesis.  Initiation of a phase III trial 
evaluating the efficacy of NiCord® compared to unmanipulated cord blood is warranted.  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 43 
[IP_ADDRESS]. Study GC P#0 4.01.020/030 
The study GC P#04.01.020/030 entitled: “ Long Term Follow Up for Patients who have received 
Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood- derived Ex 
Vivo Expanded Stem and Progenitor Cells.” is an ongoing long- term observational  study of 
patients who have received either a NiCord® or CordIn™ transplant.  The overall study obj ective 
is to describe the clinical outcomes of patients through [ADDRESS_409599]® or CordIn™ 
transplantation . 
[IP_ADDRESS]. Study GC P#0 5.01.020 
The study GC P#05.01.02 0 entitled: “ A Multicenter, Phase III, Randomized Trial of 
Transplantation of NiCord®, Umbilical Cord Blood -derived Ex Vivo Expanded Stem and 
Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological 
Malignancies” is an open -label stud y to compare the safety and efficacy of NiCord® single ex 
vivo expanded cord blood unit transplantation to unmanipulated cord blood unit transplantation 
in patients with hematological malignancies following conditioning therapy . 
3.7.2. CordIn ™ Clinic al Experience in Hemoglobinopathies  
Table 3: Overview of ongoing clinical stud ies of CordIn™ 
Protocol Number 
(ClinicalTrials.gov 
Number)  Study Title  Study 
Status  Institution/Principal 
Investigator  
[CONTACT_27199] P #01.01.0 30 a 
([STUDY_ID_REMOVED] b) Allogeneic Stem Cell 
Transplantation of 
CordIn ™, Umbilical Cord 
Blood-Der ived Ex Vivo 
Expanded Stem and Progenitor Cells, in Patients 
with Hemoglobinopathies   Ongoing  Robert Debré Hospi[INVESTIGATOR_307] / 
[CONTACT_52409]-Hugues Dalle  
UCSF Benioff Children's 
Hospi[INVESTIGATOR_307] /  
[CONTACT_331323]’s National Medical 
Center, Washington/  
[CONTACT_331324]  
a IND Number:  [ZIP_CODE] 
b https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=GC+P%23 01.01.030&rank=1  
[IP_ADDRESS]. Study GC P#01.01.030 
The study GC P#01.01.030 entitled: “ Allogeneic Stem Cell Transplantation of CordIn™, 
Umbilical Cord Blood -Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients with 
Hemoglobinopathies” is an open- label study to evaluate the safety and efficacy of CordIn™  in 
patients with Hemoglobinopathies following conditioning therapy with Busulfan, Thi otepa, and 
Fludarabine .  As of 09Oct2017, one patient has been transplanted on this protocol.  
3.8. Rationale  for Study Design & Do sages  
For HSCT to become a realistic therapeutic option available to a majority of patients with severe 
SCD and thalassemia, effective and safe use of alternat ive donors such as umbilical cord blood 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 44 
needs to be established. Given that previous attempts with  UCB graft s result in too high a level 
of graft failure, this study proposes an innovative strategy for unrelated allogeneic 
transplantation of SCD patients a nd thalassemia patients using an  ex-vivo expanded UCB graft  
utilizing  a novel technology ( NiCord®), with  or without  a second unmanipulated CBU , following 
preparative conditioning . This approach aims to address the need for improved donor access, as 
well as the CD34 cell dose limitation. We will gain information about engraftment and safety of unrelate d UCB transplantation with NiCord
® grafts , as well as additional aspects, including 
immune reconstitution and GvHD.  
3.8.1. Study Population  
This study will include patients who are candidates  for myeloablative HSCT for treatment of 
SCD or thalassemia. As described above a llogeneic HS CT with  sibling  donor cell engraftment 
can ameliorate SCD or t halassemia symptoms, improve quality of life, and stabilize vasculopathy 
with acceptable rates of early and late toxicities. Unfortunately, for a very large number of 
patien ts such a match is not available. CBU s are widely available but their  limited cell dose is 
associated with limited stem/progenitor cell subpopulations and is a key hurdle precluding broader 
use of this stem cell source in this population. Therefore, the st udy population of SCD or thalassemia  
using expanded cord blood will be included in this study.  For ethical reasons, the study will only 
enroll patients wh o do not have a n adequate suitably matched and readily available stem cell 
donor.  
3.8.2. CBU Cell Dose  
Part 1 only : as a safety precaution, the unmanipulated UCB unit  is required to contain at least 
3.5x107 TNC/kg body weight.  
 
Part 1 and Part 2 : 
The manipulated  UCB unit is required to contain ≥1.8x109 TNC and ≥1.8x107 TNC/kg  body 
weight  for patients weighing ≥ 25kg, and TNC ≥1.6x109 for patients weighing <25kg.  
 The manipulated CBU should contain a pre -cryopreserved  (post processing) , total CD34+ cell 
count  of ≥ 8x10
6 for patients weighing ≥ 25 kg and a pre -cryopreserved  (post processing) , total 
CD34+ cell count  of ≥7x106 for patients weighing < [ADDRESS_409600] importance, some examine CD34+ 
dose, and others prioritize HLA matching. For this reason, the protocol does not s pecify 
prioritization rules when more than one eligible CBU is identified.  
 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 45 
4. STUDY OBJECTIVES, HYPOTHESIS & STUDY ENDPOINTS  
4.1. Objectives   
Primary Objectives  
• Assessment of the acute toxicity associated with the infusion of NiCord®, within [ADDRESS_409601]-infusion 
• Part 1: Assessment of cumulative incidence  of donor -derived neutrophil engraftment by [CONTACT_4475] 
[ADDRESS_409602]® and unmanipulated cord blood grafts  
• Part 2: Assessment of cumulative incidence  of donor -derived neutrophil engraftment by [CONTACT_4475] 
[ADDRESS_409603] ®  
Secondary Objectives  
• Proportion of t ransplant -related mortality at 100 days  
• Event -free survival at 100 days ( death, autologous recovery, primary or secondary graft 
failure will be considered events for this endpoint)  
• Overall survival at 180 days  
Exploratory Objectives   
• Incidence of donor cell chimerism (>10%) from either donor  at 100 and 180 days  
• Percentage donor chimerism in whole blood, CD3+ and myeloid ( CD15+  or CD33+)  
fractions at 7, 14, 21, 28, 42, 70, 100 and 180 days  
• Time from infusion to neutrophil (>500/uL)  and p latelet (>50k/uL) engraftment  
• Platelet engraftment (>50k/uL) at 180 days  
• Incidence of a cute GvHD grade II -IV and III -IV at 100 days  
• Incidence of chronic GvHD (limited or extensive) at 180 days  
• Incidence of regimen -related  toxicity   
• Incidence of life -threatening  and fatal  infections  at 180 days  
• Immun e reconstitution at [ADDRESS_409604]-study Analysis  
• Event -free survival at 1 year (death, autologous recovery, primary or secondary graft failure 
will be considered events for this endpoint)  
• Overall survival at 1 year 
• Percentage donor chimerism in whole blood, CD3+ and myeloid (CD15+ or CD33+) 
fractions at 1 year  
• Incidence of chronic GvHD (limited or extensive) at 1 year  
• Incidence of life- threatening and fatal infections at 1 year  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 46 
• Immun e reconstitution at 1 year  
4.2. Hypothesis  
Part 1: Co -transplantation of NiCord® and an unmanipulated unrelated cord blood graft  in 
patients with hemoglobinopathies (SCD or thalassemia major)  following a preparative  therapy 
will be safe and will enable cord blood engraftment.  
 Part 2: T ransplantation of NiCord
® in patients with hemoglobinopathies (SCD or thalassemia 
major) following myeloablative  preparative therapy will be safe and will enable cord blood 
engraftmen t. 
4.3. Definition of  Study Endpoints  
4.3.1. Acute  Toxicity  
Acute  toxicity will be a ssessed and graded as per site practice,  guidelines and forms and in line 
with CTCAE v.4 .03 as specified in Appendix D .  
4.3.2. Neutrophil Engraftment 
Neutrophil  engraftment is defined as achieving an Absolute Neutrophil Count (ANC) of ≥ 500 
mm3 for 3 consecutive measurements on different days by [CONTACT_4475] 42 inclusive (the day of 
engraftment will be defined as the first of these 3 days). The ANC recovery must be of donor origin documented by [CONTACT_331258] a. Mixe d chimerism  - >10% 
host cells  and <90% host  cells or b. Donor chimerism – <10% host  cells . 
  
Primary graft failure  is defined as failure to achieve neutrophil engraftment by [CONTACT_4475] [ADDRESS_409605] after documented neutrophil 
engraftment will be considered secondary gr aft failure, even if it occurs on or prior to Day 42.   
 
Secondary graft failure  consists of documented engraftment as defined above, followed by 
[CONTACT_127867] (< 500/µL  for three or more consecutive laboratory values on separate days ), without 
subsequent improvement occurring either spontaneously or after growth factor treatment .  
Infusion of a second stem cell product after documented neutrophil engraftment  will be 
considered secondary graft failure.  
4.3.3. Platelet Engraftment  
Platelet engraftment is defined as t he first day of a minimum of 3 consecutive measurements on 
different day s such that the patient has achieved a platelet count >50x109/L with no platelet 
transfusions in the preceding 7 days  (count day of engraftment as one of the  preceding 7 days ). 
The first day of the three measurements will be designated the day of platelet engraftment.  
4.3.4. Autologous Recovery  
Autologous recovery is defined in patients recovering from an aplastic phase as achieving ANC 
≥500 mm3 for 3 consecutive measurements on different days with > 90% host chimerism in the 
peripheral blood or >70% Hb S level on Hemoglobin electrophoresis.   
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409606] previously recovered as presenting with ANC ≥ [ADDRESS_409607] month with ≥ 90% 
host chimerism in the peripheral blood or >70% Hb S level on Hemoglobin electrophoresis . 
4.3.5. Transplant Related Mortality  
Transplant related mortality is defined as any death n ot prece ded by [CONTACT_331259].   
4.3.6. Acute and Chronic Gv HD  
Incidence of acute GvHD grade II -IV and  III-IV will be assessed based on the Consensus 
Conference on Acute GvHD grading ( Appendix A ) on day 100.   Chronic GvHD will be 
assessed on day 180 and will be classified as limited or extensive according  to Appendix A . 
4.3.7. Immune Recon stitution  
The humoral system will be assessed based on levels of immunoglobul ins (IgG, IgA, IgM). 
Cellular immune recove ry will be assessed based on lymphocyte subset analysis to quantify the 
numbers and proportions of different lymphocyte subpopulations  (CD3, CD4, CD8, CD19, 
CD16/56) , as well as additional immunophenotypi[INVESTIGATOR_331197] .  T-Cell Receptor 
Excision C ircles (TREC) analysis will be performed.  
4.3.8. Chimerism of the Two  CBU G rafts  
Percent engraftment of both NiCord® and the un manipulated CBUs will be assessed by 
[CONTACT_331260] R FLP or microsatellite with separate assessment of the 
lymphoid and myeloid fractions  post neutrophil engraftment  and optionally an assessment of 
erythroid chimerism at 180 days pos t-transplant in patients with mixed chimerism.  
4.3.9. Life-threatening/Fatal Infection  
Any infection that involves : 
• Bacteremia with deep organ  involvement ( e.g., with new or worsening pulmonary 
infiltrates; endocarditis)  
• Severe sepsis with bacteremia  
• Fasciitis r equiring debridement  
• Pneumonia requiring intubation  
• Brain abscess or meningitis without bacteremia  
• C. Difficile toxin positive stool wi th toxic dilatation or renal insu fficiency 
with/without diarrhea  
• Fungemia including Candidemia  
• Proven or probable invasi ve fungal infections ( e.g., Aspergillus, Mucor, Fusarium, 
Scedosporium , resistant candida species)  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 48 
• Disseminated infections (defined as multifocal pneumonia, presence of urinary or 
blood antigen, and/or CNS involvement) with Histoplasmosis, Blastomycosis, Coccidiomycosis, or Cryptococcus  
• Pneumocystis jiroveci pneumonia (regardless of Pa O2 level)  
• Severe VZV infection (coa gulopathy or organ i nvolvement)  
• CMV end -organ involvement (pne umonitis, enteritis, retinitis)  
• EBV PTLD  
• Adenovirus with end- organ involvement (except enteritis, conjunctivitis and upper 
respi[INVESTIGATOR_4352])  
• Lower tract respi[INVESTIGATOR_4398]  
• Any viral encephalitis or meningitis  
• CNS or other organ toxoplasmosis  
• Strongyloides hyperinfection  
• Severe sepsis without an identified organism  
4.3.10. Regimen Related Toxicities  
Post transplant grade 3 -5 toxicities assessed using  CTCAE  v4.03 as specified in Appendix D . 
 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 49 
5. STUDY POPULATION 
5.1. Number of  Patients  
The sample size is up to 20 evaluable patients (up to [ADDRESS_409608]® and a n unmanipulated CBU plus up to [ADDRESS_409609]® only).   I n addition , patients must have met all of the following criteria:  
• Did not receive any stem cells up to day [ADDRESS_409610]® and, if in Part 1,  
the unmanipulated CBU ( e.g., second unmanipulated CBU)  
• Did not die prior to day 14 
• Received conditioning therapy a s specified in the protocol  
• Did not seriously contravene the eligibility criteria specified in  section  5.2 below  
• Did not receive a NiCord® transplant that was outside the final process quality control 
(FPQC) limits specified in  section 8.[ADDRESS_409611] received a transplant of CB cells but did not meet all of the above 
criteria will enter the main statistical analysis (ITT) but will be considered non -evaluable for  the 
per protocol analysis. For completing the per protocol analysis such patient s can  be replaced.  
 Any patient  may be removed from the study at any time if in the judgment of the Investigator 
further treatment is not in the best interests of the patient . Patients may also wit hdraw themselves 
from the study at any time and for any reason.  
 Patient s will be defined as screening failures if they are  withdrawn from the study before 
receiving NiCord
®.  All screening failures will be replaced.  
 Patient s will be defined as early t ermination/discontinuation, if dropout occurs after 
transplantation of NiCord
®.  
 For early termination/discontinuation patient s, termination visit should be completed. In case 
such patient s did not withdraw consent, study investigator will make all effort s to gather 
information on the clinical outcomes as assessed during the usual clinical management of their 
disease over the first [ADDRESS_409612] be 2 – [ADDRESS_409613] for treatment of SCD  or thalassemia :  
a. Patient must have clinically severe SCD ( e.g., SS, SC or SBeta
0 Thal) with at least one 
of the following clinical complicatio ns: 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 50 
• Recurrent painful events (at least 3 in the 2 years prior to enrollment) that cannot be 
explained by [CONTACT_22714]. Pain may occur in typi[INVESTIGATOR_331161] -
occlusive painful events and cannot be explained by [CONTACT_331239] . Pain last s 
at least [ADDRESS_409614] occur despi[INVESTIGATOR_331198] 
(e.g., hydroxyurea therapy)  
• Acute chest syndrome (ACS) with at least two epi[INVESTIGATOR_331199] a new infiltrate on chest radiograph and/or having a perfusion defect demonstrable on a 
lung radioisotope scan within the  past two years that required hospi[INVESTIGATOR_059], oxygen 
therapy, and red blood cell (RBC) transfusion.  These epi[INVESTIGATOR_331200], ( e.g., hydroxyurea therapy) .  At least one epi[INVESTIGATOR_331201] w hile on hydroxyurea therapy unless patient is 
unable to take hydroxyurea due to toxicity  
• Any combination of painful e vents and ACS epi[INVESTIGATOR_331165]  
• SCD related and clinically significant n eurologic event (stroke or hemorrhage) or 
SCD related neurologic defect lasting more than 24 hours  
• Abnormal cerebral magnetic resonance imaging (MRI) and /or abnormal cerebral 
magnetic resonance angiography (MRA)  
• Abnormal Transcranial Doppler (TCD), as defi ned by a TCD velocity that exceeds 
200 cm/sec by [CONTACT_11339]- imaging technique (or TCD measurement of >185 cm/sec by 
[CONTACT_331261]) measured at a minimum of two separate occasions one month 
or more apart  
• Patients on chronic PRBC transfusion therapy, de fined as receiving 8 or more 
transfusions per year for > 1 year to prevent vaso- occlusive clinical complications 
(e.g., pain, stroke, and acute chest syndrome), with a history of alloimmunization 
which compromises the delivery of adequate transfusion thera py 
OR; 
b. Patients with thalassemia major requiring ≥8 (or >100 ml/kg) RBC  transfusions per year 
in the two years preceding enrollment. 
3. Part1: Patients  must have two  partially HLA -matched CBUs. Units must be HLA -
matched at 4 -6/6 HLA class I (HLA -A & HLA- B, low resolution) and II (HLA -DRB1, 
high resolution) loci with the subject and 3- 6/6 HLA -A, B, DRB1 loci with each other 
(using same resolution of typi[INVESTIGATOR_007]). Double mis match at any one locus (A, B, or DRB1) is 
not permitted  
Part 2: Patients  must have one  partially HLA -matched CBU . Unit  must be HLA -matched 
at 4-6/6 HLA class I (HLA -A & HLA- B, low resolution) and II (HLA -DRB1, high 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 51 
resolution) loci with the subject. Double  mismatch at any one locus (A, B, or DRB1) is 
not permitted  
a. For patients weighing ≥ [ADDRESS_409615] a pre -
cryopreserved (post processing)  total nucleated cell dose of ≥1.8x109 and 
≥1.8x107cells per kg body weight.  
For patients weighing < [ADDRESS_409616] a pre -
cryopreserved  (post processing)  total nucleated cell dose of ≥1.6x109.  
Part 1: The unmanipulated CBU should contain a pre -cryopreserved  (post 
processing) , nucleated cell dose of at least 3.5x107/kg.  The better matched  unit 
will be the unmanipulated unit (as per inves tigator’s discretion).  
b. The manipulated CBU should contain a pre -cryopreserved  (post processing) , total 
CD34+ cell count  of ≥ 8x106 for patients weighing ≥ 25 kg and a pre -
cryopreserved  (post processing) , total CD34+ cell count  of ≥7x106 for patients 
weigh ing < [ADDRESS_409617] undergone volume reduction (both plasma and 
red blood cell depletion) prior to cryopreservation.  
d. The CBU should be procured from public banks that meet local applicable 
regulations  
e. The selected unit should be typed twice ( i.e., initial typi[INVESTIGATOR_331166]). Verification typi[INVESTIGATOR_007] (c onfirmatory typi[INVESTIGATOR_007] ) should be in a laboratory  that is 
ASHI/EFI accredited and must come from an attached segment   
4. Patients’ Performance score ≥70% by [CONTACT_331262].  
5. Patient has sufficient physiologic reserves including:  
• Cardiac: Left ventricular ejection fraction (LVEF)  > 50% by [CONTACT_331263]; or LV shor tening fraction > 26%  
• Pulmonary: Pulse oximetry with a baseline O2 saturation of ≥ 85% is required for all 
patients ; DLCO > 60% of predicted for age (corrected for hemoglobin) for patient s in 
whom pulmonary function testing can be performed. cDLCO value sh ould be from 
testing performed before the administration of a bronchodilator if applicable.   FVC 
and FEV1 > 60% of predicted for age. 
• Renal: Serum creatinine ≤ 1.5 x upper limit of normal  for age and GFR > 100 
mL/min/1.73 m2.  For patients ≥16 years of age , GFR should be >70 mL/min/1.73 m2.  
Note, estimated GRF value not acceptable; nuclear GFR testing must be performed.  
• Hepatic: Serum conjugated (direct) bilirubin < 2 x upper limit of nor mal for age as 
per local laboratory in the absence of gall bladder di sease or prior cholecystectomy; 
Hepatic transaminases (ALT and AST) < 5 x upper limit of normal range  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 52 
6. In SCD patients, HbS should be ≤ 45%  within 7 days prior to initiation of the 
conditioning regimen.  If the HbS level is >45% then the patient must receiv e RBC 
transfusions or erythrocyte exchange prior to conditioning regimen  initiation.  
7. Patient must have at least one graft source as a backup in ca se of graft failure:  
a. Autologous stem cells harvested from bone marrow ; OR  
b. A related, haplo -identical family member who is suitable for bone marrow or 
peripheral blood stem cell donation and has agreed to do so in the event of graft 
failure; OR  
c. An additional HLA -matched CBU, or two CBUs, reserved as a backup  
8. Females of childbearing potential , defined as any female  who has experienced menarche 
and is not postmenopausal or permanently sterilized ( e.g., tubal occlusion, hysterectomy, 
bilateral salpi[INVESTIGATOR_1656]) , agree to use  an appropriate method of contraception from at 
least 7 days pr ior to Hydroxyurea administration until completion of follow -up 
procedures.  An appropriate method of contraception is defined as one that results in a low failure rate ( i.e., less than 1 percent per year) when used consistently and correctly, 
such as impl ants, injectables, combined oral co ntraceptives, some intrauterine 
contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner.  
9. Patient and/ or legal guardian signs the written informed consent after being made aware 
of the nature of the pati ent’s disease and willingly consent s to the treatment program after 
being informed of alternative treatments, potential risks, benefits, and discomforts . 
Exclusion Criteria  
1. Evidence of uncontrolled bacterial, viral or fungal infections or severe concomitant 
diseases, which in the judgment o f the Principal Investigator, indicate that the patient 
could not tolerate transplantation.  
2. Evidence of HIV infection or HIV positive serology . 
3. Evidence of active Hepatitis B, Hepatitis C or EBV as determined by [CONTACT_331243].  
4. Pregnancy as indicated by a  positive serum human chorionic gonadotrophin (HCG) test , 
or lactation . 
5. Patients with 8/[ADDRESS_409618]
® CBU 
(MFI> 2000 to HLA A, B, C, or DRB1 ). 
8. Prior myeloablative  allogeneic hematopoietic stem cell transplant within last [ADDRESS_409619] which may interfere with the 
treatment.  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 53 
10. Psychologically incapable of undergoing bone marrow transplant (BMT) with associated 
strict isolation or documented history of medical non- compliance and/or p sychiatric 
illness and/or social situations that would limit compliance with study requirements . 
11. Enrolled in another clinical trial or received an investigational treatment within [ADDRESS_409620] -menopausal (amenorrhea for at least 12 consecutive 
months), surgically sterile or, if a woman of child -bearing potential (WOCP), have a negative 
urine beta human chorionic gonadotropin (HCG) pr egnancy test prior to ent ering the study and 
agree to use acceptable methods of contraception during the study.  An acceptable method of contraception is defined as one that results in a failure rate less than 1 percent per year  when used 
consistently and correctly, such as implan ts, injectables, combined oral contraceptives, some 
intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner.  
 WOCP must be advised to use acceptable contraceptives throughout the study period. If hormonal contraceptives are used, they should be taken according to the package insert. WOCP 
who are not currently sexually active must agree to use acceptable contraception, as defined above, if they decide to become sexually active during the period of the study and for [ADDRESS_409621] be recorded in the patient’s medical record and in the CRF.  If a patient is withdrawn for more than one reason, each reason should be documented in the source document and the most medically sig nificant reason should be entered on the CRF. 
 Patients may also withdraw themselves from the study at any time and for any reason, withou t 
prejudice to their future medical care by [CONTACT_8018].  
 Patient s will be defined as screenin g failures if they are  withdrawn from the study before 
receiving NiCord
®, or as early termination/discontinuation, if dropout occurs after  
transplantation of NiCord®. Screening failures can be replaced.   
5.4.2. Criteria for Withdrawal 
Patient s who are prematurel y discontinued from the study should be followed and treated by [CONTACT_331264] . Patient s who join the study will be asked for 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409622] 6 months following trea tment. This will allow us to continue to gather clinical information 
on patient s who subsequently withdraw from active  participation and did not withdraw informed 
consent, and to include them in the analyses of all clinical endpoints.  
 A patient  may withdraw or be withdrawn from the study for the following reasons:  
• Patient or legal guardian withdrew consent  
• Sponsor reque sted patient  to be withdrawn 
• Pregnancy  
• Request of primary  care physician or Investigator, based on the patient’s best interests  
• Occurrence of an AE or SAE, which, in the judgment of the investigator, justifies withdrawal due to its nature, severity or requirement for treatment, regardless of the causal relationship to the IMP  
• Non-compliance (per investigator judgment)  
• Lost to follo w-up 
At least three documented attempts must be made to contact [CONTACT_69838] -up (e.g., 
calling the patient at last known phone number, sending a certified letter to the patient’s last 
known address).  
5.4.3. Early Discontinuation of Follow -up  
For ea rly termination patients that withdraw/are withdrawn from the study post transplant, any 
assessments due at the time of withdraw  (according to Table 4) are requested.  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 55 
6. CONCOMITANT MEDICATIONS & SUPPORTIVE CARE  
6.1. Previous Medications 
All medications taken by/given to the patient , as a treatment for the primary and concomitant 
diseases within [ADDRESS_409623] transplant:  
• Methotrexate (unless approved in advance by [CONTACT_2728])  
• Any cytokines except G -CSF or GM -CSF should not be us ed (including IL -2 or others, 
unless approved by [CONTACT_2728]) ; bio-identical substitutions are allowed.  
• The use of Bactrim is discouraged on or after day - 2 and prior to engraftment as it may 
delay engraftment, and is reserved only in cases where it is assessed to be essential and 
superior to all alternative medications  
• Investigational agents, unless previously approved by [CONTACT_456]  
6.3. Preparative  & Conditioning Regimen  
All patients will receive one of two conditioning regimen s, depending on the patient’s age, as 
shown in the table s below. GvHD prophylaxis will  consist of cyclosporine and mycophenolate  in 
both regimens .  
 
Patients <21 years old  
Days  Agent  Dose  
-35 to -15 Hydroxyurea1 30mg/kg/day orally  
-14 to -10 Fludarabine  35 mg/m2 IV daily x 5 days  
-9 to -6 Busulfan  1mg/kg/dose IV q 6h x 16 doses  
-5 to -2  Cyclophosphamide2 50mg/kg/day x [ADDRESS_409624] 30mg. /kg/day.  
2 If treatment with Cyclophosphamide is contraindicated, substitute Melphalan 45 mg/m2/day IV x 3 days ( -4 to -2) 
 
Patients >21 years old  
Days  Agent  Dose  
-35 to -13 Hydroxyurea1 30mg/kg/day orally  
-12 to -8 Fludarabine  35 mg/m2 IV daily x 5 days  
-7 to -4 Busulfan  0.8 mg/kg/dose IV q 6h x 16 doses  
-3 and -2  Cyclophosphamide  60mg/kg/day x [ADDRESS_409625] 30mg./kg/day.  
6.3.1. Hydroxyurea Administration  
Start at 30mg/kg/day, once daily as a liquid or capsule. Monitor CBC, ANC and LFTs weekly. 
Hold hydroxyurea for Platelets < 50,000/uL, ANC < 1000, or if AST/ALT > 4x Upper limit of 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 56 
normal. Resume at 20% lower dose w hen laboratory values improve. Start no later than day - [ADDRESS_409626] the dose to 30 mg/kg/day and continue.  If the patient is already on a higher dose hydroxyurea, 
no adjustment is necessary.   
 Refer to Appendix E , ‘Drug Labels’, for risks and toxicities of Hydroxyurea administration  
6.3.2. Fludarabine Administration  
Fludarabine 35 mg/m2/day will be administered as a 15- 30 minute IV infusion. Fludarabine will 
be dosed as per adjusted ideal body weight (see below for cyclophosphamide).   
Refer to Appendix E , ‘Drug La bels’, for risks and toxicities of Fludarabine administration.  
6.3.3. Busulfan Administration  
For patients <21 years old, a dminister 1 mg/kg/dose intravenously as a 2 -hour infusion every 6 
hours for 16 doses.  For patients >21 years old, a dminister 0.8  mg/kg/dose  intravenously as a 2 -
hour infusion every 6 hours for 16 doses. Dilute in normal saline to a concentration of 0.5mg/ml .  
Busulfan pharmacokinetic sampling will be obtained after the 1st dose. Dose modification will target a steady state concentration (Css)  of 600- 900 ng/ml.  
 Refer to Appendix E , ‘Drug Labels’, for risks and toxicities of Busulfan administration.  
6.3.4. Cyclophosphamide (CY)  Administration  
Dose will be calculated using adjusted ideal body weight*, if  actual body weight is more than 
125% of ideal body weight. For patients < 21 years old, t he dose is 50mg/kg/day for 4 days  
(60mg/kg/day for 2 days  for patients >21 years old) diluted in normal saline and administered  
intravenous ly as a 60 minute infusion.  Provide adequate hydration 3000 ml/m2/day of 
appropriate maintenance IV solution during CY administration.  Mesna 50 mg/kg/day is given IV as a continuous infusion beginning [ADDRESS_409627] administered CY dose. 
 Refer to Appendix E , ‘Drug Labels’, for risks and toxicities of CY administration.  
 
* Ideal Body Weight Formulas : 
For patients 1 to 18 years of age: (ht = cm , IBW = kg)  
Less than 60 inches (152.4 cm): IBW = (ht2 x 1.65)/1000  
More than 60 inches (152.4 cm): Males IBW = 39.0 + [2.27 x (ht -  60)]  
Females IBW = 42.2 + [2.27 x (ht - 60)] 
 
For patients over 18 years old:  
Males IBW = 50 kg+2.3 kg/inch over 5 feet  (or 50 kg + 0.91kg/cm over 152.4cm)  
Females IBW = 45.5 kg+2.3 kg/inch over 5 feet  (or 45.5 kg + 0.91kg/cm over 152.4cm)  
 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 57 
Adjusted Ideal Body Weight Formula  for all patients :  
AIBW = IBW + [(0.25) x (ABW -  IBW)]  
6.3.5. Melphalan  
If treatment with cyclophosphamide is contraindicated  in patients <21 years old, substitute 
melphalan 45 mg/m2/day IV as a 15 -20 minute infusion x 3 days ( -4 to -2).  Melphalan must be 
infused within 60 minutes of preparation.  Refer to Appendix E , ‘Drug Labels’, for risks and toxicities of Melphalan administration.  
6.3.6. Methylprednisolone  
If methy lprednisolone is substituted for ATG, administer IV as a 1 hour  infusion.  
 
Refer to Appendix E , ‘Drug Labels’, for risks and toxicities of Methylprednisolone 
administration.  
6.4. GvHD Prophylaxis Medications  
All patients will receiv e GvHD prophylaxis wi th two drugs as follows:  
 
Cyclosporine A (CSA)  
CSA will be administered beginning on Day –3. If administering via continuous IV infusion, it is 
recommended to target cyclosporine trough level s of 200- 400 ng/mL by [CONTACT_331265] (or 100-
250 ng/mL by [CONTACT_331266]).  For intermittent 
dosing, it is recommended to  target cyclosporine trough levels of 150- 300 ng/mL by [CONTACT_331267] (or equivalent level for other CSA testing methods).   
 Dose adjustment s will be made on the basis of toxicity and high or low CSA levels.  Once the 
patient can tolerate oral medications and  has a normal gastro -intestinal transit time, CSA can be 
converted to an oral form at 2 -3x the current IV dose. CSA dosing will be monitored and altered 
as clinically appropriate.   
 In the absence of actual toxicity, patients will receive CSA until Day + 180 or graft failure .  
Following day +180 patients will receive CSA according to institutional protocols.  
 In the event of toxicity or GvH D, centers may switch to Tacrolimus. Dosing should be adjusted 
to maintain a tacrolimus trough blood level of 5- 15 ng/m L. In the event of toxicity to 
Tacrolimus, treat per institutional practice.  
 Refer to Appendix E , ‘Drug Labels’, for risks and toxicities of CSA administration.  
 
Mycophenolate Mofetil (MMF)  
MMF will be given at a dose of 15 mg/kg/dose IV q 8 hours beginning the morning of Day –3.  (If renal failure and GFR < 25 mL/min do not exceed dose of 1 gm q 8 hours.  No dose adjustment is required for liver disease.)  MMF sh ould be given IV until patient can tolerate oral 
medications and has a normal gastro -intestinal transit time.  Capsules/t ablets or suspension may 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409628] capsule/tablet si ze per standard of care at the site.  MMF will be dosed 
based on the patient’s  actual body weight.  
 
MMF should be continued for 45 days or 7 days after engraftment, whichever da y is later, if 
acute G vHD or graft failure has not occurred.  If G vHD occurs before Day 45, treat according to 
institutional protocols.  
 
In the event of toxicity to MMF, dosing may be adjusted or discontinued per institutional practice.  
 Refer to Appendix E , ‘Drug Labels’, for risks and toxicities of MMF administration.  
6.5. Acute & Chronic GvHD Treatment  
Management of acute and chronic GvHD will be at the Investigator's discretion and in accordance with the institution's guidelines . The following guidelines are suggested:  
 
• The diagnosis of acute GvHD will be made on clinical and histological grounds (see 
Appendix A  for grading system).  Acute GvHD, manifest as skin rash (ranging from 
palmar erythema to bullous dermatitis), mucositis (manifest most dramatically as 
diarrhea), hepatitis, and delayed hematopoietic recovery, usually occurs within the first 
[ADDRESS_409629] -line therapy methylprednisolone, 1-10 mg/kg/day (IV or PO) for [ADDRESS_409630]- line 
regimen of methylprednisolone 500 mg/m2/dose q 12 hours x2 doses, repeated every 48-
72 hours for up to 4 courses may also be used.  If acute GvHD persists, or does  not 
respond to institution of steroids, treatment should be instituted at the discretion of the attending physician.  
o Enrollment in phase I/II studies of novel anti -GvHD therapy is permitted per 
approval of the Sponsor.  
• Chronic GvHD, seen much more freque ntly in patient s who have had acute GvHD, is 
manifested by [CONTACT_331268], xerophthalmia, xerostomia, weight loss, and immunodeficiency (with particular susceptibility to sinopulmonary infections), and will be diagnosed by [CONTACT_331269]. Treatment with 
prednisone and cyclosporine or azathioprine or other medications per institutional 
guidelines should be instituted if systemic disease is diagnosed; this therapy may contribute to the susceptibility to infection.  
6.6. Supportive Care  
Institutional standard of care practice guidelines will be followed after transplantation for nutritional support, treatment of infections, and blood product support. Supporti ve care 
guidelines are detailed below.   
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409631] frequently reported manifestations are 
transient fever, rash, and respi[INVESTIGATOR_331202]. The pathophysi ology is poorly understood, but is thought to be multifactorial mediated by [CONTACT_2967], 
complement and cytokine components.  
 Diagnostic criteria include fever (temperature >38.5° C) without an identifiable infectious cause prior to or with neutrophil recovery with or without an erythematous rash or capi[INVESTIGATOR_7946] (weight  gain, edema, ascites, effusions) or respi[INVESTIGATOR_331203]. Mild 
symptoms may not require therapy due to the self -limiting nature of this syndrome. 
Methylprednisolone should not be given as prophylaxis  for engraftment syndrome prevention . 
For progressive symptoms, methylprednisolone at 2 mg/kg/day is recommended with tapering once response is achieved. If recurrent or prolonged, investigation for GvHD is recommended.  
6.6.2. Veno us Access  
Recipi[INVESTIGATOR_331204] -term central venous access placed, per institutional 
standard practice, prior to beginning the conditioning regimen. The placement of a triple lumen tunneled catheter is recommended.  
6.6.3. Seizure Prophylaxis for SCD Patients  
Prophylaxis against  seizures is mandatory in all  SCD patients  and should be commenced at the 
start of  conditioning. Suitable drugs for prophylaxis include phenytoin, clonazepam, or 
levetiracetam, and should be administered according to institution guidelines. Seizure prophyl axis should be continued in SCD patients until cyclosporine or any other calcineurin 
inhibitor is discontinued.  In patients with pre -existing seizures, continued prophylaxis may be 
given per standard of care. 
 Serum magnesi um level should be maintained >1 .5 mg/dL in all SCD patients during the period 
of treatment with calcineurin inhibitors cyclosporine or tacrolimus to reduce the risk of seizures.  
6.6.4. Hypertension   
Hypertension should be strictly controlled to prevent CNS toxic ity. Blood pressure should be 
monitored closely and both systolic and diastolic hypertension should be treated promptly to 
maintain blood pressure at the patient’s pre- transplant baseline ± 20% . 
6.6.5. Growth Factor   
G-CSF ( e.g., Filgrastim,  Neupogen, Granix, Zar xio) therapy will be given IV starting Day +1 at 
dose of 5 μg/kg/day (rounding to nearest vial dose). G -CSF will be continued until the absolute 
neutrophil count (ANC) is > 2,000/μL on 3 consecutive days after the nadir.  
6.6.6. Blood Products  
All blood products (except the unman ipulated UCB and NiCord
®) must be irradiated to at least 
[ADDRESS_409632] disease.  
 
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409633] be ma intained between 9.0 and 11.0 g/dL for at 
least [ADDRESS_409634] -transplant and platelet count > 50,000/μL post -transplant until recovered to 
avoid neurological adverse events  (AEs) , as described previously .[ADDRESS_409635] be free of active infections. Rigorous 
hand washing is crucial.  
[IP_ADDRESS]. Anti -viral  Prophylaxis  
Acyclovir [ADDRESS_409636] transplant or until 6 
months after immunosupression is discontinued. If unable to tolerate PO medications, IV prophylaxis will be necessary.  Other anti -viral prophylaxis regimens may  be administered per 
institutional guidelines, howeve r, prophylaxis with ganciclovir or valganciclovir is strongly 
discouraged  on or after day - 2 until engraftment is achieved.  
[IP_ADDRESS]. Anti -bacteri al Prophylaxis  
Anti-bacterial prophylaxis is required.  Ciprofloxacin 500 mg PO BID day 0- 100 is 
recommended.  Other ant i-bacterial prophylaxis regimens may be administered per institutional 
guidelines.  
[IP_ADDRESS]. PCP P rophylaxis  
Trimethoprim- sulfamethoxazole or an e quivalent drug should be administered after engraftment 
as per institutional guidelines.  The use of Bactrim is discouraged on or after day - 2 and prior to 
engraftment as it may delay engraftment, and is reserved only for cases where it is assessed to be 
essential and superior to all alternative medications .  
[IP_ADDRESS]. Fungal Prophylaxis  
Anti-fungal prophylaxis against Aspergillus sp. is recommended with agents such as 
itraconazole, voriconazole, or posaconazole .   
[IP_ADDRESS]. CMV S urveillance  
All recipi[INVESTIGATOR_331205], at the weekly protocol specified visits up through Day 42, and then at day 
70 and day 100 or more frequently as clinically indicated . Antiviral therapy for CMV 
reactivation should comme nce preemptively if CMV testing reveals a high or rising viral load. If 
CMV reactivation occurs at or before engraftment , foscarnet may be considered to prevent 
marrow suppression.  
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 61 
[IP_ADDRESS]. Adenovirus I ntervention G uideline  
Testing for adenovirus infection in the blood by [CONTACT_331270][INVESTIGATOR_331206], hepatic dysfunction or respi[INVESTIGATOR_120340]. If an active systemic infection is diagnosed, therapy should be inst ituted with 
cidofovir or other active agents per institution guidelines.  
[IP_ADDRESS]. Intravenous Immune Globulin  
Intravenous immune globulin may be administered according to  institutional practice guidelines. 
Weekly IVIG infusions (500 mg/kg/dose) are recommended for immunoprophylaxis through Day [ADDRESS_409637] a high incidence of new CNS toxicities 
(seizures, labile hypertension, RPLS, PRES, intracranial hemorrhage, stroke, etc.) during the entire transplant process, beginning with the conditioning regimen and lasting throu gh the time 
that immunosuppression is eventually discontinued. In order to minimize or avoid these risks, adherence to the following guidelines is strongly recom mended for all patients:  
 
1. The baseline blood pressure in patients with SCD is often less than “normal” for age. Hypertension can ensue following fluid infusions, or with the use of medications such as corticosteroids and calcineurin inhibitors, even after short term use. Blood pres sure (both 
systolic and diastolic) should be monitored closely (at least every 4 hours) and strictly maintained within 20% of the baseline blood pressure of the patient – aggressive (and often parenteral) use of anti -hypertensive drugs may be required to c ontrol hypertension. 
 
2. Seizure prophylaxis  is mandatory.  Prophylaxis  with phenytoin, gabapentin or  
levetiracetam should be commenced with conditioning therapy per standard guidelines and continued for [ADDRESS_409638] of care.    
 
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 62 
 
3. Platelet counts will be monitored frequently after starting the  conditioning therapy and 
platelet transfusions will be administered as needed to keep levels > 50,000/μL. 
6.6.11. Nutrition  
All patients will be candidates for total parenteral nutrition; length of use is at the attending physician's discretion.   
6.6.12. Guidelines for  Infusing a Second Stem Ce ll Product or Donor Cellular Infusion  
A second transplant or donor cellular infusion (DCI) should not be considered unless the patient 
has graft failure . If graft failure occurs  then the patient may be treated per institutional 
guidelines.  
6.7. Investigational Agents  
Unless approved by [CONTACT_1034], investigational agents should not be administered from  30 days 
prior to  CBU shipment to the production facility  until the end of study follow -up for all patients 
transplanted . 
6.8. Other Medicati ons  
Patient s should receive full supportive care according to institutions’ practice patterns and 
clinical guidance as described above, including transfusions of blood and platelets, antibiotics, anti-emetics, or any other supportive care according to cli nical  judgment.  
  All concomitant medications administered, from time of signature [CONTACT_331301], will be recorded in the source documents  and the reason for administration should be 
clearly stated in the indications and if need ed al so documented as AEs. 
 
Rescue equipment (oxygen) and drugs such as hydrocortisone, epi[INVESTIGATOR_238] (other inotropic agents), and antihistamines should be available at the transplantation unit and will be administered at the Investigator’s discretion.
  
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
   
NiCord® Hemoglobinopathy Protocol  Page 63 
Tabl e 4: Evaluations & Examinations Flow Sheet  
 
NiCord® Study for Hemoglobinopathies - Schedule of Assessments Summary  
 Before transplant  Days Post -transplant  
  
Eligibility / 
Screening 
Phase   
Baseline  
Phase   
Preparative and  
Conditio ning 
Phase   
Transplantation and Post Transplantation FU Phase  Post-
Study 
FU 
Days  Within 45 
days prior to 
CBU 
shipment  Within 4 
weeks prior to 
start of 
conditioning1 -35 to -15/-13 
Preparative  
 
-14/-12 to -2 
Conditioning2 0 1 7 14
±3 21
±3 28
±3 35
±3 42
±3 70
±3 100 
±14 180 
±21 365 
±21 
Part 1: Identify two UCB 
matching units 3 
Part 2: Identify one UCB 
matching unit 3 X               
Written Informed 
Consent4 X               
Backup Identification 
/BM Harvest5 X               
Eligibility Criteria  X               
hCG Test for Pregnancy  
(if of child bearing 
potential)  X X              
Ship selected CBU for 
manipulation to arrive at 
the production site preferably no later than 
two days before the start 
of manufacturing  X  
               
Medical History  X X              
Historical Medications  X               
Concomitant Medications  X X X X X X X X X X X X X X X 
Karnofsky/Lansky 
performance scale  X X       X   X X X X 
Confirm Eligibility within 
one week prior to 
conditioning   X              
  
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
   
NiCord® Hemoglobinopathy Protocol  Page [ADDRESS_409639]® Study for Hemoglobinopathies - Schedule of Assessments Summary  
 Before transplant  Days Post -transplant  
  
Eligibility / 
Screening 
Phase   
Baseline  
Phase   
Preparative and  
Conditio ning 
Phase   
Transplantation and Post Transplantation FU Phase  Post-
Study 
FU 
Days  Within 45 
days prior to 
CBU 
shipment  Within 4 
weeks prior to 
start of 
conditioning1 -35 to -15/-13 
Preparative  
 
-14/-12 to -2 
Conditioning2 0 1 7 14
±3 21
±3 28
±3 35
±3 42
±3 70
±3 100 
±14 180 
±21 365 
±21 
Physical Examinat ion  X X X6 X X    X   X X X X 
Vital Signs7 X8 X8 X6 X X X X X X X X X X X X 
Laboratory  
CBC & Chemistry 9 X X X6 X X X X X X X X X X X X 
Complete urinalysis with 
microscopic examination  X               
CBU confirmatory HLA 
typi[INVESTIGATOR_007]10 X               
Infectious disease 
markers11 X X              
Viral Screening   X              
Radionuclide GFR12 X X              
Anti-HLA antibodies23 X               
CMV PCR     X13   X X X X X X X X   
Immunophenotypi[INVESTIGATOR_331207]14, 15  X           X X X 
Imm unoglobulins (IgG, 
IgA, IgM)15  X           X X X 
T-cell Receptor Excision 
Circles (TREC)15  X           X X X 
Peripheral blood baseline 
sample for Chimerism16   X              
Peripheral blood 
chimerism17      X X X X  X X X X X 
Hb-electrophoresis18  X            X X 
  
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
   
NiCord® Hemoglobinopathy Protocol  Page [ADDRESS_409640]® Study for Hemoglobinopathies - Schedule of Assessments Summary  
 Before transplant  Days Post -transplant  
  
Eligibility / 
Screening 
Phase   
Baseline  
Phase   
Preparative and  
Conditio ning 
Phase   
Transplantation and Post Transplantation FU Phase  Post-
Study 
FU 
Days  Within 45 
days prior to 
CBU 
shipment  Within 4 
weeks prior to 
start of 
conditioning1 -35 to -15/-13 
Preparative  
 
-14/-12 to -2 
Conditioning2 0 1 7 14
±3 21
±3 28
±3 35
±3 42
±3 70
±3 100 
±14 180 
±21 365 
±[ADDRESS_409641]® CF, NF, and 
infusion solutions shipped 
to transplant center    X             
NiCord® CF thawing and 
infusion     X            
NiCord® NF thawing and 
infusion     X            
Toxicity assessment [ADDRESS_409642] infusion19    X X           
GvHD prophylaxis20   X X X X X X X X X X X X  
G-CSF Therapy21     X X X X X X X     
Infection prophylaxis22   X   X X X X X X     
Cardiac:  
• ECG23 
• Echocardiography  
LVEF or shor tening 
fraction, tricuspid 
regurgitation, and jet 
velocity (if present)[ADDRESS_409643] X -ray25  X              
MRA/MRI26  X              
Pulmonary Function Test 
with cDLCO, FEV1, 
FVC, O223 X            X X  
  
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
   
NiCord® Hemoglobinopathy Protocol  Page [ADDRESS_409644]® Study for Hemoglobinopathies - Schedule of Assessments Summary  
 Before transplant  Days Post -transplant  
  
Eligibility / 
Screening 
Phase   
Baseline  
Phase   
Preparative and  
Conditio ning 
Phase   
Transplantation and Post Transplantation FU Phase  Post-
Study 
FU 
Days  Within 45 
days prior to 
CBU 
shipment  Within 4 
weeks prior to 
start of 
conditioning1 -35 to -15/-13 
Preparative  
 
-14/-12 to -2 
Conditioning2 0 1 7 14
±3 21
±3 28
±3 35
±3 42
±3 70
±3 100 
±14 180 
±21 365 
±[ADDRESS_409645]    RBC and platelet transfusion  recording from transplant until d180   
Infections    Report all grade 2/[ADDRESS_409646] study follow -up. 
Serious adverse events    From in itiation of conditioning regimen until end of study   
1 Baseline assessments should be completed and resulted prior to initiation of the conditioning regimen.   
2  Transition from preparative to conditioning phase is dependent on the patient’s age .  Condit ioning begins at day -12 for patients ≥21 years of age w hereas conditioning 
begins on day -14  for patients <[ADDRESS_409647] of the patient regardless of the 
patient’s participation in the trial.   
[ADDRESS_409648] ed from bone marrow should be obtained, or related haploide ntical donor/back-up CBU(s) to be identified  (as detailed in inclusion criteria), 
in case of engraftment failure . If Autologous stem cells harvest from BM is chosen as the backup graft source, the ba ckup BM harvest can be obtained during Baseline, but 
prior to the start of conditioning treatment, for patients who have an alternative back-up stem cell source identified. 
6    As per site practice.  
7  Temperature, blood pressure, pulse, respi[INVESTIGATOR_697]; saturation (pulse oxymetry)  required through the Day 42 visit . 
8  Including  height, weight and BSA.  
9 CBC performed daily from Day 0 until neutrophil engraftment.  Differentials not required if WBC<0.2.  Blood chemistries inclu de (at a minimum) : serum cre atinine,  
    total bilirubin, alkaline phosphatase, AST,  ALT, and magnesium at screening, baseline (before start of conditioning), day -1, day 0, and then at least twice weekly until 
Day 28, and weekly after Day [ADDRESS_409649] -transplant).  
[ADDRESS_409650] ABO and Rh typi[INVESTIGATOR_276603].   
11 Infectious disease markers include: CMV, Hepatitis panel (HepB sAg, HepB Core Ab, HepC Ab), EBV Ab, herpes simplex virus, syphilis  Ab (such as RPR), HIV and  
     HTLV I/II antibody, and varicella zoster.  
12 Tests from 90 days prior to screening are acceptable for eligibility, provided the patient has been asymptomatic since the ti me of the tests . For baseline testing, can be done 
up to 90 days prior to initiation of  the conditioning regimen, provided the patient has been asymptomatic since the time of the tests . 
13 After start of chemotherapy.  
14 CD3, CD4, CD8, CD19, CD16/56 and others as per sit e practice.  
15  Blood sample collection may be done at any time before t he start of the conditioning regimen as long as the tests are resulted before the initiation of conditioning. 
16  Sample can be collected  during screening  if more convenient . 
  
 
GC P#02.01.020  Date : December 1 3, 2017 (Amdt VI)  
   
NiCord® Hemoglobinopathy Protocol  Page 67 
17 Measured by [CONTACT_331271], in whole blood and fractionated for lymphoid an d myeloid components; Bone marrow chimerism is an acceptable alternative.  
 Optional: Red cell chimerism measured after day 180 and 365 when RBC transfusion independence has been achieved for a minimum of 2 months.  
18 Hb-electrophoresis only needed pre -transplant (within 7 days prior to initiation of conditioning) in SCD non-chronically RBC transfused patients . If the HbS level is >45% 
then the patient must receive RBC transfusions or erythrocyte exchange prior to conditioning initiation.  Post transplant Hb-electrophoresis at day [ADDRESS_409651] reconstitution has occurred.  
19 (fever, chills, allergic reaction/hypersensitivity, anaphy laxis, sinus bradycardia, sinus tachycardia, hypertension, hypotension, nausea, vomiting, diarrhea, dyspnea, 
hypoxia, hemoglobinuria, infection, flank pain and any other skin, CNS,  cardiac, pulmonary or other toxicity manifestations) . 
[ADDRESS_409652] vial starting day +1 until the ANC is > 2,000/µl x 3 consecutive days . 
22 As per site practice . 
23 Tests performed 30 days prior to screening are acceptable.  
24 It is recommended that these tests be performed ≤ 90 days prior to the initiation of conditioning regimen. However, provided the patient has been asymptomatic since the 
time of the tests, they can be done up to 6 months  prior to the initiation of conditioning regimen.  
25  It is recommended that the X -ray be performed ≤ 30 days prior to the initiation of the conditioning regimen.  However,  it can be done < 60 days prior to the initiation of 
the conditioning regimen, provided the patient has been asymptomatic  since the time of the X -ray scan . 
26 The requirement for a baseline MRI/MRA of the brain to assess for radiologic disease applies only to the patients with SCD; it is not required for patients with 
Thalassemia. Tests from within [ADDRESS_409653] - transplant.  
 
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 68 
7. DETAILED STUDY PLAN  
7.1. Pre-Screening Activities: Search for  Matching CBUs  
In Part 1: potential cand idates for double CBT for whom a searc h yielded matched 
unmanipulated and manipulated CBUs will be identified as screen candidates for the study.  
 In Part 2: potential candidates for single  CBT for whom a search yielded a matched CBU  
will be identified as screen candidates for the study.   Units must be HLA -matched at 4 -6/6 HLA class I (HLA -A & HLA- B, low resolution) 
and II (HLA -DRB1, high res olution) loci with the patient  and, for Part 1, 3-6/6 HLA -A, 
B, DRB1 loci with each other (using same resolution of typi[INVESTIGATOR_007]). Double mismatch at any one locus (A, B, or DRB1) is not permitted.  
 The manipulated CBU should contain a  pre-cryopreserved (post -processing) total 
nucleated cell dose of ≥1.8x10
9 and ≥1.8x107/kg for patients weighing ≥ 25 kg or a pre -
cryopreserved  (post -processing) total nucleated cell dose of ≥1.6x109 for patients 
weighing < 25kg. In Part 1: the unmanipulated CBU  should contain a pre -cryopreserved  
(post -processing) , nucleated cell dose of at least [ADDRESS_409654] matched unit (as per Investigator's discretion).  
 
The manipulated CBU should contain a pre -cryopreserved  (post -processing) , total 
CD34+ cell count  of ≥ 8x106 for patients weighing ≥ 25 kg and a pre -cryopreserved  
(post-processing) , total CD34+ cell count  of ≥7x106 for patients weighing < [ADDRESS_409655] undergone volume reduction (both pl asma and red blood cell 
depletion) prior to cryopreservation.  
 
All CBUs should be procured from public banks that meet local applicable re gulations. 
Donors are screened and tested in accordance with the relevant regulatory requirements . 
The CBU should be tested for the applicable infectious diseases and be eligible. In case 
the CBU is ineligible or with unusual findings, the clinical site sh ould fill out an urgent 
medical need document.  
 
The selected units  should be typed twice ( i.e., initial typi[INVESTIGATOR_331208]).  
Verification (confirmatory) typi[INVESTIGATOR_331209] a lab that is ASHI/EFI accredited and 
must come from an attached segme nt.  
 
An acceptable CBU (meeting CBU acceptance criteria as defined above) must be 
identified and available prior to patient’s screening.  
7.2. Informed Consent and Registration  
A conference will be held with the patient and family to discuss this study and alte rnative 
treatments available for the treatment of the underlying disease. The conference will be conducted by [CONTACT_458] [INVESTIGATOR_331210] (accordi ng to local regulations) that has been delegated by [CONTACT_331272].  
 Standard of care workup for transplant may be done prior to patient consent. Prior to performing any study activities/evaluations that are not part of the site’s routine clinical practices, the patient  and/ or his/her legal guardian must be thorou ghly informed about all 
aspects of the study, including scheduled study visits and acti vities, and must sign the 
  
 GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)
 
 
NiCord® Hemoglobinopathy Protocol   Page 69 
written informed consent. Informed consent from the patient and/or his/her legal guardian will be obtained using a form approved by [CONTACT_331273].  A si gned copy of the written informed 
consent should be given to the patient  and/or his/her legal guardian . 
 Standard of care h ydroxyurea dose adjustment is permitted prior to consent  if it is in  the 
best interest of the patient regardless of the patient’s participation in the trial.  
   
7.2.1. C
 onsent of minors  
As a rule, a pediatric subject is legally unable to provide informed consent. Therefore , 
pediatric study participants are dependent on their parent(s)/legal guardian to assume 
responsibility for their participation in clinical studies.  Fully informed consent should be 
obtained from the legal guardian in accordance with regional laws or regulations. All participants should be informed to the fullest extent possible about the study in language and terms they are able to understand. Where appropriate, participants should assent to enroll in a study (age of assent to be determined by [CONTACT_1744]'s/EC's or be consistent with local legal requirements). Participants of appropriate intellectual maturity should personally sign and date either a separatel y designed, written assent form or the written informed 
consent. In all cases, pa rticipants should be made aware of their rights to decline to 
participate or to withdraw from the study at any time. Attention should be paid to signs of undue distress in pat ients who are unable to clearly articulate their distress. Although a 
participant ’s wish to withdraw from a study must be respected, there may be 
circumstances in therapeutic studies for serious or life -threatening diseases in which, in 
the opi[INVESTIGATOR_331211](s)/legal guardian, the welfare of a pediatric 
patient wou ld be jeopardized by [CONTACT_331274]. In this 
situation, continued parental (legal guardian) consent should be sufficient to allow participation  in the study. Emancipated or mature minors (defined by [CONTACT_1207]) may be 
capabl e of giving autonomous consent. 
7.3. Eligibility/Screening Assessments (within 45 days prior to CBU shipment to the production site)
 
Tests performed during screening period according to the Centers’ routine evaluation of candidates for stem cell transplantation  need not be repeated, provided they were 
performed recently enough, as detailed below.   Patient 's eligibility for the study will be assessed. The activities will be performe d as 
detailed in Table 4 and will include:  
• Routine screening  evaluation: 
 Medical history including primary and concomitant disease and historical medications  
 Concomitant medications will be recorded in the patient’s medical record 
 Patient s’ Performance score by [CONTACT_175739] (age ≥ 16) or Lansky Pl ay-
Performance scale (age < 16) 
 Physical examination and vital signs (including height, weight and BSA) 

  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 70 
 Laboratory: CBC  with WBC differential  
 Blood chemistry (serum creatinine, total bilirub in, alkaline phosphates, AST, 
ALT, and magnesium at a minimum)   
 Serum beta hCG (females of childbearing potential )  
 Complete urinalysis with microscopic examination 
 Anti-HLA antibodies  (tests from within 30 days prior to screening are 
acceptable)  
 Radionucl ide GFR is strongly recommended as the test of choice. Measurement 
of 24- hour urine creatinine clearance is acceptable if the former is not available.  
Estimated GFR using the serum creatinine and patient weight/age/sex is not an 
acceptable alternative.  Te sts from 90 days prior to screening are acceptable for 
eligibility, provided the patient has been asymptomatic since the time of the tests  
 Serologic infectious disease markers for: CMV, Hepatitis panel (HepB sAg, 
HepB Core Ab, HepC Ab), EBV Ab , herpes simp lex virus, syphilis  Ab (such as 
RPR) , HIV and HTLV I/II  antibody, and varicella zoster  
 Dental Consultant (recommended, optional)  
 Physiologic reserves assessment:  
− Pulmonary Function Tests including Carbon Monoxide Diffusing 
Capacity (DLCOc ), FEV1, FVC, and oxygen saturation, if the patient is 
able to perform.  (If PFT testing included the use of bronchodilators, then the baseline results prior to the administration of any medications should be used when determining eligibility).  It is recommended that these  tests 
be performed ≤ 90 days prior to initiation of the conditioning regimen. However, provided the patient has been asymptomatic since the time of the tests  they can be done  up to 6 months  prior to initiation of the 
conditioning regimen  
− 12 lead ECG (test s performed within 30 days  prior to screening are 
acceptable)  
− Baseline echocardiography for left ventricular ejection fraction (LVEF), left ventricular shortening fraction and presence or absence of tricuspid regurgitation. If present, measure jet ve locity  as a measure of pulmonary 
hypertension. It is recommended that these tests be performed ≤ 90 days prior to initiation of the conditioning regimen. However, provided the patient has been asymptomatic since the time of the tests, they can be done  
up to 6 months  prior to initiation of the conditioning regimen  
 Autologous stem cells harvest from BM should be obtained as per site practice, 
or related haploidentical donor/back -up CBU(s) to be identified (as detailed in 
the inclusion criteria), in case of en graftment failure. If Autologous stem cells 
harvest from BM is chosen as the backup graft source, the backup BM harvest can be obtained during Baseline , but prior to the start of conditioning treatment, 
for patients who have an alternative back -up stem cel l sour ce identified.  
• CBU match:  
 Patient and CBU ABO and Rh typi[INVESTIGATOR_007]  
 Patient HLA class I & II high resolution typi[INVESTIGATOR_007]  
 Peripheral blood baseline sample for chimerism laboratory  
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 71 
 CBU HLA class I  (A, B, and C)  & II (DRB1) high resolution typi[INVESTIGATOR_007].  Note that 
although the matching requirement per protocol only requires low resolution A 
and B matching, high resolution DNA based typi[INVESTIGATOR_331212] A, B, C  as 
well as DRB1  
All above  mentioned activities should be completed prior to sending the  CBU to the 
production site for expansion. Sites may perform standard of care preparation for transplantation ( i.e., hydroxyurea administration) during the eligibility/screening phase in 
order not to delay the date of transplantation.  
7.4. Baseline Assessments (Within 4 weeks  prior to start of conditioning)  
All tests must be perform ed during baseline period  unless exception  as detailed below.  
Baseline activities will be performed as detailed in Table 4 and will include:   
• Medical history including pr imary and concomitant disease  
• Concomitant medications will be recorded in the patient’s medical record  
• Patients’ Performance score by [CONTACT_175739]  (age ≥16) or Lansky Play- Performance 
scale (age < 16) 
• Physical examination and vital signs (including height, weight and BSA)  
• Laboratory: CBC with WBC differential, blood chemistry (serum creatinine, total 
bilirubin, alkaline phosphates, AST, ALT, and magnesium at a minimum)  
• Serum beta hCG (females)  
• Peripheral blood baseline sample for chimerism laboratory . Sample can be 
collec ted during screening if more convenient . 
• Radionuclide GFR is strongly recommended as the test of choice. Measurement of 24- hour u rine creatinine clearance is acceptable if the former is not available. 
For baseline testing, can be done up to 90 days prior t o initiation of the 
conditioning regimen, provided the patient has been asymptomatic since the time of the tests  
• Immunophenotypi[INVESTIGATOR_007] – Lymphocyte subsets: CD3, CD4, CD8, CD19, CD16/56 
and additional immunophenotypi[INVESTIGATOR_331197]  
• Immunoglobulin levels (IgG, IgA, IgM)  
• Blood sample for T -cell Receptor Excision Circles (TREC)  
• Chest X -ray. It is recommended that the X -ray be perfo rmed ≤ 30 days prior to 
the initiation of the conditioning regimen.  However, it can be done < 60 days prior to the initiation of the conditioning regimen, provided the patient has been 
asymptomatic since the time of the X -ray scan.  
• CT sinus, chest, abdome n, pelvis  (Tests performed 30 days prior to screening are 
acceptable)  
• Serologic tests for: CMV, Hepatitis panel (HepB sAg, HepB Core Ab, HepC Ab), 
EBV Ab , herpes simplex virus, syphilis  Ab (such as RPR) , HIV and HTLV I/II 
antibody, and varicella zoster  
• MRA/MRI of the brain to assess for radiologic disease - applies only to SCD 
patients; it is not required for p atients with Thalassemia. MRA/MRI tests from 
within [ADDRESS_409656] history 
  
 GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)
 
 
NiCord® Hemoglobinopathy Protocol   Page 72 
of CNS complications tests from up to within 30 days prior to screening are 
recommended .   
All above mentioned activities should be completed and resulted  prior to initiation of the  
conditioning r egimen . 
7.6. Preparat ive Phase  (Day –35 to one day prior to start of conditioning 
regimen ) 
In Part 1: Prior to the initiation of the conditioning reg imen (i.e., Day -10 for patients on 
Regimen #1 or Day -15 for patients on Regimen #2), the unmanipulated CBU must be present at the Clinical Site. Patient's monitoring during the preparative period  (including 
physical examination, vital signs, CBC and blood chemistry ) will be evaluated per 
section 6.3.1 .  
 In SCD patients, Hb -electrophoresis (Hb F, Hb S, Hb A2) will be assessed within [ADDRESS_409657] be ≤45% or the 
patient must receive appropriate therapy calculated to reduce Hb S to ≤ 45%.  Viral 
screening is suggested prior to administration of the conditioning regimen to confirm 
absence of infection.  Patients with fev er or suspected minor infection should await 
resolution of symptoms before starting the conditioning regimen.   
7.7. Eligibility Confirmation: (one week prior to start of conditioning 
regim en) 
Confirm that all previous eligibility tests are still up to date, an d repeat any tests that are 
outside of the acceptable timeframe for eligibility.   Viral screening is suggested prior to 
administration of the conditioning regimen to confirm absence of infection.  At the investigator’s discretion, patients with fever or su spected minor infection should await 
resolution of symptoms before starting the conditioning regimen. 
7.8. Conditioning Phase  
The preparative & conditioning regimen will be administered  as detailed in section 6.3
. 
The choice of conditioning regimen will be at the Investigator’s discretion. GvHD 
prophylaxis will be administered as deta iled in s ection 6.4
Patient monitoring during the 
conditioning phase (including physical examination, vital signs, CBC and blood 

  
 GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)
 
 
NiCord® Hemoglobinopathy Protocol   Page 73 
chemistry) will be evaluated as per site practice.  CMV PCR is required  as outlined in 
section [IP_ADDRESS]). 
7.9. Pre-Transplantation Day (Day 0) 
Safety A ssessment  
Prior to transplantation, the patient will be evaluated  by [CONTACT_331275]: 
• Physical Examination including weight 
• CBC, blood chemistry 
• Vital Signs: temperature, blood pressure, pulse, respi[INVESTIGATOR_184013]  
7.9.1. Preparation and Infusion of t he Unmanipulated CBU and NiCord®  
[IP_ADDRESS]. Unmanipulated CBU Preparation  (Part 1) 
The unmanipulated CBU should be thawed and diluted by [CONTACT_331276].   The CBU will be placed in a sterilized zip lock bag. The bag will then be submerged in a 37°C water bath and agit ated until almost all ice crystals ha ve dissolved followed by 
[CONTACT_331277] (as per institutional practice) to preserve cell viability. The thawed and diluted CBU should be next weighed and centrifuged, supernatant should be removed and the CBU pellet sh ould be re-suspended (as per institutional practice) . An aliquot from the 
unmanipulated CBU will be removed prior to infusion to measure the total number of nucleated cells, percent of cell viability  and percentage of the CD34
+ cell population. As 
per inst itutional practice, additional tests may include CFU, ALDHbr, 7 -AAD, glyA cell 
content and FACS analysis for the percentage of the CD133+, CD45+, CD3+, CD4+, 
CD8+, CD19+, CD16+CD56+ cell populations. The CBU should be labeled with the 
patient identification information and transferred to the bedside for infusion.   
[IP_ADDRESS]. Preparation of NiCord® Non -cultured  Fraction (NF)  
 
NiCo
rd® NF will be kept frozen until the day of transplantation . It will be shipped to the 
clinical site , together with NiCord® CF, in a cryo shipper equipped with a calibrated data 
logger, prior to transplantation.  The SLM will fax /email the NiCord® NF final CoA to 
the clinical site.  NiCord® NF will be sent  with the required documentation according to 
the manufacturer's SOP.   
 Upon arrival, NiCord
® NF should be kept in a controlled Liquid Nitrogen freezer  (≤ -
150°C) until transplant.   
 

  
 GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)
 
 
NiCord® Hemoglobinopathy Protocol   Page 74 
 
[IP_ADDRESS]. Prepa ration of NiCord® Cultured Fraction (C F)  
Upon completion of the manufacturing process, final QC tests of NiCord® CF are 
initiated , and NiCord® CF is label ed and cryopreserved according to the Manufacturer's 
SOPs . The QC tests performed are divided into bioassays and safety tests. The results of 
the tests should meet predefined specifications.  
 
NiCord® CF will be kept frozen until the day of transplantation.  
In parallel to product testing and prior to transplantation, NiCord® CF and NF will be 
shipped with all available CBU segments to the clinical site in a cryoshipper equipped 
with a calibrated data logger, and with any other required documentation accord ing to the 
manufacturer's SOP. 
Upon a
rrival, NiCord® CF should be kept in a controlled Liquid Nitrogen freezer  (≤ -
150°C). 
   

  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 75 
[IP_ADDRESS]. Infusion of the Unmanipulated CBU and/or  NiCord® on Day 0 
The u nmanipulated CBU and/or  NiCord® should not be irradiated under any 
circumstances.    
The i mmediate pre -transplant evaluation will be carried out according to the operating 
procedures of the participating institutions and should be in keepi[INVESTIGATOR_331213].  
 In Part 1: NiCord
® and the unmanipulated CBU will be transplanted on the same day 
with a minimal interval of [ADDRESS_409658]®.   
 
The unmanipulated CBU should be infused via the patient's central venous catheter using 
an in-line filter as per site practice. Rate of infusion will be according to site practice  
 With regards to the NiCord
® infusion: NiCord® CF will be infused first, follo wed 
immediately (up to 1 hour)  by [CONTACT_331278]® NF.  
 Prior to its infusion, NiCord
® must be identified at the Clinical Site according to the 
Sponsor's SOP  and designated Form.  The Clinical Site should check the product labels as 
well as the CoAs and will make sure that all NiCord® fractions & the infusion so lutions 
were shipped in appropriate conditions and are within their shelf life time prior to 
infusing them .  NiCord® CF and NiCord® NF should be in fused via the patient's central 
venous cathet er as per site practice.  
 NiCord
® is intended to be given by [CONTACT_331279].  Infusion of NiCord
® CF and NiCord® NF should not exceed  5 cc/kg/h. NiCord® CF 
and NiCord® NF should be infused as soon as possible after thaw.  
• Total duration of NiCord® CF infusion should target a maximum of [ADDRESS_409659]'s CoA.  
• Total  duration of NiCord® NF infusion should not exceed [ADDRESS_409660]'s CoA.    
• The minimal infusion time is calculated based on  the actual endotoxin test result 
and the endotoxin limit of 5 EU/Kg weight/[ADDRESS_409661] (1 -2 minutes) may 
be required before proceeding with the remainder of the infusion.  
 
A physici an or physician extender (NP or PA) must be present on the patient care unit 
during the infusions and for [ADDRESS_409662] blood infusion should be administered per institutional procedure. Rescue equipment (oxygen) and drugs such as hydrocortisone, epi[INVESTIGATOR_331214], should be available at the bedside for emergency use if infusion reacti ons occur . Furosemide (0.5- 1.0 mg/kg/dose) may be given if volume overload or 
decreased urine output occurs.   
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409663] proves positive  after transplantation , the clinical  
site will be notified and the following steps will be implemented:  
1. Blood cultures will be drawn  
2. Antibiotic coverage will be modified such that the known isolate  will be 
adeq uately covered  
3. Antibiotic coverage will be discontinued if blood cultures prove negative and antibiotic cessation is clinically indicated  
 
The clinical site will receive a final CoA containing all test results . 
7.9.3. Post Transplantation Follow -Up (Day 0 to 1)  
Safety assessment including:  
• Physical Examination  
• Vital Signs: temperature, blood pressure, pulse, respi[INVESTIGATOR_184013] 30, [ADDRESS_409664]
® NF infusion  
• CBC, blood chemistry  
• Assess ment of acute toxicity : 
o Part 1:  F rom the start of the Unmanipulated CBU  infusion up through [ADDRESS_409665]® NF 
o Part 2: From the start of NiCord® CF infusion up through [ADDRESS_409666]® NF 
• Cardiac one lead monitor i s optional; however, ECG twice a day will be 
mandato ry in case of acute  toxicity  
• AEs Reporting 
• G-CSF will be administered beginning on day +1 
• Record RBC and platelet transfusion s  
7.10. Scheduled Treatment Visits ( As Detailed i n Table 4)  
7.10.1. Scheduled Visits on Day 7/ Days (±3) 14, 21, 28, 35, 42, 70/ Day ( ±14) 100/ 
Day ( ±21) 180  
The following assessments are mandatory:  
• AEs and concomitant medications will be recorded  in the patient’s medical record  
• Vital Signs  (note, pulse oximetry not required after the Day 42 visit)  
• Physical examinat ion (days 28, 70, 100, and 180)  including cardiac and 
pulmonary monitoring  
• Karnofsky/ Lansky performance status score (days 28, 70, 100, and 180)  
• CBC with WBC differential (differential not req uired if WBC<0. 2), blood 
chemistry  (serum creatinine, total bilirubin, alkaline phosphatase, AST, ALT and 
magnesium, at a minimum)  
• CMV PCR weekly at the protocol specified visits up through Day 42 and then at 
day 70and day 100or more frequently as clinical ly indicated  
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 77 
• Hb-electrophoresis: H b F, Hb S, Hb A2 (day [ADDRESS_409667] reconstitution has 
occurred )   
• Pulmonary Function Tests including Carbon Monoxide Diffusing Capacity 
(DLCOc ), FEV1, and FVC if the patient is able to perform, and oxygen saturation 
(days 100 and 180)  
• 12 lead ECG (days 100 and 180)  
• Echocardiography for left ventricular ejection fraction (LVEF), left ventricular 
shortening fraction and presence or absence of tricuspid regurgitation.  If present, measure jet velocity as a measure of pulmonary hypertension (days 100 and 180)     
• Cyclosporine  levels as per institutional guidelines to ensure blood levels are 
within target range  
• Peripheral blood collection for chimerism (days 7, 14, 21, 28, 42, 70, 100 and 180 only). Whole blood and lineage specific (CD3 and either CD15 or CD33) 
chimerism will be performed . Optional ly, red cell chimerism will be asse ssed 
after day 180 when RBC transfusion independence has been achieved for a minimum of 2 months.  
• Immunophenotypi[INVESTIGATOR_007] – Lymphocyte subsets: CD3, CD4, CD8, CD19, CD16/56 
(days 100 & 180) , additional immunophenotypi[INVESTIGATOR_331197]   
• Immunoglobulin levels (IgG, IgA, IgM) (days 100 & 180)  
• Blood sample for T -cell Receptor Excision Circles (TREC)  (days 100 & 180)  
• GvHD assessment:  
o Acute: Weekly up to 10 0 days (inclusive)  and at 180 da y visit , or more 
frequently as clinically indicated .  Acute GvHD will be assessed according to 
the Consensus Conference on Acute GvHD grading ( Appendix A ). 
o Chronic: day [ADDRESS_409668] criteria ( Appendix A ) on days [ADDRESS_409669] -transplant, or more 
frequently as clinically indicated  
• GvHD prophylaxis  as specified in section 6.4  
• Infection prophylaxis as specified in section  6.6.7 
• Hospi[INVESTIGATOR_331215]  
• Record RBC and platelet transfusion s through Day 180 
7.10.2. Evaluation and Treatment of Graft Failure  
Evaluation of Graft Failure : should a patient  suffer primary or secondary graft failure,  an 
attempt will be made to determine the cause of failure. Evaluation will include:  
• Chimerism studies, viral/bacterial cultures including PCR analysis for Herpes  
viruses (including CMV and HHV6) . Assessment should be performed between 
day 21 and 42 for pr imary graft failure  
Treatment of Graft Failure : If the patient  meets the definition of primary or secondary 
graft failure , they will be treated at the discretion of the treating physician.  
7.10.3. Early Discontinuation of Follow -up  
Reasons for withdrawal of the patient prior to Day [ADDRESS_409670] be stated in the CRF and in 
the site source documentat ion for all study patient s who were enrolled in the study. This 
  
 GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)
 
 
NiCord® Hemoglobinopathy Protocol   Page 78 
includes patient s who were screened and assigned a screening number but did not start 
the treatment. (Patients will be defined as screening failures when withdrawn from the study before receiv ing the NiCord
® infusion). For early termination patients that 
withdr aw/are withdrawn from the study post transplant, any  assessments due  at the 
time of withdraw  (according to Table 4) are requested . 
Patients who experience graft failure or autologous recovery post transplant will continue 
to be followed for survival.  No other study related assessments are required for these 
subjects after the date of graft failure  or autologous recovery. 
7.10.4. Criteria for Early Termina tion/Discontinuation  
Patient s who are prematurely discontinued from the study should be followed and treated 
by [CONTACT_166842]. Patient s who join the study will 
be asked for permission that their clinical investigato r be allowed to transmit information 
to the trial center on the clinical outcomes as assessed during the usual clinical 
management of their disease over the first year  following treatment. This will allow us to 
continue to gather clinical information on pa tients who subsequently withdraw from 
active participation and did not withdraw informed consent, and to include them in the analyses of all clinical endpoints.  
 A patient may withdraw or be withdrawn from the study for the following reasons : 
• Patient with drew consent  
• Sponsor requested patient  to be withdrawn 
• Request of primary  care physician or Investigator 
• Non-compliance (per investig ator judgment)  
• Lost to follow -up 
• AE 
7.11. Unscheduled Visit  
An unscheduled visit may be performed at any time during the study at the patient's request, or as deemed necessary by [CONTACT_737]. The date and reason for the unscheduled visit will be recorded  in the patient medical record . Vital signs, AEs  and 
concomitant medications will be assessed.  
7.12. Post-study Follow -up 
Clinical outcomes including secondary  graft failure, chronic GvHD , cardiac and 
pulmonary function tests, chimerism, Hb- electropheresis, incidence of life -threatening 
infections, immune re constitution,  routine labs, vital signs, physical exam, performance 
scale, and survival status (including causes of death), will be collected from the center at 
six months post study completion ([ADDRESS_409671] transplantation) , as per site practice. Other 
than life threatening infections and events resulting in death, SAE reporting is not required during post-study follow-up.  Data from the post-study follow-up period will be used in the post -study analysis of one year  post transplant  outcomes. 
7.13. Data Reporting  
7.13.1. Criteria for Forms Submission  

  
 GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)
 
 
NiCord® Hemoglobinopathy Protocol   Page 79 
 

  
 GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)
 
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409672]® 
NiCord® is a cryopreserved cell -based product of allogeneic, ex vivo  expanded, umbilical 
cord blood-derived, hematopoietic CD34+ proge nitor cells ( NiCord® CF) and the non-
expanded cell fraction of the same cord blood unit ( NiCord® NF) consisting of mature 
myeloid and lymphoid cells.  See further details on the cell expansion process in section 3.5 . 
8.2.  
 CBU Supply  
All CBUs should be procured from public banks that meet local applicable regulations. If 
the optimal unit(s) for the patient was determined ineligible or with unusual findings as 
per local regulations, the unit may be used under the urgent medical need provision and 
in consultation with the sponsor. 
8.3. Manufacturing  
NiCord® CF, NF and infusion solution manufacturing will be performed at Gamida Cell 
manufacturing site  by [CONTACT_331280]'s SOPs. 
 NiCord
® is manufactured in  a production site, inside a laminar flow hood (class 100, ISO 
5) within a room that has been qualified as a Class 10,000 (ISO 7), in compliance with the production instructions and procedures as provided by [CONTACT_1034].  QC tests are performed throughout the course of the manufacturing and on the final product and their results are documented. The testing includes in- process quality  controls 
(IPQC) and final process quality controls (FPQC) performed according to the relevant Manufacturer’s SOP . The IPQC and FPQC tests are performed according to written  
analytical methods either by [CONTACT_331281].  
 
IPQC samples from NiCord
® are taken at different identified stages during the process.  
 FPQC samples from NiCord
® NF are taken prior to cryopreservation on day [ADDRESS_409673]® CF are taken prior to cryopreservation on the 
harve st day.   
 All safety and some of the IPQC and FPQC bioassay tests have specifications and the results should be within the provided specifications. Some of the IPQC and FPQC bioassays do not have specifications and results are only collected and documented. 

  
 GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)
 
 
NiCord® Hemoglobinopathy Protocol   Page 81 

  
 GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)
 
NiCord® Hemoglobinopathy Protocol   Page 82 
Tab
le 7: Final Process Quality Control Tests for the NiCord® CF/NF 
Thawing/Infusion Solution 
Test Acceptance Criteria  
Appearance  Clear solution, free of foreign particles  
Safety Tests  
Sterility – bacteria No growth 
Sterility – yeast and molds  No growth 
Endotoxin content (EU/ml)  ≤0.5 
 
8.3.1. Out of Specification Results  
In case an Ou t of Specification (OOS) result is found, a deviation report will be filled out, 
an investigation will be conducted and completed in a timely manner and any corrective 
action sugges ted will be implemented promptly to avoid recurrence  of the incident.  The 
resulting report will be attached to the deviation report and filed in the Batch Record.  
Ni
Cord® NF will be released with a final CoA specifying QC test results.   
 
The infusion solution, used to thaw and dilute the NiCord® CF and NF, will be released 
with a final CoA specifying QC test results.  

  
 GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)
 
NiCord® Hemoglobinopathy Protocol   Page 83 
[IP_ADDRESS]. NiCord® NF OOS  
8.4. Handl ing of Cord Blood Unit  
Packagin g of NiCord® CF, NiCord® NF and the infusion solutions will be performed 
according to the Sponsor’s procedures. 
 
Labeling of NiCord® CF, NiCord® NF and the infusion solutions an d will be performed 
according to the Manufac turer’s SOP.  
8.5. Shipment  
NiCord® CF and NF will be kept frozen at the production site until release, and then will 
be shipped together with all available CBU segments/samples to the clinical site in a cryoshipper equipped with a calibrated data logger and wi th all necessary 
documentations. The infusion solutions for NiCord
® CF and NF will  be shipped to the 
clinical site in parallel in a 2 -8°C package equipped with a calibrated data logger. 
  

  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409674]® will be controlled by [CONTACT_331282] t o assure that 
shipment conditions were maintained as described in the Sponsors procedures. The checks performed will be documented in a special form according to the Manufacturer's SOP. When a shipment is received, the Investigator/Coordinator will acknowl edge 
receipt.  
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 85 
9. SAFETY MONITORING  
9.1. Definitions  
9.1.1. Adverse Event (AE)  
Adverse event means any untoward medical occurrence associated with the use of the 
investigational product, whether or not considered related to the investigational product.  
9.1.2. Infusion Reaction  
Part 1: Any adverse event that begins or worsens ( i.e., increases in grade) between the 
start of the first CBU infusion and 24 hours after the end of the second CBU infusion.   
 
Part 2: Any adverse event that begins or worsens ( i.e., increases in grade) b etween the 
start of the NiC ord® infusion and 24 hours after the end of the infusion.  
9.1.3. Serious Adverse Event (SAE)  
An adverse event or suspected adverse reaction (see section 9.1.4) is considered “serious” 
if, in the view of eith er the investigator or sponsor, it fulfils one or more of the following 
criteria:  
• Results in death  
• Is life -threatening  
NOTE: An event is considered "life -threatening" if, in the view of either the 
investigator or sponsor, its occurrence places the patie nt or subject at immediate 
risk of death. It does not include an adverse event or suspected adverse reaction 
that, had it  occurred in a more severe form, might have caused death.  CTCAE 
grade four events are not automatically defined as life threatening for SAE determination.  For example, a grade four increase in ALT/SGPT may or may not be deemed as life threatening by [CONTACT_1755]/or sponsor. 
• Requires inpatient hospi[INVESTIGATOR_12331]:  Complications that occur during hospi[INVESTIGATOR_1084].  If a complication prolongs hospi[INVESTIGATOR_9236], the 
event is serious.  Elective or previously scheduled hospi[INVESTIGATOR_31643]- existing 
conditions which have not worsened after init iation of treatment should not be 
classified as SAEs.  Any hospi[INVESTIGATOR_331216].   
• Results in p ersistent or significant disability or incapacity  
NOTE:  The term disability is defined as a substantial disruption of the ability to 
conduct normal life functions.   This definition is not intended to include experiences of relatively minor medical signif icance, such as uncomplicated 
headache, nausea, vomiting, diarrhea, influenza, or accidental trauma ( i.e., 
sprained ankle) that may interfere or prevent everyday life functions but do not constitute a substantial disruption.  
• Is a congenital anomaly/birth defect  
Important medical events that do not meet any of the criteria above should be considered 
serious w hen, based upon appropriate medical judgment, they jeopardize the patient or 
subject or require medical or surgical intervention to prevent one of the outcomes listed in this definition.  
  
 GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)
 
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409675]  caused the event. “Reasonable possibility” 
means there is evid ence to suggest a causal relationship between the drug and adverse 
event.  The Investigator must make the determination of relationship to the study product for 
each AE/SAE.  Alternative causes, such as natural history of the underlying diseases, concomitant therapy, other risk factors, and the temporal relationship of the event to the study product, will be considered and investigated. The Investigator will also consult the Clinical Investigator’s Brochure and/or Product Information for marketed products in the determination of his/her assessment . 
9.1.5. Causality  
The Investigator must make the determination of c ausal relationship to the study product 
for each AE/SAE. The Investigator should decide whether, in his or her medical judgment there is a reasonable poss ibility that the event may have been caused by [CONTACT_331283]. Alternative causes, such as natural history of the underlying diseases, concomitant therapy, other risk factors, and the temporal relationship of the event to the study product, will be cons idered and investigated.   
9.1.6. Expectation 
Unexpected: An event is considered “unexpected” when it is not listed in the IB or it is not listed at the specificity and severity that has been observed. It also refers to AEs  or 
suspected adverse reactions that are mentioned in the investigator’s brochure but are not specifically mentioned as occurring with the particular drug under investigation.  
9.1.7. Toxicity Grading  
All AEs will be graded using NCI’s CTCAE Version 4.03. An AE that is assessed as grade three ( i.e., “severe”)  should not be confused with an SAE.  Severity is a category 
used for rating the intensity of an event; both AEs and SAEs can be assessed as severe.  An event is described as ‘serious’ when it fulfils one or more of the criteria  described in 
section  9.1.3 . 
9.1.8. Expedited Reporting  
• G
rade 3 -5 infusion reactions  
• Part 1: Non -engraftment at [ADDRESS_409676] ® cultured cell and 
unmanipulated CBU infusion   
• Part 2: Non -engraftment at [ADDRESS_409677] ® infusion 
• All serious, unexpected, suspected adverse reactions as defined in 21 CFR312.32  
After initial notification within 24 hours, a detailed summary of the events above is  
required from the Investigator within 2 working days of knowledge of the event.  The summary will include date of onset, peak grade, potential causes, resolution date (if applicable), past medical history, concomitant medications, an event narrative, and actions taken.  A discharge summary or hospi[INVESTIGATOR_331217].  
 

  
 GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)
 
 
NiCord® Hemoglobinopathy Protocol   Page 87 
Other  SAEs that do not meet the criteria for expedited reporting should also be reported 
within 24 hours of the transplant team’s knowledge of the event. Other non serious AEs  
should be recorded in the database as outlined in Appendix B .   
Clinical centers are expected to report AEs to their IRB according to their own institutional guidelines.  
9.2. Observ ation, Detection and Recording of AEs and SAEs  
The Investigator and/or study personnel will enquire about the occurrence of AEs at 
every  visit, after the subject has had the opportunity to spontaneously mention any 
problems.  Because of their underlying di sease and toxic preparative therapy, a wide 
range of adverse events are anticipated.   
All AEs will be recorded in the source documents with sufficient detail to allow for 
grading per CTCAE v4.03, and reported on the appropriate CRF page.  
• All infections p ost transplant will be reported on an infection form.   
• Graft versus Host Disease (GvHD) will be reported on GvHD forms.   
• Common events post transplant  (summarized in Appendix C) will be reported on 
the Toxicity Form.  For these common events, the highest grade over a given 
interval will be recorded on a Toxicity form, with the exception of some GvHD 
symptoms which will be recorded on the GvHD forms.  
• Serious Adverse Events post transplant will be reported on SAE summary forms  
• Hospi[INVESTIGATOR_331218]; this is reported on the Hospi[INVESTIGATOR_331219].  
Serious Adverse Events  
At all times during the transplant  and post transplant follow-up phase , SAEs will be 
reported on SAE summary forms.  These events may require reporting on other forms as well (e.g., Death form when applicable).  SAEs must be reported within 24hrs of the 
transplant team’s  knowledge of the event.    
Where possible, a diagnosis rather than  a
  list of symp toms should be recorded. The 
investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. In such cases, the diagnosis should be documented as 
the AE/SAE and not the individual signs/symptoms.  If a diagnosis has not been made 
then each symptom should be listed individually. 

  
 GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)
 
 
NiCord® Hemoglobinopathy Protocol   Page 88 
9.3. Follow- up of AEs  and SAEs  
All reported AEs and SAEs will be followed and recorded until resolution with or 
without sequelae (the patient’s health has returned to baseline status or all variables have returned to normal), until the condition stabilizes (the investigator do es not expect any 
further improvement or worsening of the event), until an outcome is reached or the event is otherwise explained, or until there is agreement between the investigator and Sponsor that additional follow -up is not warranted. The investigator will ensure th at follow -up 
includes any supplemental investigations as may be indicated to elucidate the nature and/or causality of the AE/SAE.  This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other he alth care 
professionals. Where appropriate, medical tests and examinations will be performed to document resolution of the event(s).  Additional follow-up information, if required, or available, must be reported in the same timelines as init ial information .  New or updated 
information will be recorded on the originally completed CRF, with all changes to SAEs signed and dated by [CONTACT_30036] a source document and maintained in the site’s study files. 
9.4. Clinical Laboratory Evaluations  
All laboratory measurements will be evaluated for abnormalities.  An abnormal 
laboratory finding is not by [CONTACT_331284].  The abnormal laboratory finding does not ha ve to be associated with the use of NiCord
® to be considered clinically 
significant.  
9.5. Pregnancy  
Investigators must inform all female subjects of child -bearing potential that it is currently 
unknown whether NiCord® poses any risk to an unborn child, and should instruct subjects 
to use appropriate methods of contraception. Subjects should also be instructed to inform the investigator immediately should they become pregnant during the study. The investigator should counsel the subject, discuss th e risks of continuing with the pregnancy 
and the possible effects on the fetus. The investigator should also recommend that the subject be closely monitored by [CONTACT_331285], and once concluded, that both the subject and her infant be carefully monitored throughout the puerperium. Breast feeding is not recommended as there is no data regarding the safety of a nursing child either during or following NiCord
® administration to the mother. All 
AEs will be communicated  to the investigator by [CONTACT_423]. 
 Pregnancy will not be considered as an AE. Any report of pregnancy recorded for any female study participant or a female partner of a male study participant should be reported immediately within [ADDRESS_409678] notify the Sponsor of the outcome within 24 hours of the Investigator’s knowledge of the pregnancy outcome.  This notification includes pregnancies resulting in live, “normal” births.  

  
 GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)
 
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409679] experiences an SAE during pregnancy, or the outcome of the pregnancy meets the criteria for classification as an SAE, the Investigator should follow the procedures for reporting SAEs ( i.e., report the event to the Sponsor within 24 hours of 
the Investigator’s knowledge of the event). 
All neonatal deaths and congenital anomalies that occur within 30 days of birth (regardless 
of causality) should be reported as SAEs to the Sponsor.  In addition, any infant death or congenital anomaly occurring after [ADDRESS_409680]. Full d etails of withdrawal criteria are provided in section 5.4 .   
9.7. Medical Monitor Review  
• Grade 3 -
 5 infusion reactions  
• Part 1: Non -engraftment at [ADDRESS_409681] ® cultured cell and 
unmanipulated CBU infusion 
• Part 2: Non -engraftment at [ADDRESS_409682] ® infusion   
• All serious adverse events as defined in [ADDRESS_409683]
® cultured cell and unmanipulated CBU infusion 
(Part 1), non- engraftment at [ADDRESS_409684]® infusion (Part 2), and all serious, 
unexpected, suspected adverse reactions are reported to the FDA by [CONTACT_124730] a written report within fifteen da ys of receipt of the information (21 CFR 312.32).   
 

  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409685]
® with or without an unmanipulated cord blood unit to patients 
with Hemoglobinopathies  following myeloablative therapy.  
 
Safety and efficacy data from all participating patients will be reviewed periodically by [CONTACT_23275] (DMC). Interim analyses will be conducted to check for safety with regard to ser ious acute toxicity, neutrophil engraftment by [CONTACT_4475] 
42, and transplant related mortality at [ADDRESS_409686]
® will be included in th e statistical 
analyses. Summary data and listings of the patients who were ex cluded from efficacy and 
safety analyses will be appended to the clinical trial report in order to enable an assessment of the nature of the missing data.  
 Final analysis will be performed when the planned [ADDRESS_409687]
® and unm anipulated cord blood have been assessed [ADDRESS_409688]® without unmanipulated cord 
blood have been assessed  [ADDRESS_409689] evaluable patient has been 
assessed after transp lant.  The final analysis for Part 2 will include a seconda ry analysis 
in which Part 1 and Part 2 patients are evaluated together , however, the results of the 
separate analyses will be shown with the combined analysis.  
 
Interim analyses may be conducted as  the study is on- going at the Sponsor’s discretion.  
There will be no adjustment to control the overall Type I error.  
10.1. Patients & Analysis Cohorts  
The following data analysis sets are defined for the final analysis of this study:  
Part 1 and Part 2 Primary  (ITT) Data Analysis Sets  consist of all patients who have 
entered the study under Part [ADDRESS_409690] 6 patients who enrolled in Part 1 and were  evaluated for 
acute toxicity, neutrophil engraftment  and percent  donor derived engraftment/chimerism 
(of either NiCord
®, unmanipulated CBU or both) by [CONTACT_4475] [ADDRESS_409691] been evaluated for acute toxicity, neutrophil engraftment and percent donor derived engraftment/chimerism by [CONTACT_4475] 42 and 100- day transplant related mortality  
10.1.1. Per Protocol (PP) Data Analysis Set  
The two  Per Protoco l Data Analysis Set s will include all patients enrolled in Part [ADDRESS_409692]
® with or without the unmanipulated 
CBU and who, in addition, met all of the following criteria:  
a) Did not receive any stem cel ls up to day [ADDRESS_409693]® and, if in Part 
1, the unmanipulated CBU ( e.g., second unmanipulated CBU)  
b) Did not die prior to day 14 
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 91 
c) Received myeloablative conditioning therapy according to or similar to that 
specified in the protocol  
d) Did not seriously contravene the eligibility criteria specified in section 5.2  
e) Did not receive a NiCord® transplant that was outside FPQC  limits, as specified 
in section 8.3  
 
Patients satisfying the above criteria will be termed "evaluable".  All study endpoints will 
be assessed in the PP cohort s. 
10.1.2. Withdrawals from the Trial  
• Patients who enter the study but do not receive a transplant of CB cells (screening 
failures) will not be included in the main statistical analysis and wi ll be replaced.  
• Patients who join the study will be asked for permission that their clinical 
investigator be allowed to transmit information to the trial center on the clinical 
outcomes as assessed during th e usual clinical management of their disease over the 
first year  following treatment. This will allow us to continue to gather clinical 
information on patients who subsequently withdraw from active participation without withdrawal of the informed consent, and to include them in the analyses of 
all clinical endpoints  
10.2. Sample Size  
Up to [ADDRESS_409694] satisfied all the per protocol criteria (as specified in section 10.1.1), then further patients will be recruited. The se sample size s were  chosen 
for this pi[INVESTIGATOR_331220] w ere not calculated to meet any specific considerations 
of statistic al power. It is however, rather  typi[INVESTIGATOR_331221]. The number is large enough to provide reasonable experience with the practical issues involved in administering the treatment and small enough to allow a reasonably 
rapid progression to the next phase of the research, should the treatment appear both safe and promising.  
10.3. Interim Analysis & Early Stoppi[INVESTIGATOR_331222]. This 
committee review ed the accumulated data after [ADDRESS_409695]
® as a single expanded graft , including:  
• Any occurrence of primary or secondary graft failure  
• Any substantial decrease in donor chim erism (especially myeloid chimerism), 
or evidence of impending graft failure .  
 Particular consideration  will be given to cases of graft failure which can be attributed to 
post-transplant complications such as HHV6 infection,  CMV infection, severe GvHD, 
prolonged ganciclovir usage, or other medicine -related, e.g., MMF, Cidofovir, etc.  
 The committee will mak e recommendations to the Sponsor regarding early stoppi[INVESTIGATOR_331223].  
 
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 92 
Early safety assessment guidelines will  be used to monitor the following events, and alert 
the DMC.  If an alert occurs, accrual to the study will be halted. The DMC will con sider the data in 
depth and make recommendations to the sponsor. It is understood that DMC recommendations to the sponsor  are not binding and that the sponsor is the sole party 
responsible for final decisions regarding termination or continuation of the tr ial. 
10.3.1. Part 1 Guidelines  
The following events will prompt consideration of early stoppi[INVESTIGATOR_331224] 1. 
[IP_ADDRESS]. Serious (Grade 4+5) Acute Toxicities  
If ≥[ADDRESS_409696] 7 or ≥[ADDRESS_409697] 14 patients experience grade 4 or 5 acute toxicity  
[IP_ADDRESS]. Neutrophil Engraftment  
If ≥[ADDRESS_409698] 5 patients, ≥[ADDRESS_409699] 8 patients, or ≥[ADDRESS_409700] 11 patients or >[ADDRESS_409701] 14 patients fail to  achieve neutrophil engraftment by [CONTACT_4475] 42 (from either 
NiCord®, the unmanipulated CBU or both), as defined in Section 4.3.2. Additionally, 
early consideration will  be given by [CONTACT_331245] [ADDRESS_409702] 2 patients fail to en graft.  
[IP_ADDRESS]. Seconda ry Graft Failure  
If ≥[ADDRESS_409703] 5 patients, ≥[ADDRESS_409704] 8 patients, or ≥[ADDRESS_409705] 11 patients or >[ADDRESS_409706] 14 patients experience secondary graft failure, as defined in Section 4.3.2
. 
[IP_ADDRESS]. Transplant Related Mortality At 100 D ays  
If ≥[ADDRESS_409707] 5 patients, ≥[ADDRESS_409708] 8 patients, or ≥[ADDRESS_409709] 11 patients or >[ADDRESS_409710] 14 patients die before 100 days from treatment -related causes.  
 In the case of an early stoppi[INVESTIGATOR_249209], study recruitment may be r enewed based on both 
the recommendation and rationale of the DMC and local IRB approval.  
 
Statistical Notes : The above guidelines are formulated so that an alert will occur if the 
posterior probability is sufficiently high that the chance of an event excee ds a given 
threshold.  
Acute Toxicity : posterior probability that chance of grade 4 or 5 toxicity is greater than 
5% exceeds 0.95. Prior distribution: beta (0.05, 0.95).  Neutrophil Engraftment: posterior probability that chance of no neutrophil engraftment by [CONTACT_4475] 42 is greater than 20% exceeds 0.95. Prior distribution: beta (0.2, 0.8).  Secondary Graft Failure: posterior probability that chance of secondary graft failure  is 
greater than 20% exceeds 0.95. Prior distribution: beta (0.2, 0.8). 
 
Transplant Rel ated Mortality : posterior probability that chance of transplant related 
mortality within 100 days of transplant is greater than 20% exceeds 0.95.  Prior distribution: beta (0.2, 0.8). 
10.3.2. Part 2 Guidelines  
The following events will prompt consideration of ear ly stoppi[INVESTIGATOR_331225] 2, using the same statistical considerations as provided in Part 1 . 
 
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 93 
[IP_ADDRESS]. Serious (Grade 4+5) Acute Toxicities  
If [ADDRESS_409711] 1, or >[ADDRESS_409712] 5 patients experience grade 4 or 5 acute 
toxicity  
[IP_ADDRESS]. Neutrophil Engraftment  
If [ADDRESS_409713] 2 patients,  or ≥[ADDRESS_409714] patient in Part 2 fails to engraft.  
[IP_ADDRESS]. Secondary  Graft Failure  
If [ADDRESS_409715] 2 patients,  or ≥[ADDRESS_409716] 5 patients experience secondary graft failure, 
as defined in Section 4.3.2. 
[IP_ADDRESS]. Transplant Related Mortality At [ADDRESS_409717] 2 patients,  or ≥[ADDRESS_409718] 5 patients die before 100 days from treatment -
related causes.  
10.4. Statistic al Analysis  
Patients enrolled in Part 1 and Part 2  will be analyzed separately.  Data listings will be 
provided for Part 2 results, given the small sample size.   A secondary analys is will 
analyze the data from Part 1 and Part 2 patients  combined, however, the results from the 
separate analyses will also be presented with the combined results.   
10.4.1. Primary Endpoints  
[IP_ADDRESS]. Acute Toxicity  
The proportion of patients with grade 4 or 5 toxicity wi ll be estimated together with 95% 
confidence limits based on the binomial distribution. The proportion with toxicity grades 
1, 2, and 3 will also be estimated.  
[IP_ADDRESS]. Neutrophil Engraftment 
To assess the incidence of neutrophil engraftment post transplant , a cumu lative incidence 
curve will be computed along with a 95% confidence interval at [ADDRESS_409719] -transplant.  
Death , autologous recovery, and second transplant  prior to engraftment will be 
considered as a competing risk.  
10.4.2. Secondary Endpoints & Analysis  
Planned secondary endpoints are defined in Section 4 and will be analyzed as follows:  
[IP_ADDRESS]. Transplant Related Mortality  
To assess the incidence of transplant related m ortality , a cumulative incidence curve of 
death occurring in a subject  not preceded by [CONTACT_331286] a 95% confidence interval at [ADDRESS_409720] -transplant.   Autologous recovery will be 
considered as a competing risk.  
[IP_ADDRESS]. Event -free Survival  
The proportion of patients with event -free survival at [ADDRESS_409721] transplant will be 
estimated along with a 95% confidence interval using the Kaplan -Meier method.  Death, 
autologous recovery, primary or secondary graft failure will be considered events for this 
endpoint.   
[IP_ADDRESS]. Overall Survival  
The proportion of patients alive at [ADDRESS_409722] transplant will be estimated using the 
Kaplan -Meier method.  
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 94 
10.4.3. Exploratory Endpoints & Analyses  
The list of exploratory endpoints and their pre -planned a nalyses is as follows:  
[IP_ADDRESS]. Incidence of Donor Cell Chimerism  
The incidenc e of patients achieving donor chimerism (< 90% host cells), from either 
NiCord® or the unmanipulated CBU  if transplanted in P art 1 , at day 100 will be 
estimated.   Death, autologous recovery, and graft failure will be considered competing 
risks for this end point.  
[IP_ADDRESS]. Percentage Donor Chimerism in Whole Blood , CD3+ and Myeloid 
(CD15+ or CD33+) Fractions  
The chimerism proportions of the unm anipulated CBU and NiCord® will be measured on 
days 7, 14, 21, 28, 42, 70, [ADDRESS_409723] transplant  in patients with neutrophil 
engraftment before target day . The distribution of these portions (median, quartiles) will 
be estimated at each time point.  Patients who do not have neutrophil engraftment  will be 
excluded from this analysis.  Patients  who have secondary graft failu re, autologous 
recovery, or who die before target day ( 14, 21, 28, 42, 70, 100 and 180 respectively) will 
be excluded from this analysis after the  event .  The contribution of NiCord® alone will be 
estimated as will the total donor (NiCord® + unmanipulated CBU) contribution.  
[IP_ADDRESS]. Time from Transplantation to Neutrophil Engraftment  
Median time to neutrophil (>500/uL) engraftment will be estimated among those in whom engraftment is achieved.  
[IP_ADDRESS]. Time from Transplantation to Platelet Engraftment  
Median time to platele t (>50K/uL) engraftment will be estimated among those in whom 
engraftment is achieved.  
[IP_ADDRESS]. Platelet Engraftment (>50k/uL) at 180 Da ys  
To assess the incidence of platelet engraftment (>50k/uL) post transplant a cumulative 
incidence curve will be computed along with a 95% confidence interval at [ADDRESS_409724] -
transplant.  Death , autologous recovery, and second transplant  prior to engraftment will 
be considered as a competing risk.  
[IP_ADDRESS]. Acute GvHD Grade II- IV and III- IV 
The cumulative incidence of patients who experie nce these events will be computed 
along with a 95% confidence interval at day 100. Death, autologous recovery, graft failure  
and second transplant will be counted as competing risks  in the estimation.  
[IP_ADDRESS]. Chronic GvHD (Limited or E xtensive)  
The cumulative inc idence of patients who experience this event will be computed along 
with a 95% confidence interval at day 180. Death, autologous  recovery, graft failure  and 
second transplant will be counted as competing risks in the estimation.  
[IP_ADDRESS]. Regimen -related Toxicity  
The cumulative incidence of patients who experience regimen- related toxicity by [CONTACT_4475] 180 
will be estimated.  
[IP_ADDRESS]. Life-threatening or F atal Infections  
The cumulative incidence of patients who experience life -threatening or fatal infections 
by [CONTACT_4475] 180 will be esti mated.  Death will be counted as competing risk in the estimation  
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 95 
[IP_ADDRESS]. Immune Reconstitution  
The distributions of total immunoglobulin levels at days 100 and 180 (mean, standard 
deviation, median, quartiles) will be estimated. The distributions of the numbers and proportions of different lymphocyte subpopulations at days 100 and 180 (mean, standard deviation, median, quartiles) will also  be estimated.  The distributions of T -cell excision 
circles at days 100 and 180 (mean, standard deviation, median, quartiles) w ill also be 
estimated.  Patients who have graft failure , 
who have autologous reconstitution, or who die 
before target day (100 or 180 respectively) will be excluded from this analysis  after the 
event .   
10.4.4. Post Study Analysis  
The following secondary, and exploratory endpoints will also be analyzed as noted in 
sections 10.4.[ADDRESS_409725] transplant; event -free survival, overall survival, percentage donor chimerism, 
incidence of chronic GvHD, incidence of life -threatening and fatal infections, and 
immune reconstitution.  
10.5. Safety Assessment  
10.5.1. Adverse Experiences  
The incidence and frequency of adverse experiences will be presented by [CONTACT_331287]. AEs will also be presented by [CONTACT_1196], High Level Term  and 
preferred terminology. Serious adverse experiences will be listed and discussed on a 
case- by-case basis.  
10.6. Statistical Software  
SAS® version 9.1 or  higher software and R version 2.10.0 or higher will be used for 
statistical analysis and data presentat ion of the information collected in this study.  
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 96 
11. CLINICAL DATA MANAGEMENT  
11.1. Data Quality Assurance  
This study will be organized, performed, and reported i n compliance with the 
Sponsor/CRO’s SOPs, protocols and working practice documents, and the requirements  
of the Declaration of Helsinki and ICH/GCP guidelines. Compliance will be achieved through a combination of study specific audits of investigative site s and audits at regular 
intervals of the Sponsor/CRO’s systems for data handling, analysis, and reporting.  
 A quality assurance audit of this trial may be conducted by [CONTACT_4209]’s designees. The quality assurance auditor will have access to al l medical records, the 
investigator’s trial -related files and correspondence, and the informed consent 
documentation that is relevant to this clinical trial.  
11.2. Data Collection  
Investigators or designees will enter the information required by [CONTACT_331288] o the 
CRFs. Each investigative site will be visited as frequently as documented in the monitoring plan by [CONTACT_331289]. The CRO representative will highlight any discrepancies found betwe en source documents and the completed CRFs and ensure that appropriate 
site personnel address the discrepancies. When a discrepancy results in corrected CRF data, the correction will be reviewed again against the correct source documentation. 
Uniform proce dures will be discussed at the Site Initiation Visit.  
11.3. Source Documents  
Source documents provide evidence  for the existence of the patient and substantiate the  
integrity of the data collected. All clinical data entered onto the CRF must be supported 
by [CONTACT_331290].  Data entered in the CRFs that 
are transcribed from so urce documents must be consistent with the source documents or 
the discrepancies must be explained. The investigator may need to request previous medica l records or transfer records, depending on the trial; also current medical records 
must be available.   
Direct access to source data -  documents  
• The investigator / institution will permit trial -related monitoring, audits, IRB / 
IEC review and regulatory i nspection, providing direct access to all related source 
data / documents.  
• CRFs and all source documents , including progress notes and copi[INVESTIGATOR_331226]’s 
clinical trial monitor and inspection by [CONTACT_21652] ( e.g., MS CA/EMA). 
The Clinical Research Associate (CRA) / o n site monitor may review all CRFs, 
and written informed consents. The accuracy of the data will be verified by [CONTACT_331291]. 
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409726] safety, and adherence to guidelines in the Site Operations 
Manuals.  
 At each site visit, the CRA will review recruitment guidelines and study eligibility criteria.  As the study progresses, completed data forms may be reviewed during site visits and compared to source documentation (medical or site records) to confirm accuracy.  
11.6. Confidentiality  
Individual names of participants will be masked by [CONTACT_331292] a patient identifier code.  The link between the patient’s identity and the ID code will be kept securely  at the center. Only the ID code will be used to identify the 
patient when submitting study data .  Patient identity will not be revealed in any 
presentations or publications resulting from this study. 
 
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 98 
APPENDIX A.  GVHD CLASSIFICATION  
 Acute GvHD Definition  
Acute GvHD will be assessed at every visit from transplantation (day 0) until end of 
study or more fre quently as clinically indicated. GvHD will be classified according to the 
Consensus Conference on Acute GvHD grading:115  
  
Overall Grade  Skin Liver  Gut 
I Stage 1 -2 None  None  
II Stage 3 or  Stage 1 or  Stage 1  
III  Stage 2 -3 or Stage 2 -4 
IV Stage 4 or  Stage 4  
 *See following table for individual organ staging. The overall grade of GvHD, however, reflects the actual extent of disease. For each overall grade, an assessment of skin disease plus liver and/or gut involvement is required.  
 
Acute GvHD may be doc umented after day 99 (“late acute”) if according to the clinical 
judgment the investigator feels it should be classified as acute rather t han chronic.  
 
Clinical Manifestations and Staging of Acute Graft -versus -Host Disease  
Organ  Clinical Manifestations  Staginge 
Skina Erythematous, maculopapular rash 
involving palms and soles; may become confluent  
Severe disease: bullae.  Stage 1: <25% rash  
Stage 2: 25 -50% rash 
Stage 3: generalized erythroderma  
Stage 4: bullae  
Liverb Painless jaundice with conjugated hyper bilirubinemia and increased 
alkaline phosphatase.  Stage 1: bilirubin 2 -3 mg/dL  
Stage 2: bilirubin 3.1 -6 mg/dL  
Stage 3: bilirubin 6.1 -15 mg/dL  
Stage 4: bilirubin >15 mg/dL  
Gastrointestinal tractc Upper: nausea, vomiting, anorexia.  
Lower: diarrhea, abdomina l cramps, 
distention, ileus, bleeding.  Stage 1: diarrhea >500 ml/day  or 
persistent nausea , vomiting, or anorexiad 
Stage 2: diarrhea >1000 ml/day  
Stage 3: diarrhea >1500 ml/day  
Stage 4: large volume diarrhea and 
severe abdominal pain +/ - ileus 
a Use ‘Rule of Nines’ or burn chart to determine extent of rash  
b  Range given as total bilirubin.  Downgrade one stage if a cause of elevated bilirubin  other than GvHD has been documented.  
c  Downgrade  one stage if a cause of diarrhea other than GvHD has been documented.  
d  Persistent nausea with histologic evidence of GvHD in the stomach or duodenum.   Downgrade upper GI one stage if biopsy 
result is negative, or if no biopsy done and GvHD is not an etiology, or if the biopsy is equivocal and GvHD is not an etiology.  
e Although GvHD will be assessed at every protocol- specified visit, GvHD will only be analyzed if it occurs after primary 
neutrophil engraftment.  If GvHD is not an etiology for any organ, t hen GvHD is downgraded to stage 0.  
 
 
 
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page [ADDRESS_409727] Disease  
Involvement  Clinical Criteria  
Limited  Localized skin involvement, liver dysfunction, or both.  
Extensive  Generalized skin involvement  
OR 
Localized skin involvement or liver dysfunction plus any one of the following:  
Chronic aggressive hepatitis, bridging necrosis, cirrhosis.  
Eye involvement (result on Schirmer test: <5 mm).  
Involvement of mucosalivary glands.  
Mucosal involvement (on lip biopsy).  
Involvement of other target or gans.  
 Chronic GvHD will also be classified as mild, moderate, or severe, according to the National Institute of Health consensus grading criteria
51. 
  
 
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol   Page 100 
APPENDIX B.  SAFETY DATA REPORTING  
 
 
 
< [ADDRESS_409728] infusion   Prior to infusion or > [ADDRESS_409729] infusion  
Protocol Specifieda Unspecifiedb  Non engraftment 
@ [ADDRESS_409730] tx  Protocol Specifieda Unspecifiedb 
  Grade [ADDRESS_409731] name & grade on 
 Infusion form  
    -- Submit SAE summary 
 forms  
    -- Expedited report  
   Grade 1 -2* 
    -- Capture name & grade only  
        on Infusion form    Grade 3 -5 
    -- Submit SAE 
 summary forms  
    -- Expedited report  
   Grade 1 -2
*   
    -- Submit AD1       -- Submit SAE 
 summary forms  
   -- Expedited  report    Grade 3 -5
* 
    -- Capture name [CONTACT_331302]
c 
   Grade 1 -2
* 
    -- Not reported    SAE  
    -- Submit SAE 
 summary forms  
    -- If associated w/  
        NiCord® and un-  
        expected then  
        expedited report  
   Grade 3 non SAE  
    -- Submit AD1  
   Grade 1 -2 non SAE  
    -- Not reported  
* If SAE, submit SAE summary forms .  If SAE associated with NiCord®, then submit expedited report  
a Protocol specified events and database reporting location are listed in Appendix C  of this document  
b Unspecified events are events that are not listed as protoco l specified events  
c Visit Summary Forms include: “Transplant Toxicity”, “Acute GvHD”, and “Follow -up GvHD” The following forms are also required when 
applicable:  
• Hospi[INVESTIGATOR_331227], Death Form, Infection Form  required if applicable   
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
  
NiCord® Hemoglobinopathy Protocol    Page 101 
APPENDIX C.  PROTOCOL SPECIFIED ADVERSE EVENTS  
 
< [ADDRESS_409732]® infusion  
Event  Database Location*  
Allergic reaction/ Hypersensitivity  Infusion Form  
Anaphylaxis  Infusion Form  
Diarrhea  Infusion Form  
Dyspnea  Infusion Form  
Fever  Infusion Form  
Hemoglobinuria  Infusion Fo rm  
Hypertension  Infusion Form  
Hypotension  Infusion Form  
Hypoxia  Infusion Form  
Infection  Infusion Form and  
Infection Form  
Nausea  Infusion Form  
Rigors, Chills  Infusion Form  
Sinus bradycardia  Infusion Form  
Sinus tachycardia  Infusion Form  
Vomiting  Infusion Form  
*Grade 3 -5 events also require SAE summary  forms.  
 >[ADDRESS_409733]
® infusion with or without unmanipulated CBU up to [ADDRESS_409734] transplant  
Event  Database Location*  
Acute chest syndrome  Transplant Toxicity  
Alkaline ph osphatase increased  Transplant Toxicity  
ALT increased  Transplant Toxicity  
Avascular necrosis  Transplant Toxicity  
Bilirubin increased  Acute GvHD Form**  
Capi[INVESTIGATOR_331228]**  
Dyspnea  Transplant Toxicity  
Fever  Transplant Toxicity  
Hemorrhage  Transplant Toxicity  
HUS/TTP/Microangiopathy  Transplant Toxicity  
Hypertension  Transplant Toxicity  
Hypotension  Transpla nt Toxicity  
Hypoxia  Transplant Toxicity  
Infection  Infection Form  
Intracranial Hemorrhage  Transplant Toxicity  
Left ventricular systolic dysfunction  Transplant Toxicity  
Maculopapular rash/ Erythroderma  Acute GvHD Form**  
Nausea/ Vomiting/ Anorexia  Acute GvHD Form**  
Non-infective cystitis  Transplant Toxicity  
Oral Mucositis  Transplant Toxicity  
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
  
NiCord® Hemoglobinopathy Protocol    Page 102 
Event  Database Location*  
Pericardial Effusion  Transplant Toxicity  
Pulmonary hypertension   Transplant Toxicity  
Restrictive cardiomyopathy  Transplant Toxicity  
Rigors, Chills  Transplant Toxicity  
RPLS - Reversible Posterior 
Leukoencephalopathy Syndrome  Transplant Toxicity  
Seizure  Transplant Toxicity  
Somnolence  Transplant Toxicity  
Stroke  Transplant Toxicity  
Thrombocytopenia  Transplant Toxicity ***  
*Grade 1 -2 events are not reported.  SAEs also require SAE summary  forms.  
**Note that events on the Acute GvHD form are not graded using the CTCAE  
*** Note that all post transplant related Thrombocytopenia events (grade 0-4) will be captured 
on the Transplant Toxicity  form only, and will not require AE reporting unless associated with 
an SAE.  
 
101-[ADDRESS_409735] transplant  
Event  Database Location*  
Acute chest syndrome  Transplant Toxicity  
Alkaline phosphatase increased  Transplant Toxicity  
ALT increased  Transplant Toxicity  
Avascular necrosis  Transplant Toxicity  
Bilirubin increased  Follow -up GvHD**  
Capi[INVESTIGATOR_331229] -up GvHD**  
Dry eye  Follow -up GvHD**  
Dysphagia  Follow -up GvHD**  
Dyspnea  Transplant Toxicity  and Follow -up 
GvHD**   
Forced expi[INVESTIGATOR_331230] -up GvHD**  
Fever  Transplant Toxicity  
Hemorrhage  Transplant Toxicity  
HUS/TTP/Microangiopathy  Transplant Toxicity  
Hyper tension  Transplant Toxicity  
Hypotension  Transplant Toxicity  
Hypoxia  Transplant Toxicity and  
Follow -up GvHD **  
Infection  Infection Form  
Intracranial Hemorrhage  Transplant Toxicity  
Left ventricular systolic dysfunction  Transplant Toxicity  
Malab sorption  Follow -up GvHD**  
Myositis  Follow -up GvHD**  
Nausea/ Vomiting/ Anorexia  Follow -up GvHD**  
Non-infective cystitis  Transplant Toxicity (  
Oral Mucositis  Transplant Toxicity and  
Follow -up GvHD** (  
Pericardial Effusion  Transplant Toxicity  
Pulmon ary Fibrosis  Follow -up GvHD**  
  
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
  
NiCord® Hemoglobinopathy Protocol    Page 103 
Event  Database Location*  
Pulmonary hypertension  Transplant Toxicity  
Rash  Follow -up GvHD**  
Restrictive cardiomyopathy  Transplant Toxicity  
Rigors, Chills  Transplant Toxicity  
RPLS - Reversible Posterior 
Leukoencephalopathy Syndrome  Transplant To xicity  
Seizure  Transplant Toxicity  
Somnolence  Transplant Toxicity  
Stroke  Transplant Toxicity  
Thrombocytopenia  Transplant Toxicity ***  
Vaginal inflammation  Follow -up GvHD**  
*Grade 1 -2 events are not reported.  SAEs also require adverse event form s SAE summary 
forms.  
**Note that events on the Follow -up GvHD) form are not graded using the CTCAE  
*** Note that all post transplant related Thrombocytopenia events (grade 0-4) will b e captured 
on the Transplant Toxicity  form only, and will not require AE reporting unless associated with 
an SAE.  
 
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol    Page 104 
APPENDIX D.  COMMON TERMINOLOGY CRITERA FOR 
ADVERSE EVENTS V4.0 3  
(CTCAE)   
 
Document available upon request . 
   
 
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol    Page [ADDRESS_409736]  
 
 
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol    Page 106 
REFERENCES  
 
1 Rees DC, Williams TN, Gladwin MT. (2010). "Sickle -cell disease." The Lancet  
376:2018- 2031. 
 
2 Herrick JB. (1910). "Peculiar elongated and sickle -shaped red blood corpuscles in a 
case of severe anemia." Archives of Internal Medicine  6:517 -521. 
 
3 Pauling L, Itano HA, Singer SJ, Wells IC. (1949). "Sickle Cell Anemia, a Molecular 
Disease" Science 110:543 -548. 
 
4 Ingram VM. (1957). "Gene Mutations in Human Hæmoglobi n: the Chemical Difference 
Between Normal and Sickle Cell Hæmoglobin" Nature  180:326- 328. 
 
5 Friedrich MJ. (2011). "Advances Reshapi[INVESTIGATOR_331231]." JAMA: The Journal 
of the American  Medical Association  305:239- 242. 
 
[ADDRESS_409737], Sleeper LA, Pegelo w CH, et al. (2000). "Prediction of Adverse Outcomes in 
Children with Sickle Cell Disease." New England Journal of Medicine  342:83- 89. 
 
7 Gladwin MT, Sachdev V, Jison ML, et al. (2004). "Pul monary Hypertension as a Risk 
Factor for Death in Patients with Si ckle Cell Disease." N Engl J Med  350:886-
895. 
 
8 Panepi[INVESTIGATOR_29416], O'Mahar KM, DeBaun MR, Loberiza FR, Scott JP. (2005). "Health -
related quality of life in children with sickle cell disease: child and parent perception." British Journal of Haematology 130:437- 444. 
 
9 Platt OS, Brambilla DJ, Rosse WF, et al. (1994). "Mortality In Sickle Cell Disease -- 
Life Expectancy and Risk Factors for Early Death." N Engl J Med  330:1639-
1644. 
 
10 Diggs LM. (1973). Anatomic lesions in sickle cell disease. In: Abramson H, Bertl es J, 
DL W, eds. Sickle cell disease: diagnosis, management, education, and research.  
St. Louis: C.V.Mosby; 189- 229. 
 
11 Vichinsky E. (2002). "New therapi[INVESTIGATOR_331232]." The Lancet  360:629- 631. 
 
12 Adams RJ, McKie VC, Hsu L, et al. (1998). "Preve ntion of a First Stroke by 
[CONTACT_331293]." New England Journal of Medicine  
339:5-11. 
 
13 Pegelow CH, Adams RJ, McKie V, et al. (1995). "Risk of recurrent stroke in patients 
with sickle cell disease treated with erythrocyte transfusions." The Journal of 
Pediatrics 126:896- 899. 
 
14 Scothorn DJ, Price C, Schwartz D, et al. (2002). "Risk of recurrent stroke in children 
with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke." The Journal of Pediatrics  140:348- 354. 
  
 
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol    Page 107 
 
15 Hulbert ML, McKinstry RC, Lacey JL, et al. (2011). "Silent cerebral infarcts occur 
despi[INVESTIGATOR_331233]." Blood 117:772- 779. 
 
[ADDRESS_409738], et al. (1995). "Effect of Hydroxyurea on the 
Frequency of Painful Crises in Sickle Cell Anemia." New England Journal of 
Medicine  332:1317- 1322. 
 
17 Walters MC, Patience M, Leisenring W, et al. (1996). "Barriers to bone marrow 
transplantation for sickle cell anemia." Biol Blood Marrow Transplant  2:100 -104. 
 
18 Vermylen C, Cornu G, Ferster A, et al. (1998). "Haematopoietic stem cell 
transplantation for sickle cell anaemia: the first 50 patients transplanted in 
Belgium." Bone Marrow Transplant  22:1- 6. 
 
19 Bernaudin F, Socie G, Kuentz M, et al. (2007). "Long- term results of related 
myeloablative stem -cell transplantation to cure sickle cell disease." Blood  
110:2749- 2756. 
 
20 Locatelli F, Rocha V, Reed W, et al. (2003). "Related umbilical cord blood 
transplantation in patients with thalassemia and sickle cell disease." Blood  
101:2137- 2143. 
 
[ADDRESS_409739] orb R, Patience M, et al. (2000). "Impact of bone marr ow 
transplantation for symptomatic sickle cell disease: an interim report. Multicenter 
investigation of bone marrow transplantation for sickle cell disease." Blood  
95:1918- 1924. 
 
22 Hsieh, M. M., C. D. F itzhugh and J. F. Tisdale (2011). "Allogeneic hematopoietic stem 
cell transplantation for sickle cell disease: the time is now." Blood 118(5): 1197-
1207. 
 
[ADDRESS_409740], A. Fasth, L. Lo Nigro, M. Ayas, D. Purtill, K. Boudjedir, W. Chaves, M. C. Walters, J. Wagner, E. Gluckman and V. Rocha (2011). "Umbilical cord blood transplantation for children with thalassemia and sickle cell disease." Biol 
Blood Marrow Transplant  17(9): 1375- 1382. 
 
24 Rund D, Rachmilewitz E. Beta -thalassemia. N Engl J Med . 2005; 353:1135- 46. 
 
25 Thomas ED, Buckner CD, Sanders JE, et al. Marrow transplantation for thalassaemia. 
Lancet  1982; 2:227- 229. 
 
26 Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow tran splantation in patients 
with thalassemia. N Eng J Med  1990; 322:417- 421. 
 
27 Giardini C , Lucarelli G. Bone marrow transplantation for beta -thalassemia. Hematol 
Oncol Clin North Am , 1999; 13:1059- 1064. 
  
 
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol    Page 108 
 
28 Locatelli F, De Stefano P. New insights into haematopoietic stem cell transplantation 
for patients with haemoglobinopathies. British Journa l of Haematology , 2004; 
125:3- 11. 
 
29 Lucarelli G, Clift RA, Galimberti M, et al. Bone marrow transplantation in adult 
thalassemic patients. Blood  1999; 93, 1164- 1167. 
 
30 Storb RF, Lucarelli G, McSweeney PA, Childs RW. Hematopoietic cell transplantation 
for benign hematological disorders and solid tumors. Hematology (Am Soc 
Hematol Educ Program) . 2003; 372- 97. 
 
31 Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplant ation for patients with 
thalassemia: results in class 3 patients. Blood 1996; 87:2082- 2088. 
 
32 Sodani P, Gaziev D; Polchi P, et al. A new approach for bone marrow transplantation 
in class 3 thalassemic patients aged less than 17 years. Blood  2004; 104: 1201- 3. 
 
33 Ghavamzadeh A, Nasseri P, Eshraghian MR, et al. Prognostic factors in bone mar row 
transplantation for beta thalassemia major: experiences from Iran. Bone Marrow 
Transplant  1998; 22:1167- 1169. 
 
34 Lawson SE, Roberts IA, Amrolia P, Dokal I, Szydlo R, Darby[CONTACT_317954]. () Bone marrow 
transplantation for beta -thalassaemia major: the [LOCATION_006] experience in two paediatric 
centres. Br J Haematol  2003; 120:289- 295. 
 
35 Andreani M., Manna M, Lucarelli G, et al. Persistence of mixed chimerism in patients 
transplanted fo r the treatment of thalassemia. Blood  1996; 87:3494- 3499. 
 
[ADDRESS_409741] disease prophylaxis in patients with severe aplastic anemia given allog eneic bone marrow transplantation from HLA -
identical sibling: results of a GITMO/EBMT randomized trial. Blood 2000; 
96:1690- 1697. 
 
[ADDRESS_409742] 
disease in murine mixed allogeneic chimeras.  Development of a null cell 
population suppressive of cell -mediated lympholysis responses and derived from 
the syngeneic bone marrow component. J Immunol  1988; 140:2903- 2911. 
 
38 Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplanta tion and 
cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease s. Blood 1998; 91:756- 763. 
 
39 Hongeng S, Chuansumrit A, Hathirat P, Rerkamnuayc hoke B, Chaisiripoomkere W, 
Jootar S. Full chimerism in nonmyeloablative stem cell transplantation in a beta -
thalassemia major patient (class 3 Lucarelli). Bone Marrow Transplan t 2002; 
30:409- 410. 
  
 
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol    Page 109 
 
40 Iannone R, Casella JF, Fuchs, EJ, et al. Results of mini mally toxic nonmyeloablative 
transplantation in patients with sickle cell anemia and beta -thalassemia. Biol 
Blood and Marrow Transplant 2003; 9:519- 28. 
 
41 Ende M, Ende N. (1918).  "Hematopoietic trans plantation by [CONTACT_331294] (cord) 
blood. A new method." Va Med Mon  99:276- 280. 
 
42 Broxmeyer HE, Douglas GW, Hangoc G, et al. (1989). "Human Umbilical Cord Blood 
as a Potential Source of Transplantable Hematopoietic Stem/Progenitor Cells." PNAS  86:3828- 3832. 
 
43 Gluckman E, Rocha V. (2005). "History of the clin ical use of umbilical cord blood 
hematopoietic cells." Cytotherapy 7:219- 227. 
 
44 Frassoni F, Podesta M, Maccario R, et al. (2003). "Cord blood transplantation provides 
better reconstitution of hematop oietic reservoir compared with bone marrow 
transplantati on." Blood 102:1138- 1141. 
 
[ADDRESS_409743], J. S. Miller, C. 
M. Verfaillie and J. E. Wagner (2005). "Transplantation of [ADDRESS_409744] blood units to enhance engraftment in a dults with 
hematologic malignancy." Blood 105(3): 1343 -1347. 
 
46 Laughlin, M. J., J. Barker, B. Bambach, O. N. Koc, D. A. Rizzieri, J. E. Wagner, S. L. 
Gerson, H. M. Lazarus, M. Cairo, C. E. Stevens, P . Rubinstein and J. Kurtzberg 
(2001). "Hematopoietic engraftment and survival in adult recipi[INVESTIGATOR_183606] -
cord blood from unrelated donors." N Engl J Med  344(24): 1815- 1822. 
 
47 Scaradavou, A., C. G. Brunstein, M. Eapen, J. Le -Rademacher, J. N. Barker, N. Chao, 
C. Cutler, C. Delaney, F. Kan, L. Isola, C. Ka ranes, M. J. Laughlin, J. E. Wagner 
and E. J. Shpall (2013). "Double unit grafts successfully extend the application of umbil ical cord blood transplantation in adults with acute leukemia." Blood  
121(5): [ADDRESS_409745], D. J. Weisdorf and J. E . Wagner (2009). "Relapse risk after umbilical cord blood transplantation: 
enhanced graft -versus -leukemia effect in recipi[INVESTIGATOR_22880] 2  units." Blood 114(19): 
4293- 4299. 
 
49 Wagner, J., Eapen, M., Carter, S.L., Haut, P.R., Peres, E., Schultz, K.R., Thompson, J., 
Wall, D.A., Kurtzberg, J. (2012). No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant  in Children with 
Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501)  Randomized Trial. ASH. Atlanta.  
 
50 Sideri, A., N. Neokleous, P. B. De La Grange, B. Guerton, M. C. Le Bousse Kerdilles, 
G. Uzan, C . Peste- Tsilimidos and E. Gluckman (2011). "An overview of the 
progress on double umbilical cord blood transplantation." Haem atologica  96(8): 
1213- 1220. 
  
 
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol    Page [ADDRESS_409746] and C. G. Brunstein (2012). "Factors 
predicting single -unit predominance after double umbilical cord blood 
transplantation." Bone Marrow Transplant  47(6): 799- 803. 
 
52 Newell, L. F., F. Milano, I. B. Nicoud, S. Pereira, T. A. Gooley, S. Heimfeld and C. 
Delaney (2012). "Early CD3 Peripheral Blood Chimerism Predicts the Long-Term Engrafting Unit Following Myeloablative Double -Cord Blood 
Transplantation." Biol Blood Marrow Transplant . 
 
53 Eldjerou, L. K., S. Chaudhury, A. Baisre -de Leon, M. He, M. E. Arcila, G. Heller, R. J. 
O'Reilly, J. N. Barker and M. A. Moore (2010). "An in vivo model of double -unit 
cord blood transplantation that correlates with clinical engraftment." Blood  
116(19): 3999- 4006. 
 
54 Moretta, A., G. Andriolo, D. Lisi ni, M. Martinetti, A. Pasi, P. Rebulla, D. Soligo, R. 
Giordano, L. Lazzari and R. Maccario (2012). "In Vitro Evaluation of Gr aft-
versus -Graft Alloreactivity as a Tool to Identify the Predominant Cord Blood Unit 
before Double Cord Blood Transplantation." Bi ol Blood Marrow Transplant  
18(7): 1108 -1118. 
 
55 Gluckman E, Ruggeri A, Volt F, Cunha R, Boudjedir K, Rocha V. (2011). "Milestones 
in umbilical cord blood transplantation." British Journal of Haematology  154:441-
447. 
 
56 Barker, J. N., D. J. Weisdorf, et al. (2005). "Transplantation of [ADDRESS_409747] blood units to enhance engraftment in adults with 
hematologic malignancy." Blood 105(3): 1343 -1347. 
 
57 McKenna DH, Brunstein CG. (2011). "Umbilical cord blood: current status and future 
directions." Vox Sanguinis  100:150- 162. 
 
58 Ballen, K. K., T. R. Spi[INVESTIGATOR_626], et al. (2007). "Double unrelated reduced -intensity 
umbilical cord blood transplantation in adults." Biol Blood Marrow Transplant  
13(1): 82 -89. 
 
59 Kanda J, Rizzieri DA, Gasparetto C, et al. (2011).  "Adult Dual Umbilical Cord Blood 
Transplantation Using Myeloablative Total Body Irradiation (1350 cGy) and 
Fludarabine Conditioning." Biology of Blood and Marrow Transplantation 
17:867- 874. 
 
[ADDRESS_409748] 
Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical  
Trials Network (BMT CTN 0501) Randomized Trial, in ASH . 2012: Atlanta.  
 
61 Pi[INVESTIGATOR_331234], W., F. Sanavio, et al. (1998). "Differential growth factor requirement of 
primitive cord blood hematopoietic stem cell for self -renewal and amplification vs 
proliferatio n and differentiation." Leukemia 12(5): 718- 727. 
  
 
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol    Page 111 
 
62 Vavrova, J., S. Filip, et al. (1999). "Ex vivo expansion CD34+/AC133+ -selected 
autologous peripheral blood progenitor cells (PBPC) in high- risk breast cancer 
patien ts receiving intensive chemotherapy." He matol Cell Ther  41(3): 105 -112. 
 
63 Filip, S., J. Vavrova, et al. (2000). "Myeloid differentiation and maturation of SCF+IL -
3+IL -11 expanded AC133+/CD34+ cells selected from high- risk breast cancer 
patients." Neoplasm a 47(2): 73 -80. 
 
64 Lazzari, L., S. Lucch i, et al. (2001). "Comparison of different serum -free media for ex 
vivo expansion of HPCs from cord blood using thrombopoietin, Flt -3 ligand, IL -
6, and IL -11." Transfusion  41(5): 718- 719. 
 
65 Lazzari, L., S. Lucchi, et al. (2001). "Long- term expansion and m aintenance of cord 
blood haematopoietic stem cells using thrombopoietin, Flt3 -ligand, interleukin 
(IL)- 6 and IL -11 in a serum -free and stroma- free culture system." Br J Haematol  
112(2): 397 -404. 
 
66 Yao, C. L., I. M. Chu, et al. (2004). "A systematic strate gy to optimize ex vivo 
expansion medium for human hematopoietic stem cells derived from umbilical cord blood mononuclear cells." Exp Hematol  32(8): 720 -727. 
 
67 Mohamed, A. A., A. M. Ibrahim, et al. (2006). "Ex vivo expansion of stem cells: 
defining optimum  conditions using various cytokines." Lab Hematol  12(2): 86- 93. 
 
68 Young, J. C., S. Wu, et al. (2004). "Inhibitors of histone deacetylases promote 
hematopoietic stem cell self -renewal." Cytot herapy 6(4): 328 -336. 
 
69 Sato, N., L. Meijer, et al. (2004). "Mai ntenance of pluripotency in human and mouse 
embryonic stem cells through activation of Wnt signaling by a pharmacological 
[COMPANY_004]- 3-specific inhibitor." Nat Med  10(1): 55 -63. 
 
70 Delaney, C., S. H eimfeld, et al. (2010). "Notch -mediated expansion of human cord 
blood progenitor cells capable of rapid myeloid reconstitution." Nat Med  16(2): 
232-236. 
 
71 Delaney, C., B. Varnum -Finney, et al. (2005). "Dose -dependent effects of the Notch 
ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability 
of cord blood cells." Blood  106: 2693- 2699. 
 
[ADDRESS_409749]- blood engraftment with ex vivo mesenchymal -cell coculture.  
N Engl J Med , 2012. 367(24): p. 2305- 15. 
 
[ADDRESS_409750] blood progenitor cell s 
capable of rapid myeloid reconstitution. Nature Medicine, 2010. 16(2): p. 232- 6. 
 
74 Peled, T., E. Landau, et al. (2002). "Cellular copper content modulates differentiation 
and self -renewal in cultures of cord blood- derived CD34+ cells." Br J Haematol  
116(3): 655 -661. 
 
75 Peled, T., Mandel, J., Goudsmid, R.N., Lador, C., Hasson, N., Harati, D., Austin, M., 
and A. Hasson, Fibach, E., Shpall, E.J., Nagler, A. (2004). "Pre -clinical 
 
 
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol    Page [ADDRESS_409751] blood- derived progenitor cell graft expanded ex vivo with 
cytokines and the polyamine copper chelator tetraethylenepentamine." 
Cytotherapy  6(4): 344 -355. 
 
76 Peled, T., E. Landau, et al. (2004). "Linear polyamine copper chelator 
tetraethylenepentamine augments long -term ex vivo expansion of cord blood-
derived CD34( +) cells and increases their engraftment potential in NOD/SCID 
mice." Exp Hematol  32(6 ): 547- 555. 
 
77 Stiff, P.J., Montesinos, P., Peled, T., et. al., StemEx®(Copper Chelation Based) Ex 
Vivo Expanded Umbilical Cord Blood Stem Cell Transplantation (UCBT) Accelerates Engraftment and Improves 100 Day Survival In Myeloablated 
Patients Compared T o a Registry Cohort Undergoing Double Unit UCBT: Results 
Of a Multicenter Study Of 101 Patients With Hematologic Malignancies, in ASH. 
2013: New Orleans.  
 
78 Lapi[INVESTIGATOR_148595], T., Dar, A., Kollet, O. (2005). "How do stem cells find their way home?" 
Blood 106(6): 1901- 1910. 
 
79 Szilvassy, S. J., Bass, M. J., Van Zant, G., Grimes, B. (1999). "Organ- selective homing 
defines engraftment kinetics of murine hematopoietic stem cells and is compromised by [CONTACT_331295]." Blood 93(5): 1557- 1566. 
 
80 Ahmed, F., S. J. Ings, e t al. (2004). "Impaired bone marrow homing of cytokine -
activated CD34+ cells in the NOD/SCID model." Blood 103(6): 2079 -2087. 
 
81 Foguenne, J., Huygen, S., Greimers, R., B eguin, Y., Gothot, A. (2005). "Modulation of 
homing properties of primitive progenitor cells generated by [CONTACT_331296]." Haematologica 90(4): 445- 451. 
 
82 Von Drygalski, A., G. Alespeiti, et al. (2004). "Murine bone marrow cells cultured ex 
vivo in the  presence of multiple cytokine combinations lose radioprotective and 
long- term engraftment potential." Stem Cells Dev  13(1): 101- 111. 
 
83 Xu, R. and J. A. Reems (2001). "Umbilical cord blood progeny cells that retain a 
CD34+ phenotype after ex vivo expansion have less engraftment potential than unexpanded CD34+ cells." Transfusion  41(2): 213 -218. 
 
84 Szilvassy, S. J., Bass, M. J., Van Zant, G., Grimes, B. (1999). "Organ- selective homing 
defines engraftment kinetics of murine hematopoietic stem cells and is compromised by [CONTACT_331295]." Blood 93(5): 1557- 1566. 
 
85 Szilvassy, S. J., T. E. Meyerrose, et al. (2000). "Effects of cell cycle act ivation on the 
short -term engraftment properties of ex vivo expanded murine hematopoietic 
cells." Blood  95(9): 2829- 2837. 
 
86 Takatoku, M., S. Sellers, et al. (2001). "Avoidance of stimulation improves 
engraftment of cultured and retrovirally transduced hem atopoietic cells in 
primates." J Clin Invest  108(3): 447 -455. 
  
 
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol    Page 113 
 
87 Ahmed, F., S. J. Ings, et al. (2004). "Impaired bone ma rrow homing of cytokine -
activated CD34+ cells in the NOD/SCID model." Blood 103(6): 2079 -2087. 
 
88 Hofmeister, C. C., Zhang, J., Knight, K. L., Le, P., Stiff, P. J. (2007). "Ex vivo 
expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche." 
Bone Marrow Transplant  39(1): 11 -23. 
 
89 Berger, F., M. H. Ramirez -Hernandez, et al. (2004). "The new life of a centenarian: 
signalling functions of NAD(P)." Trends Biochem Sci  29(3): 111- 118. 
 
90 Banasik, M., H. Komur a, et al. (1992). "Specific inhibitors of poly(ADP -ribose) 
synthetase and mono(A DP-ribosyl)transferase." J Biol Chem  267(3): 1569- 1575. 
 
91 Corda, D. and M. Di Girolamo (2003). "Functional aspects of protein mono- ADP -
ribosylation." Embo J  22(9): 1953 -1958. 
 
92 Krebs, C., S. Adriouch, et al. (2005). "CD38 controls ADP -ribosyltransferase- 2-
catalyzed ADP -ribosylation of T cell surface proteins." J Immunol  174(6): 3298-
3305. 
 
93 Glowacki, G., R. Braren, et al. (2002). "The family of toxin -related ecto -ADP -
ribosylt ransferases in humans and the mouse." Protein Sci  11(7): 1657- 1670. 
 
94 Papaccio,  G., E. Ammendola, et al. (1999). "Nicotinamide decreases MHC class II but 
not MHC class I expression and increases intercellular adhesion molecule -1 
structures in non -obese di abetic mouse pancreas." J Endocrinol  160(3): 389 -400. 
 
95 Papaccio, G., E. Ammendola, et al. (1999). "Nicotinamide decreases MHC class II but 
not MHC class I expression and increases intercellular adhesion molecule -1 
structures in non -obese diabetic mouse p ancreas." J Endocrinol  160(3): 389 -400. 
 
96 Sato, F., T. Mitaka, et al. (1999). "Effects of nicotinamide -related agents on the growth 
of primary rat hepatocytes and formation of small hepatocyte colonies." Liver  
19(6): 481 -488. 
 
97 Miura, M. and Y. Kameda (2005). "Nicotinamide promotes long- term surv ival and 
extensive neurite outgrowth in ultimobranchial C cells cultured from chick embryos." 
J Comp Neurol  492(3): 334- 348. 
 
98 Munshi, C. B., R. Graeff, et al. (2002). "Evidence for a Causal Role of CD38 
Expressi on in Granulocytic Differentiation of Human  HL-60 Cells." J Biol Chem  
277(51): [ZIP_CODE]- [ZIP_CODE]. 
 
99 Iwata, K., S. Ogata, et al. (2003). "Induction of differentiation in human promyelocytic 
leukemia HL -60 cell line by [CONTACT_331297]- related compounds." Biosci Biotechnol  
Biochem  67(5): 1132 -1135. 
 
100 Denu, J. M. (2005). "Vitamin B3 and sirtuin function." Trends Biochem Sci  30(9): 
479-483. 
  
 
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol    Page 114 
 
101 Bitterman, K. J., R. M. Anderson, et al. (2002). "Inhibition of silencing and 
accelerated aging by [CONTACT_331298], a putative negative regulator of yeast sir2 and 
human SIRT1." J Biol Chem  277(47): [ZIP_CODE]- [ZIP_CODE]. 
 
102 Vaca, P., G. Berna, et al. (2003). "Nicotinamide induces both proliferation and 
differentiation of embryonic stem cells into insulin -producing cells." Transplant 
Proc 35(5): 2021- 2023. 
 
103 Blander, G., A. Bhi mavarapu, et al. (2008). "SIRT1 Promotes Differentiation of 
Normal Human Keratinocytes." J Invest Dermatol . 
 
104 Kim, M. J., K. Ahn, et al. (2009). "SIRT1 regulates tyrosine hydroxylase expression 
and differentiation of neurobla stoma cells via FOXO3a." FEBS Lett  583(7): 
1183- 1188. 
 
105 Peled T, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates  
expansion of hematopoietic progenitor cells with enhanced bone marrow homing 
and engraftment. (2012) Exp Hema tol. 40(4):342- 55. 
 
106 Srour, E. F., R. Abonour, et al. (1999). "Ex vivo expansion of hematopoietic stem and 
progenitor cells: are we there yet?" J Hematother 8(2): 93 -102. 
 
107 Ando, K., T. Yahata, et al. (2006). "Direct evidence for ex vivo expansion of hum an 
hematopoietic stem cells." Blood 107(8): 3371 -3377. 
 
108 Drake, A. C., M. Khoury, et al. (2011). "Human CD34+ CD133+ hematopoietic stem 
cells cultured with growth factors including Angptl5 efficiently engraft adult 
NOD- SCID Il2rgamma -/- (NSG) mice." PLoS ONE 6(4): e18382. 
 
109 Holmes, T., F. Yan, et al. (2012). "Ex vivo expansion of cord blood progenitors 
impairs their short- term and long- term repopulating acti vity associated with 
transcriptional dysregulation of signalling networks." Cell Prolif 45(3): 266 -278. 
 
110 Laughlin, M. J., J. Barker, et al. (2001). "Hematopoietic engraftment and survival in 
adult recipi[INVESTIGATOR_183606]- cord blood from unrelated donors." N Engl J Med  
344(24): 1815- 1822. 
 
111 Rocha, V., M. Labopin, et al. (2004). "Transplants of Umbilic al-Cord Blood or Bone 
Marrow from Unrelated Donors in Adults with Acute Leukemia." N Engl J Med  
351(22): 2276- 2285. 
 
112 Barker, J. N., D. J. Weisdorf, et al. (2005). "Transplantation of [ADDRESS_409752] blood units to enhance engraftme nt in adults with 
hematologic malignancy." Blood 105(3): [ADDRESS_409753] bloo d expansion with nicotinamide 
provides long- term multilineage engraftment.   The Journal of Clinical 
Investigation.  2014 Jul; 124(7): 312 1-3128 
  
 
 
GC P# 02.01.020  Date : December 1 3, 2017 (Amdt VI)  
 
NiCord® Hemoglobinopathy Protocol    Page 115 
 
114 Walters, M.C., Sullivan, K. M., et al. Neurologic complications after allogeneic 
marrow transplantation for s ickle cell anemia. Blood . 1995 Feb; 85(4): 879- 84 
 
115 Przepi[INVESTIGATOR_12776], D., Weisdorf, D., et al.  Meeting Report: Consensus Conference on Acute 
GvHD Grading. Bone Marrow Transplantation.  1995; 15: 825- 828 